MONDAY, DECEMBER 5, 2016

P1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION
- TOBACCO, RADON, AIR POLLUTION, OTHER RISK FACTORS
- PROTECTIVE FACTORS, RISK REDUCTION, SMOKING CESSATION
- LUNG CANCER SCREENING, DIAGNOSIS
- PROGNOSTIC FACTORS, TREATMENT
- DESCRIPTIVE EPIDEMIOLOGY
P1.01 - 001 - P1.01 - 014

P1.02 BIOLOGY/PATHOLOGY
- DRIVER GENES IN NSCLC, RESISTANCE, AND OTHER
- OTHER MUTATIONS IN THORACIC MALIGNANCIES
- MISCELLANEOUS
P1.02 - 001 - P1.02 - 061

P1.03 RADIOLOGY/STAGING/SCREENING
- BIOLOGY
- PNEUMONOLOGY
- RADIOLOGY
- SCREENING
- STAGING
P1.03 - 001 - P1.03 - 007

P1.04 PULMONOLOGY
- PULMONOLOGY
P1.04 - 001 - P1.04 - 028

P1.05 EARLY STAGE NSCLC
- TRANSLATIONAL RESEARCH & BIOMARKERS
- SBRT
- SURGERY
- NEOADJUVANT AND ADJUVANT CHEMOTHERAPY
- RECURRENCE
- MISCELLANEOUS
P1.05 - 001 - P1.05 - 055

P1.06 ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
- ADVANCED GENERAL
- ADVANCED ELDERLY
P1.06 - 001 - P1.06 - 059

P1.07 SCLC/NEUROENDOCRINE TUMORS
- DRUG TREATMENT ALONE AND IN COMBINATION WITH RADIOTHERAPY
- LOCAL TREATMENT
- MOLECULAR CHANGES
- PATHOLOGY
- PROGNOSTIC FACTORS
- SCLC/NEUROENDOCRINE TUMORS IN GENERAL
P1.07 - 001 - P1.07 - 059

P1.08 SURGERY
- RISK ASSESSMENT & PROGNOSTIC FACTORS
- EPIDEMIOLOGIC STUDIES IN SURGERY FOR NSCLC
- TRANSLATIONAL STUDIES
- MINIMAL INVASIVE SURGERY
- SURGERY FOR LOCALLY ADVANCED AND ADVANCED NSCLC
- MISCELLANEOUS
P1.08 - 001 - P1.08 - 083
Monday, December 5, 2016
Poster Setup Time: Monday, December 5, 08:30 - 10:15
Poster Takedown Time: Monday, December 5, 15:45 - 18:00
(Posters not taken down by 18:00 will be discarded by management)

POSTER SESSION WITH PRESENTERS PRESENT (PRESENTING AUTHOR STAND BY TIME)
Session in which Poster Presenters remains at his/her poster board and is available to discuss/present their research personally with interested delegates.
Monday, December 5, 14:30 - 15:45 (Hall B - Poster Area)

P1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION

P1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION - TOBACCO, RADON, AIR POLLUTION, OTHER RISK FACTORS

P1.01-001: Reduction of Cigarette Consumption through a National Policy for Tobacco Control in Brazil
Ana Paula Teixeira, National Cancer Institute-Ministry of Health, Brazil

P1.01-002: Environmental Tobacco Smoke Exposure and EGFR Mutations/ALK Translocation in Never Smokers. A Multicentre Study in Spanish Never-Smokers
Mónica Pérez-Ríos, University of Santiago de Compostela, Spain

P1.01-003: Novel Associations between Lung Cancer-Related Genes and Indoor Radon Exposure
Jung Ran Choi, Yonsei University Wonju College of Medicine, South Korea

P1.01-004: Is There Any Role of Residential Radon in Non Small Cell Lung Cancer (NSCLC) Patients Harboring Molecular Alterations?
Laura Mezquita, Gustave Roussy, France

P1.01-005: First of Its Kind Study in India Finds That Government's Ban on Gutka (Highly Popular Smokeless Tobacco Product) DID NOT Increase Smoking at All
Gaurav Kumar, GMERS Medical College, India

P1.01-006: Interstitial Lung Diseases Are an Antecedent of Lung Cancer
Wonil Choi, Keimyung University School of Medicine, South Korea

P1.01-007: A Cross-Sectional Study on Tobacco Consumption Pattern among Auto Rickshaw Drivers in Chennai City, Tamil Nadu, India
Delfin Lovelina Francis, Tagore Dental College and Hospital, India

P1.01-008: Knowledge, Attitudes, and Smoking Behaviours among Dental and Medical Students in Chennai, Tamil Nadu, India
Delfin Lovelina Francis, Tagore Dental College and Hospital, India

P1.01-009: Smoking and Lung Cancer: Data from the Single Center in Albania
Fatmir Caushi, University Hospital of Lung Diseases, Albania

P1.01-010: Awareness of Lung Cancer Risk Factors among Lay Persons and Physicians
Laurent Greillier, Hôpital Nord, France
P1.01-011: Roflumilast Attenuates Benzo(a)Pyrene-Induced Lung Cancer via Suppression of Airway Inflammation in Murine Model
Chang Dong Yeo, Catholic University of Korea, South Korea

P1.01-012: Kava Effects on the Metabolism of Tobacco-Specific Carcinogen 4-(Methylnitrosamo)ino-1-(3-Pyridyl)-1-Butanone (NNK) in Humans
Drew Oostra, University of Minnesota, USA

P1.01-013: Emphysematous Changes and Pulmonary Function for Asbestos-Related Lung Cancer in Japan
Takumi Kishimoto, Okayama Rosai Hospital, Japan

P1.01-014: The Role of Hereditary Factor, Profession and the Habit of Cigarette Smoking in Developing Lung Cancer
Irina Pavlovska, Institute of Epidemiology and Biostatistics, Macedonia

P1.01: EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION - PROTECTIVE FACTORS, RISK REDUCTION, SMOKING CESSATION

P1.01-015: Polyphenols-Rich Fruit Extracts Prevent Tobacco Specific Nitrosamine-Induced DNA Damage in Lung Epithelial Cells
D.I.M. Amararathna, Dalhousie University, Canada

P1.01-016: An International Epidemiological Analysis of Young Patients Diagnosed with NSCLC (AduJov - CLiCaP)
Luis Corrales-Rodriguez, CIMCA / Hospital San Juan de Dios, Costa Rica

P1.01-017: The Dramatic Shift of Lung Cancer toward Young in Prisons
Luc Renault, Hospices Civils de Lyon, Hôpital Lyon Sud, France

P1.01-018: Tobacco Use and Perceptions about Cessation Training among Health Professions Students: Estimates by Countries and WHO Regions
Chandrashekhar Sreeramareddy, International Medical University, Malaysia

P1.01-019: Integration of Tobacco Cessation Counseling in a Lung Screening Program
Matthew Steliga, University of Arkansas for Medical Sciences, USA

P1.01-020: Chemopreventive Effect of Catechin Hydrates against Benzo(a)Pyrene Induced Lung Carcinogenesis in Mice: Plausible Role of ALDH1
Ayaz Shahid, Jamia Hamdard University, India

P1.01-021: The Impact of Smoking Status on Overall Survival in a Population-Based Non-Small Cell Lung Cancer (NSCLC) Surgical Resection Cohort
Nicholas Faris, Baptist Cancer Center, USA

P1.01-022: Smoking Cessation Related to Lung Resection
Tanel Laisaar, Tartu University, Estonia

P1.01-023: Smoking Cessation before Initiation of Chemotherapy in Metastatic Non-Small Lung Cancer: Influence on Prognosis
Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal
P1.01-024: University Students’ Perceptions about Effectiveness of MPOWER Policies on Tobacco Control in Panama City Panama
Omar Castillo-Fernandez, Instituto Oncologico Nacional, Panama

P1.01-025: Mass Media and Tobacco in Bangladesh: An Investigation on the Role of Mass Media in the Light of Tobacco Control
Tahsina Sadeque, Somoy Television, Bangladesh

P1.01-026: Tobacco Use, Awareness and Cessation among Malayali Tribes, Yelagiri Hills, Tamil Nadu, India
Delfin Lovelina Francis, Tagore Dental College and Hospital, India

P1.01: EPIDEMIOLOGY/TOBACCO CONTROL AND CESSION/PREVENTION - LUNG CANCER SCREENING, DIAGNOSIS

P1.01-027: Increased Risk of Lung Cancer among Women with Superficial TCC: A Potential Risk Cohort for Lung Cancer Screening
Yaakov Tolwin, Tel Aviv University, Israel

P1.01-028: High Risk Older Smokers’ Perceptions, Attitudes and Beliefs About Lung Cancer Screening
Janine Cataldo, University of California, San Francisco, USA

P1.01-029: Personal and Hospital Factors Associated with Limited Surgical Resection, In-Hospital Mortality and Complications in New York State
Wil Lieberman-Cribbin, Icahn School of Medicine at Mount Sinai, USA

P1.01-030: Factors Associated with Margin Positive Resections for Non-Small Cell Lung Cancer (NSCLC) in the Mid-South Region of the US
Matthew Smeltzer, University of Memphis School of Public Health, USA

P1.01-031: Does Malignant Pleural Mesothelioma (MPM) Behaviour Differ among Decades?
Fatma Abou Elkasem, National Cancer Institute, Egypt

P1.01-032: Emergency Department Visits by Lung Cancer Patients in Korea
Dong Won Park, Hanyang University College of Medicine, South Korea

P1.01-033: EGFR Mutation and ALK: Are Patients Being Adequately Tested in Brazil?
Gilberto Lopes, Nucleo de Oncologia da Bahia, Brazil

P1.01-034: ECOG Scale of Performance Status in Lung Cancer at the First Consultation at a National Cancer Institute in a Developing Country in Latin America
Silvia Josefina Ayala Leon, National Cancer Institute Prof.Manuel Riveros, Paraguay

P1.01: EPIDEMIOLOGY/TOBACCO CONTROL AND CESSION/PREVENTION - PROGNOSTIC FACTORS, TREATMENT

P1.01-035: Trends, Patterns of Treatment and Outcomes in Non-Small Cell Lung Cancer (NSCLC) as a Second Primary: A National Cancer Data Base (NCDB) Analysis
Madhusmita Behera, Winship Cancer Institute of Emory University, USA

P1.01-036: Lung Cancer Screening Program Is Cost Effective in French Setting: A Model Based Study
Christos Chouaid, GRC OncoEst Creteil, France
P1.01-037: Baseline Demographics and Comorbidities of Patients with Advanced NSCLC Compared to the General Population from Two Regions in Sweden
Patrice Verpillat, Boehringer Ingelheim, Germany

P1.01-038: Prognosis Value of Body Mass Index (BMI) and Weight Loss at Diagnosis in Primary Lung Cancer: Results of KBP-2010-CPHG Study
Didier Debieuvre, Groupe Hospitalier Régional Mulhouse Sud Alsace (GHRMSA) - Hôpital Emile Muller, France

P1.01-039: Does Distance between Chest and Surgery Departments Impact Outcome in Lung Cancer Patients? Results of KBP-2010-CPHG Study
Didier Debieuvre, Groupe Hospitalier Régional Mulhouse Sud Alsace (GHRMSA) - Hôpital Emile Muller, France

P1.01-040: Long-Term Survival in Metastatic Non-Small-Cell Lung Cancer: An Investigation Using Surveillance, Epidemiology and End Results Data
Eva Szabo, National Cancer Institute, USA

P1.01-041: Quantitative Imaging Features Predict Response of Immunotherapy in Non-Small Cell Lung Cancer Patients
Ilke Tunali, Namik Kemal University, Turkey

P1.01-042: Molecular Epidemiology of Programmed Cell Death 1-Ligand 1 (PD-L1) Protein Expression in Non-Small Cell Lung Cancer
Matthew Schabath, H Lee Moffitt Cancer Center and Research Institute, USA

P1.01-043: Comparison of Gender, Race Distribution, and Survival in the 1990s to 2010s in Lung Cancer Patients at a Single Institution
Bahar Laderian, University of Miami, Miller School of Medicine, USA

P1.01-044: Accelerometer-Determined Physical Activity and Sedentary Time among Lung Cancer Survivors
Adrijana D'Silva, University of Calgary, Canada

P1.01-045: Patient to Hospital Distance in Access to Care and Lung Cancer Surgical Treatment
Wil Lieberman-Cribbin, Icahn School of Medicine at Mount Sinai, USA

P1.01-046: Heterogeneity of NSCLC Surgery Exists in Treatment Patterns and Hospital Costs among Different Centers of China, a Study of 5060 Patients
Jian Zhou, Peking University People’s Hospital, China

P1.01-047: Clinical Presentation and Outcome of Neuroendocrine Lung Tumors in a Brazilian Cohort from 2000 to 2016
Marcelo Corassa, A.C.Camargo Cancer Center, Brazil

P1.01-048: Factors Contributing Delays during Management of Lung Cancer: A Study from Tertiary Level Hospital in Nepal
Sandhya Acharya, National Academy Of Medical Sciences, Bir Hospital, Nepal

P1.01-049: Predictors of High Grade Toxicity of Chemotherapy among Malignant Pleural Mesothelioma Patients
Fatma Abou Elkasem, National Cancer Institute, Egypt
P1.01-050: Overall Survival in Advanced Lung Cancer Patients Treated at Oncosalud-AUNA  
Alfredo Aguilar, Oncosalud - AUNA, Peru

P1.01-051: Predictor Variables to ECOG Scale of Performance Status in Lung Cancer at a Developing Country in Latin America  
Silvia Josefina Ayala Leon, National Cancer Institute Prof.Manuel Riveros, Paraguay

P1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND CESSION/PREVENTION - DESCRIPTIVE EPIDEMIOLOGY

P1.01-052: Lung Cancer Mortality in Mexico, 1990-2014  
Oscar Arrieta, Instituto Nacional de Cancerología, Mexico

P1.01-053: Lung Cancer in Brazil: Men and Women Differences  
Maria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, Brazil

P1.01-054: Lung Cancer: Histology, Gender and Age Changes Over Past 30 Years in Brazil  
Maria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, Brazil

P1.01-055: Clinicoepidemiological Trends of Lung Cancer from a Premier Regional Cancer Centre in South India  
Abhijit Das, Cancer Institute (WIA), India

P1.01-056: Lung Cancer Epidemiology in Croatia  
Robert Zorica, University Hospital “Split”, Croatia

P1.01-057: Metastatic Lung Cancer at a Tertiary Cancer Centre in South India  
Govind Babu, Kidwai Memorial Institute Of Oncology, India

P1.01-058: Demographic Profile of Lung Cancer from Eastern India  
Prasanta Mohapatra, All India Institute of Medical Sciences, India

P1.01-059: Lung Cancer Epidemiology among the Bahraini Population, 2000-2011  
Randah Hamadeh, Arabian Gulf University, Bahrain

P1.02 BIOLOGY/PATHOLOGY

P1.02 BIOLOGY/PATHOLOGY - DRIVER GENES IN NSCLC, RESISTANCE, AND OTHER

P1.02-001: Expressions of Resistance EGFR TKIs in Non Small Cell Lung CancerAt Pham Ngoc Thach Hospital - Viet Nam  
Nguyen Lam, Pham Ngoc Thach Hospital, Vietnam

P1.02-002: Is T790M Mutation A “Regulator” for EGFR Signal Pathway Not an Oncogene?  
Zheng Wang, Beijing Hospital, China

P1.02-003: ROS1 (D4D6) is Reliable for Immunohistochemistry Detecting of ROS1 Fusion Lung Adenocarcinoma in Malignant Pleural Effusion  
Zheng Wang, Beijing Hospital, China

P1.02-004: A Retrospective Analysis of Frequency of ALK Gene Rearrangement in Saudi Lung Patients  
Fouad Al Dayel, King Faisal Specialist Hospital and Research Centre, Saudi Arabia
P1.02-005: Frequency of Actionable Alterations in EGFR wt NSCLC: Experience of the Wide Catchment Area of Romagna (AVR)
Paola Ulivi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy

P1.02-006: Interlaboratory Variation in Molecular Testing (EGFR, KRAS and ALK) in Stage IV Non-Squamous Non-Small Cell Lung Cancer in the Netherlands in 2013
Chantal Kuijpers, University Medical Center Utrecht, Netherlands

P1.02-007: Alk Translocated NSCLC in the West of Scotland: Patient Demographics and Outcomes
Nicola Steele, Beatson West of Scotland Cancer Centre, UK

P1.02-008: 2-Year Single Institution Experience with EGFR Plasma Testing in Advanced NSCLC
Izidor Kern, University Clinic of Respiratory and Allergic Diseases Golnik, Slovenia

P1.02-009: High Concordance of ALK Rearrangement Testing between ALK RNA-In Situ Hybridization and IHC/FISH in Patients with Lung Adenocarcinoma
Akihiko Yoshizawa, Kyoto University Hospital, Japan

P1.02-010: Frequency of Uncommon EGFR Mutations in NSCLC in an Argentinean University Institution
Carolina Gabay, Instituto de Oncologia Angel H.Roffo, University of Buenos Aires, Argentina

P1.02-011: Comparison of EGFR and KRAS Mutations in Archival Tissue and Circulating Tumor DNA: The Impact of Tumor Heterogeneity
Ying Wang, BC Cancer Agency, Canada

P1.02-012: Frequencies of Actionable Mutations and Survival in Variants of Invasive Adenocarcinoma of the Lung
Zhengbo Song, Zhejiang Cancer Hospital, China

P1.02-013: Clinicopathological Characteristics and Survival of ALK, ROS1 and RET Arrangements in Non-Adenocarcinoma Non-Small Cell Lung Cancer Patients
Zhengbo Song, Zhejiang Cancer Hospital, China

P1.02-014: HER2 Mutations in Chinese Patients with Non-Small Cell Lung Cancer
Zhengbo Song, Zhejiang Cancer Hospital, China

P1.02-015: A Multicenter Study of EGFR and EML4-ALK Detection in Non-Squamous, Non-Small-Cell Lung Cancer Patients with Malignant Pleural Effusion
Zhengbo Song, Zhejiang Cancer Hospital, China

P1.02-016: HER4 Expression Was Related to the Sensitivity of EGFR-TKI in Non-Small Cell Lung Cancer
Masaaki Inoue, Shimonoseki City Hospital, Japan

P1.02-017: Relative Abundance of EGFR Mutations Predict Tumor Metastasis and EGFR-TKIs Prognosis in Patients with Non-Small Cell Lung Cancer
Qiming Wang, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, China

P1.02-018: Osteosarcomatous Differentiation in the Rebiopsy Specimens of Patients Harboring Pulmonary Adenocarcinoma with EGFR-TKI Resistance
Hyun Jung Kwon, Seoul National University Bundang Hospital, South Korea
P1.02-019: Complex Mutation of Epidermal Growth Factor Receptor (EGFR) in Patients with Non-Small Lung Cancer
Hiromasa Arai, Kanagawa Cardiovascular and Respiratory Center, Japan

P1.02-020: The Effect of EGF-Pathway Targeted Immunization (EGF PTI) on STAT3 and Cancer Stem Cells in EGFR Mutant NSCLC Cells
Jordi Codony Servat, Pangaea Biotech SL, IOR Quirón-Dexeus University Institute, Spain

P1.02-021: Review of Clinical Outcomes Attributable to Next Generation Sequencing Based Broad Mutation Panel Testing in Lung Adenocarcinoma
Cathal O'Brien, St James's Hospital, Ireland

P1.02-022: Establishing Reflex NGS Testing in NSCLC in a Regional Network of County Hospitals in Central Sweden
Johan Isaksson, Gävle Hospital, Sweden

P1.02-023: Application of an Amplicon-Based NGS Strategy in the Molecular Diagnosis of NSCLC: Comparable Performance with FISH and ARMS-PCR
Dongmei Lin, Peking University Cancer Hospital & Institute, China

P1.02-024: The Molecular Breakdown: A Comprehensive Look at Non-Small-Cell Lung Cancer with ALK Rearrangement
Ka-Won Noh, Sungkyunkwan University, South Korea

P1.02-025: Evaluation of NGS and RT-PCR Methods for ALK Assessment in European NSCLC Patients: Results from the ETOP Lungscape Project
Stephen Finn, St James's Hospital, Ireland

P1.02-026: Detection of Low-Abundant EGFR Somatic Mutations by PNA Clamping-Assisted Fluorescence Melting Curve Analysis
Jihye Yoon, PANAGENE Inc., South Korea

P1.02-027: A Comparative Analysis of Different Cytological Samples for the Assessment of ALK Gene Rearrangements in NSCLC Patients
Maria Lozano Escario, University of Navarra, Spain

P1.02-028: Detection of Oncogenic Drivers in Pleural Effusions and Archived FNA Smears of Pulmonary Adenocarcinoma
Deepali Jain, All India Institute of Medical Sciences, India

P1.02-029: Infrequent Staining Patterns in ALK Immunohistochemistry: Correlation with Fish Analysis
Paola De La Iglesia, Hospital Italiano de Buenos Aires, Argentina

P1.02-030: Performance Evaluation of ALK/ROS1 Dual Break Apart FISH Probe Kit (RUO) in Non-Small-Cell Lung Cancer
Hyun Chang, Catholic Kwandong University International St. Mary's Hospital, South Korea

P1.02-031: Mutations in TP53, PIK3CA, PTEN and Other Genes in EGFR Mutated Lung Cancers: Correlation with Clinical Outcomes
Paul Vanderlaan, Beth Israel Deaconess Medical Center, Harvard Medical School, USA
P1.02-032: Diagnosis and Treatment of EGFR Mutated NSCLC among Arabic Patients
Abed Agbaria, Bnay Zion Medical Center, Israel

P1.02-033: Mesenchymal Transformation is the Most Common Histomorphologic Changes in the Rebiopsy of Lung Cancer Patients with EGFR-TKI Resistance
Hyein Ahn, Seoul National University Bundang Hospital, South Korea

P1.02-034: EGFR Mutations and ALK Translocations in Lung Cancer - A National Study
Erik Jakobsen, Odense University Hospital, Denmark

P1.02-035: Concomitant Driver Mutation Determines Tumor Growth in EGFR Mutation-Positive Lung Adenocarcinoma
Kazuhiro Nagayama, The University of Tokyo Hospital, Japan

P1.02-036: An EGFR Tyrosine Kinase Inhibitor Sensitive Patient-Derived Lung Cancer Xenograft Model without Classical Sensitizing Mutations
Hirotugu Notsuda, Ontario Cancer Institute, Canada

P1.02-037: Mutations of EGFR and KRAS Genes in Belorussian Patients With Non-Small Cell Lung Cancer
Alena Mikhalenka, Institute of Genetics and Cytology of the National Academy of Sciences of Belarus, Belarus

P1.02-038: Over-Expression of Epidermal Growth Factor Receptor 1 (EGFR1) Gene in Serum of Adenocarcinoma Lung at a Tertiary Level Centre in North India
Ashraf Ansari, All India Institute of Medical Sciences, India

P1.02-039: Assessment of KRASmutations (by Digital PCR) in Circulating Tumoral DNA from Lung Adenocarcinoma Patients
Álvaro Taus, Hospital del Mar, Spain

P1.02-040: Heterogeneity of the EGFR / KRAS Gene Mutation in Multifocal Lung Adenocarcinoma and the Clinical Significance
Lin Li, Cancer Hospital, Chinese Academy of Medical Sciences, China

P1.02-041: Characterization of MET-N375S as an Activating Mutation in Squamous Cell Carcinoma of the Lung
Li Ren Kong, Cancer Science Institute Singapore, Singapore

P1.02-042: Detection of ALK Protein Expression in Lung Adenocarcinomas, a Consecutive Series of Cases from Northeastern Brazil
Ana Claudia Oliveira, Argos Patologia / Hospital de Messejana do Coração e do Pulmão, Brazil

P1.02-043: Multiplexed FISH (ALK/ROS1, RET, NTRK1) in Lung Adenocarcinomas: Novel Dual ALK/ROS1 Probe and Automated Scanning System
Susana Hernandez, Hospital Universitario HM Sanchinarro, Spain

P1.02-044: EGFR Status in a Previously Untested Population from Northeastern Brazil
Ana Claudia Oliveira, Argos Patologia / Hospital de Messejana do Coração e do Pulmão, Brazil

P1.02-045: Discordance (FISH+, IHC-) between FISH and IHC Analysis of ALK Status in Advanced Non Small Cell Lung Cancer (NSCLC): A Unexpected Issue in 7 Cases
Annamaria Catino, National Cancer Research Centre, Istituto Tumori “Giovanni Paolo II” Bari, Italy, Italy
P1.02-046: ALK IHC is Highly Sensitive to Fixation Parameters
Isabell Loftin, Ventana Medical Systems Inc., a member of the Roche Group, USA

P1.02-047: Effect of Dasatinib on EMT-Mediated-Mechanism of Resistance against EGFR Inhibitors in Lung Cancer Cells
Yuichi Sesumi, Kindai University Faculty of Medicine, Japan

P1.02-048: MET Exon 14 Skipping Mutations and Gene Amplifications Are Not Simultaneous Events in NSCLC
Sergi Clavé, Hospital del Mar, Spain

P1.02-049: EGFR, KRAS and ALK Gene Alterations in Lung Cancer Patients in Croatia
Marko Jakopovic, University Hospital Centre Zagreb, Croatia

P1.02-050: Acquired Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs) in EGFR-Mutant Lung Adenocarcinoma among Hispanics (Rbiop-CLiCaP)
Andrés Cardona, Clinical and Trasational Oncology Group, Institute of Oncology, Clinica del Country, Colombia

P1.02-051: Concomitant Driver Mutations in Advanced Stage Non-Small-Cell Lung Cancer of Adenocarcinoma Subtype with Activating EGFR-Mutation
Jens Benn Sørensen, Finsen Centre/National University Hospital, Denmark

P1.02-052: Signal Regulatory Protein a (SIRPA): A Key Regulator of the EGFR Pathway Demonstrates Both Tumor Suppressive and Oncogenic Properties
Erin Marshall, BC Cancer Research Centre, Canada

P1.02-053: Comparison of Two Different Commercially Available Probes for the Detection of ALK Rearrangements in Cytological Smears
Maria Lozano Escario, University of Navarra, Spain

P1.02-054: Genomic Complexity in KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) by Smoking Status with Comparison to EGFR Mutant NSCLC
Amanda Redig, Dana-Farber Cancer Institute, USA

P1.02-055: Synthetic Lethality Dictates the Mutual Exclusivity of Oncogenic Mutations in Lung Adenocarcinoma
William Lockwood, British Columbia Cancer Research Centre, Canada

P1.02-056: Tumor Heterogeneity in Lesion Specific Response Creates ROS1 Fusion Mediating Resistance to Gefitinib in EGFR 19 Deletion Lung Adenocarcinoma
Xiaomin Niu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.02-057: Clinical Utility of ctDNA for Detecting ALK Fusions and Resistance Events in NSCLC: Analysis of a Laboratory Cohort
Robert Doobele, University of Colorado, USA

P1.02-058: EGFR Amplification and Sensitizing Mutations Correlates with Survival from Erlotinib in Lung Adenocarcinoma Patients (MutP-CLiCaP)
Andrés Cardona, Clinical and Trasational Oncology Group, Institute of Oncology, Clinica del Country, Colombia
P1.02-059: Evaluation of Plasma DNA Extraction, Droplet PCR and Droplet next Generation Sequencing Methods for Liquid Biopsy Analysis
Lina Salleh, National University of Singapore, Singapore

P1.02-060: EGFR Mediates Activation of RET in Lung Adenocarcinoma with Neuroendocrine Differentiation Characterized by ASCL1 Expression
Farhad Kosari, Mayo Clinic, USA

P1.02-061: Kinase Fusions in Non-Small Cell Lung Carcinoma Identified by Hybrid Capture Based ctDNA Assay
Lauren Young, Foundation Medicine, USA

P1.02 - BIOLOGY/PATHOLOGY - OTHER MUTATIONS IN THORACIC MALIGNANCIES

P1.02-062: Consensus of Gene Expression Phenotypes and Prognostic Risk Predictors in Primary Lung Adenocarcinoma
Johan Staaf, Lund University, Sweden

P1.02-063: Mutation Profiling by Targeted Next-Generation Sequencing of an Unselected NSCLC Cohort
Linnea La Fleur, Uppsala University, Sweden

P1.02-064: MET-Dependent Activation of STAT3 as Mediator of Resistance to MEK Inhibitors in KRAS-Mutant Lung Cancer
Chiara Lazzari, Istituto Europeo di Oncologia - IEO, Italy

P1.02-065: Elucidating the Role of PIM Kinase and Its Therapeutic Potential in NSCLC
Gillian Moore, Trinity College Dublin/St. James's Hospital, Ireland

P1.02-066: Genomic Profiling in the Differential Diagnostics of Pulmonary Tumours: A Case Series
Hans Brunnström, Lund University, Sweden

P1.02-067: Repeated Biopsy for Immunohistochemical and Mutational Analysis of Non Small Cell Lung Cancer: Feasibility and Safety
Margarita Majem, Hospital de la Santa Creu i Sant Pau, Spain

P1.02-068: The Impact of TP53 Overexpression on EMT and the Prognosis in Lung Adenocarcinoma Harboring Driver Mutations
Shigeto Nishikawa, Graduate School of Medicine, Kyoto University, Japan

P1.02-069: Genomic Alterations and Survival in Young Patients under 40 Years with Completely Resected Non-Small Cell Lung Cancer
Zhengbo Song, Zhejiang Cancer Hospital, China

P1.02-070: Gene Spectrum and Survival Analyses of Pathologic Subtypes in Resected Lung Squamous Cell Carcinoma
Zhengbo Song, Zhejiang Cancer Hospital, China

P1.02-071: Detection of Multiple Low-Frequency Mutations by Molecular-Barcode Sequencing
Kei Namba, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
P1.02-072: Comprehensive Genomic Alterations Identified by Next-Generation Sequencing of Lung Adenocarcinoma in Japanese Population
Seijiro Sato, Niigata University Graduate School of Medical and Dental Sciences, Japan

P1.02-073: Characterizing the Genomes of Lung Adenocarcinomas from Never Smokers Reveals SHPRH as a Novel Candidate Tumour Suppressor Gene
Tanya De Silva, British Columbia Cancer Research Centre, Canada

P1.02-074: The Gene Expression Signatures of Pulmonary Adenocarcinoma with Micropapillary Features
Yuki Sata, Chiba University Graduate School of Medicine, Japan

P1.02-075: Analysis of Driver Genes Alteration and Clinicopathological Features in Pulmonary Marker-Null Large Cell Carcinoma
Likun Hou, Tongji University School of Medicine, China

P1.02-076: DNA Methylation Profiling Unravels a TGF-β Hyperresponse in Tumor Associated Fibroblasts from Lung Cancer Patients
Jordi Alcaraz, Facultat de Medicina, Universitat de Barcelona, Spain

P1.02-077: Whole-Transcriptome Gene Expression Analysis of Pulmonary Sarcomatoid Carcinomas
Greta Ali, University Hospital of Pisa, Italy

P1.02-078: Expression Profiling of LKB1 Pathway in Young and Old Lung Adenocarcinoma Patients
Mirella Giordano, University of Pisa, Italy

P1.02-079: DNA Ploidy, CPA4 and Rel B Expression in Non Small Cell Lung Cancer: Correlation with Clinicopathologic Parameter
Eleftheria Haini, Corfu General Hospital, Greece

P1.02-080: Genomic Relationship between Lung Adenocarcinoma and Synchronous AIS/AAH Lesions in the Same Lobe
Laura Tafe, Dartmouth-Hitchcock Medical Center, USA

P1.02-081: The Relationship of CDH3 Expression and DNA Methylation in Thymic Epithelial Tumors
Koichiro Kajiura, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan

P1.02-082: The Feasibility of Cell-Free DNA Sequencing for Mutation Detection in Non-Small Cell Lung Cancer Was Determined by Tumor Volume
Tatsuo Ohira, Tokyo Medical University, Japan

P1.02-083: Gene Fusion Profile in Lung Adenocarcinoma Patients in Brazil
Tatiane Montella, Neotorax, Brazil

P1.02-084: Polo-Like Kinase 1 (PLK1) Inhibition Decreases Mutational Activity in Bronchial Epithelial Cells Exposed to Tobacco Carcinogens
Daniel Merrick, University of Colorado, Anschutz Medical Campus, USA

P1.02-085: Molecular Profile in NSCLC Biopsy Samples: A Multicenter Local Study
Norma Pilnik, School Of Medicine Cordoba University, Argentina

P1.02-086: ATM Mutations in Lung Cancer Correlate to Higher Mutation Rates
Lars Petersen, University of Calgary, Canada
P1.02  BIOLOGY/PATHOLOGY - MISCELLANEOUS

P1.02-087: Sensitive Detection of Rare Cancer Cells by Preprogrp-Specific RT-PCR and Its Correlation with Clinicopathological Data and Survival
Fatma Abou Elkasem, National Cancer Institute, Egypt

P1.03  RADIOLOGY/STAGING/SCREENING

P1.03  RADIOLOGY/STAGING/SCREENING - BIOLOGY

P1.03-001: The Utility of Liquid-Biopsy for Detecting EGFR Mutation in Clinical Practice: 169 Cases in a Single Institution Research Study
Kentaro Ito, Matsusaka Municipal Hospital, Japan

P1.03-002: Can We Discriminate between Different Subtypes of Non-Small Cell Cancer Patients Based on Plasma Metabolic Fingerprint?
Michal Ciborowski, Medical University of Bialystok, Poland

P1.03-003: The Warburg Effect: Persistence of Stem Cell Metabolism in Lung Cancer as Failure of Differentiation
Robert Downey, Memorial Sloan Kettering Cancer Center, USA

P1.03-004: Percutaneous Lung Biopsy for Genomic Assessment: Comparison between Two Different next Generation Sequencing Platforms
Livia Maria Frota Lima, MD Anderson Cancer Center, USA

P1.03-005: High Resolution Metabolomics in Discovering Plasma Biomarkers of Lung Cancer Patients with EGFR Common Mutations (Exon 19 or 21)
Sung Yong Lee, College of Medicine, Korea University, South Korea

P1.03-006: Quantification of PD-L1 Expression on Tumor Cells in Non-Small Cell Lung Cancer Using Non-Enzymatic Tissue Dissociation and Flow Cytometry
Amanda Chargin, IncellDx, USA

P1.03-007: Improvement in Performance of an Autoantibody Panel Test for Detection of Lung Cancer by Addition of a Single Novel Biomarker (EDB1)
Caroline Chapman, Queen's Medical Centre, UK

P1.03  RADIOLOGY/STAGING/SCREENING - PNEUMONOLOGY

P1.03-008: Clinical Importance of Indolent Lung Cancers
Gunnar Hillerdal, Gavle Hospital, Sweden

P1.03-009: Venous Thromboembolism (VTE) in Lung Cancer - Associations and Prognostic Role: Results of a Prospective Cohort Study from North India
R Lakshmi Narasimhan, Postgraduate Institute of Medical Education and Research (PGIMER), India

P1.03-010: Characteristics of Lung Cancer Patients Diagnosed Following Emergency Admission
Neal Navani, University College London, UK
P1.03-011: Clinical Characters of 19 Bronchial Asthmatic Patients with Lung Cancer
Jie Zhang, Second Affiliated Hospital of Jilin University, China

P1.03  RADIOLOGY/STAGING/SCREENING - RADIOLOGY

P1.03-012: Experience with BioSentryTM Tract Sealant System for Percutaneous CT-Guided Lung Nodule Biopsies in an Oncology Population
Patricia de Groot, UT MD Anderson Cancer Center, USA

P1.03-013: Diagnosis, Assessment and Prediction of Early Response to Chemotherapy by Using Diffusion-Weighted MRI in Lung Cancer
Jian Zhang, Department of Pulmonary Medicine, Xijing Hospital, Fourth Military Medical University, China

P1.03-014: Value of Performing Fine Needle Aspiration with Core Biopsy for Genomic Mutation Assessment in Percutaneous Lung Biopsies
Livia Maria Frota Lima, MD Anderson Cancer Center, USA

P1.03-015: Assessment of Response of FDG-PET Using Total Lesion Glycolysis (TLG) in NSCLC Patients Treated with Nivolumab: Results of a Pilot Study
Hector Soto Parra, A.O.U. Policlinico Vittorio Emanuele, Italy

P1.03-016: Diagnostic Accuracy of Visual Assessment on Growth of Non-Measurable Target Pulmonary Nodules According to RECIST Criteria
Jeong Min Ko, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, South Korea

P1.03-017: Does PET/CT SUVmax Value Correlate with Long-Term Survival in Patients with Surgically Treated Stage I Non-Small Cell Lung Cancer
Akif Turna, Istanbul University Cerrahpasa Medical School, Turkey

P1.03-018: FDG-PET/CT in Patients with EGFR-Mutated NSCLC Treated with TKI. Can We Identify Early Lesions at Higher Risk of Progression?
Alexis Cortot, Lille University Hospital, France

P1.03-019: Imaging of Anti-PD1 Therapy Response in Advanced Non-Small Lung Cancer
Sharyn Katz, Hospital of the University of Pennsylvania, USA

P1.03-020: FDG-PET SUVmax Does Not Correlate with Glucose Metabolism in Non-Small Cell Lung Cancer
Kemp Kernstine, University of Texas Southwestern, USA

P1.03-021: Initial Results from A Novel and Low Cost Method For Measuring CT Image Quality
Ricardo Avila, Accumetra, LLC, USA

P1.03-022: Possibility of FDG-PET Predicting the Clinicopathological Characteristics and Prognosis of Lung Adenocarcinoma: Multicenter Study
Kumi Matsuura, Tokyo Medical University, Japan

P1.03-023: Ground-Glass Opacity (GGO) with Semi-Consolidation: Clinicopathological and Radiological Correlations Compared to Pure-GGOs of the Lung
Jun Suzuki, Juntendo University School of Medicine, Japan
P1.03-024: Accuracy of Combined Semantic and Computational CT Features in Predicting Non-Small Cell Lung Cancer Subtype
Andrea Bille, Guys’ & St. Thomas’ Hospitals, UK

P1.03-025: Serum KL-6 Levels in Patients with Lung Cancer
Tatsuya Yoshimasu, Wakayama Medical University, Japan

P1.03-026: Measurement of Pulmonary Artery on CT to Predict Acute Exacerbation of Interstitial Pneumonia after Pulmonary Resection for Lung Cancer
Akiko Ui, Tokyo Medical and Dental University, Japan

P1.03-027: Clinical and Histological Features Associated with SUV in FDG-PET-CT in Patients with Adenocarcinoma of the Lung
Amanda Tufman, Ludwig Maximilian University of Munich, Germany

P1.03-028: Wolf in Sheep’s Clothing - Primary Lung Cancer Mimicking Benign Diseases
Annemie Snoeckx, Antwerp University Hospital & Antwerp University, Belgium

P1.03-029: A Useful Algorithmic Model in Predicting the Likelihood of Lung Cancer in Solitary Pulmonary Nodules
Lin Gen, Fujian Provicial Cancer Hospital, The Affiliated Hospital of Fujian Medical University, China

P1.03-030: FDG-PET/CT Might Be a Predictor for Residual Disease in Advanced NSCLC after Chemoradiotherapy
Toru Sawada, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan

P1.03-031: Gynecological Malignancies and Imaging Patterns. An Interesting Case Report and Literature Surveillance
Nektarios Alevizopoulos, Evaggelismos General Hospital, Greece

P1.03-032: In vivo Imaging Models for Preclinical Screening of Molecular Targeted Drugs against Brain Metastasis
Akihiro Nishiyama, Kanazawa University, Japan

P1.03 - RADIOLOGY/STAGING/SCREENING - SCREENING

P1.03-033: Analysis of T0 Lung-RADS Scores in UI Health’s Minority-Based Lung Cancer Screening Program and Comparison to the NLST
Mary Pasquinelli, The University of Illinois Hospital and Health Sciences System, UI Cancer Center, USA

P1.03-034: Implementing Smartphone Application in Early Lung Cancer Detection and Screening
Zalan Szanto, University of Pécs, Hungary

P1.03-035: Does Screening with Low-Dose Computed Tomography (LDCT) of Asbestos Exposed Subjects Reduce Mortality for Lung Cancer (LC)?
Gianpiero Fasola, University hospital of Udine, Italy

P1.03-036: Adherence to Eligibility Criteria for Low-Dose CT Screening in an Academic Center
Jacob Bloom, Fred Hutchinson Cancer Research Center, USA

P1.03-037: Radio-Guided Localization and Resection of Small or Ill-Defined Pulmonary Lesions
Domenico Galetta, European Institute of Oncology, Italy
P1.03-038: Appropriateness of Lung Cancer Screening with Low Dose Computed Tomography
M Rivera, The University of North Carolina, USA

P1.03-039: Is It Necessary to Repeat Lung Cancer Screening with Low-Dose CT(LDCT) in Female Never Smokers?
Hyae Young Kim, National Cancer Center, South Korea

P1.03-040: Beliefs Surrounding Lung Cancer Screening among Physicians and Lay Populations: Results from the EDIFICE Survey
Alexis Cortot, Hôpital Calmette, France

P1.03-041: Do Several Rounds of Negative Screening Low Dose CT Scans Influence the Risk to Develop Lung Cancer?
Heidi Schmidt, University Health Network, Canada

P1.03-042: Nodule Size is Poorly Represented by Nodule Diameter in Low-Dose CT Lung Cancer Screening
Marjolein Heuvelmans, University of Groningen, University Medical Center Groningen, Netherlands

P1.03-043: Practical Difficulty of Low Dose Computerized Tomography as a Lung Cancer Screening Tool in an Endemic Area of Tuberculosis
Natthaya Triphuridet, Chulabhorn Hospital, Thailand

P1.03-044: EUS-Guided Sampling of Mediastinal Lymph Nodes and Abdominal Lesions in Lung Cancer
Toyoaki Hida, Aichi Cancer Center Hospital, Japan

P1.03-045: Screening for Lung Cancer with Early CDT-Lung Blood Biomarkers and Computed Tomography
James Finigan, National Jewish Health, USA

P1.03-046: Selection of Subjects at High-Risk for LDCT Lung Cancer Screening Using a Molecular Panel: Results by the ITALUNG Biomarker Study
Eugenio Paci, Institute for Cancer Prevention and Research (ISPO), Italy

P1.03-047: Community-Based Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in the US Histoplasmosis Belt: One Year Followup
Emilia Porubcin, Rivermont Collegiate, USA

P1.03-048: A Structured Lung Cancer Screening Program Facilitates Patient and Provider Compliance
Thomas D'Amico, Duke University Medical Center, USA

P1.03-049: Smoking Patterns in a Predominantly African American Population Undergoing Lung Cancer Screening
Cherie Erkmen, Temple University Hospital, USA

P1.03-050: Outcomes after the Decision to Biopsy: Results from a Nurse Practitioner Run Multidisciplinary Lung Cancer Screening Program
Candice Wilshire, Swedish Medical Center and Cancer Institute, USA

P1.03-051: Medically Underserved and Geographically Remote Individuals May Be Underrepresented in Current Lung Cancer Screening Programs
Candice Wilshire, Swedish Medical Center and Cancer Institute, USA
P1.03-052: The Effect of Rounding on Rate of Positive Results on CT Screening for Lung Cancer
Kunwei Li, Icahn School of Medicine, USA

P1.03-053: The Effect of Primary Care Physician Knowledge of Lung Cancer Screening Guidelines on Perceptions and Utilization of Low Dose CT
Dan Raz, City of Hope, USA

P1.03-054: Quantitative Accuracy and Lesion Detectability of Low-Dose FDG-PET for Lung Cancer Screening
Ivan Tham, National University Cancer Institute Singapore, Singapore

P1.03-055: LuCaS DA: A Lung Cancer Screening Decision Aid to Improve Screening Decisions
Jamie Studts, University of Kentucky, USA

P1.03-056: Implementation of a Prospective Biospecimen Collection Study in an Established Lung Cancer Screening Program
Jacob Sands, Lahey Hospital & Medical Center, USA

P1.03-057: Assessment of Lung Cancer Risk- Regional Respiratory Disease Screening Report in Jilin, China
Jie Zhang, Second Affiliated Hospital of Jilin University, China

P1.03-058: Cost-Effectiveness of CT Screening in the Early Detection of Lung Cancer
Tomasz Szczęsny, Franciszek Łukaszczyk Memorial Oncological Center in Bydgoszcz, Poland

P1.03-059: Organized High Risk Lung Cancer Screening in Ontario, Canada: A Multi-Centre Prospective Evaluation
Martin Tammemägi, Brock University, Canada

P1.03-060: Lung Cancer Screening: A Qualitative Study Exploring the Decision to Opt Out of Screening
Lisa Carter-Harris, Indiana University, USA

P1.03-061: Patient Motivations for Pursuing Low-Dose CT Lung Cancer Screening in an Integrated Healthcare System: A Qualitative Evaluation
Joshua Roth, Fred Hutchinson Cancer Research Center, USA

P1.03-062: Lung Cancer Screening with Low-Dose CT in China: Study Design and Baseline Results from the First Round Screening Arm
Baohui Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.03-063: Quantitative Imaging Features Predict Incidence Lung Cancer in Low-Dose Computed Tomography (LDCT) Screening
Matthew Schabath, H Lee Moffitt Cancer Center and Research Institute, USA

P1.03-064: Chest X-Ray (CXR) Screening Improves Lung Cancer (LC) Survival in the Prostate Lung Colon and Ovary (PLCO) Randomized Population Trial (RPT)
John Paul Flores, Tufts Medical Center, USA

P1.03 RADIOLOGY/STAGING/SCREENING - STAGING
P1.03-065: Comparison of the Proposed IASLC 8th TNM Lung Cancer Staging System to the 7th Edition
Kwun Fong, University of Queensland Thoracic Research Centre, Australia

P1.03-066: Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer TNM Staging
Gavitt Woodard, University of California, USA

P1.03-067: Validation of the IASLC 8th Edition (8E) TNM Classification for Non-Small Cell Lung Cancer by the Quality of Surgical Resection in a US Cohort
Matthew Smeltzer, University of Memphis School of Public Health, USA

P1.03-068: Impact of Positive Pleural Lavage Cytology or Malignant Effusion on Survival in Patients Having Lung Resection for NSCLC
Tomohiro Obata, Nagasaki Graduate School of Medicine, Japan

P1.03-069: EGFR Mutations Have Greater Influence on Survival Than Proposed M Descriptors of New TNM Classification for Lung Cancer
Karmen Stanic, Institute of Oncology, Slovenia

P1.03-070: The Impact of Advances in Systemic Staging on the Rate of Metachronous and Synchronous Metastases in Patients Lung Cancer
Kyle Wang, University of North Carolina Hospitals, USA

P1.03-071: Impact of Visceral Plural Invasion to T Descriptors: Based on the Forthcoming Eighth Edition of TNM Classification for Lung Cancer
Mikiko Suzuki, Juntendo University School of Medicine, Japan

P1.03-072: Mediastinal Lymphnodes Staging by PET CT for Resectable Non-Small Cell Lung Cancer in a Tuberculosis Endemic Country
VinayaKumar J R, IRCH, All India institute of Medical Sciences(AIIMS), India

P1.03-073: Predictors for Pathological N1 and N2 Disease in Clinical N1 Non-Small-Cell Lung Cancer
Takayuki Fukui, Nagoya University, Japan

P1.03-074: Combined Use of PET/CT and Clinical Features Yields a Higher Diagnostic Rate of Mediastinal Lymph Node Metastasis in Lung Adenocarcinoma
Miao Huang, Peking University Cancer Hospital and Institute, China

P1.03-075: Predictive Factors for Minimal Pleural Disease Detected at Thoracotomy or Positive Lavage Cytology
Akira Sakurada, Institute of Development, Aging and Cancer, Japan

P1.03-076: Nodal Staging of Patients with Pulmonary Malignancies - The Predictive Value of Different Patterns of Mediastinal 18FDG-PET Activity
Socrates Angelides, Westmead Hospital, Australia

P1.03-077: Analysis of the Early CDT-Blood Biomarker for Lung Cancer in Higher vs. Lower Risk Cohorts
James Finigan, National Jewish Health, USA

P1.03-078: Size Matters…but Don’t Underestimate the Power of Morphology
Annemie Snoeckx, Antwerp University Hospital & Antwerp University, Belgium
P1.03-079: Adequacy of Percutaneous Lung Biopsy for Assessing Clinically Requested Genetic Mutations in Lung Cancer
Livia Maria Frota Lima, MD Anderson Cancer Center, USA

P1.03-080: The SUVmax Ratio of Two Tumors on PET/CT May Differentiate Separate Primary Lung Cancers and Intrapulmonary Metastases
Yi Liu, The Chinese People's Liberation Army General Hospital, China

P1.03-081: Synchronous Triple Malignant Tumors of the Lung: A Case Report of Two Lung Adenocarcinomas, and Mucosa-Associated Lymphoid Tissue Lymphoma
Xun Wang, Nanjing Medical University Wuxi No.2 People's Hospital, China

P1.03-082: 18F-FDG PET/CT Value Staging NSCLC Extension to the Lymph Nodes, Single Center Experience
Ruta Vosyliute, Vilnius University, Lithuania

P1.03-083: Advances in Surgical Staging of NSCLC
Prakash Balakrishnan, Wellington Regional Hospital, New Zealand

P1.03-084: Implications of 8th Edition TNM Proposal: Invasive vs. Total Size for T Descriptor in pT1a-2bN0M0 Lung Adenocarcinoma
Takashi Eguchi, Memorial Sloan Kettering Cancer Center, USA

P1.04: PULMONOLOGY

P1.04-001: EGFR, EML4-ALK, ROS 1 and BRAF Testing in Austrian Patients with NSCLC: A Multicentre Study
Sophia Holzer, Otto Wagner Hospital, Austria

P1.04-002: Positive Airway Pressure-Enhanced CT to Improve Virtual Bronchoscopic Navigation
Marta Diez-Ferrer, Hospital Universitari de Bellvitge, Spain

P1.04-003: Incidence of Non-Caseating Granulomas Diagnosed in PET Avid Mediastinal/Hilar Nodes in Patients with Known Breast Cancer
Rabih Bechara, Cancer Treatment Centers of America, USA

P1.04-004: Bronchoscopic Cryosurgery with Carbon Dioxide; Experience in an Oncology Clinic in Colombia
Jaime Echeverri, Oncólogos del Occidente S.A., Colombia

P1.04-005: Efficacy of Photodynamic Therapy Combined with a Guide Sheath Method in Lung Cancer Patients with Endobronchial Stenosis
Masafumi Misawa, Kameda Medical Center, Japan

P1.04-006: Second Primary Lung Cancer: Five Years of a Single Center Experience in Its Diagnosis and Treatment
Fatmir Caushi, University Hospital of Lung Diseases, Albania
P1.04-007: Y Stents in Malignant Tumours - Long Time Follow up and Survival
Vitezslav Kolek, University Hospital, Czech Republic

P1.04-008: Tumor Pentaplicity - Case Report
Petra Smičková, The University Hospital of Olomouc, Czech Republic

P1.04-009: Bacterial Population Dynamics in Colonization of Airway Stents in Patients with Cancer
Antoni Rosell, Hospital Universitari de Bellvitge, Spain

P1.04-010: Neutrophil to Lymphocyte, Platelet to Lymphocyte Ratios and Systemic Inflammation in Lung Cancer Stages
Erhan Ionela Mihaela, Marius Nasta Institute of Pulmonology, Romania

P1.04-011: Demographic, Clinical and Survival Characteristics of Lung Cancer among Elderly Patients in Turkey
Guntulu Ak, ESOGU, Turkey

P1.04-012: Single Center Experience with Nivolumab Administration in NSCLC Patients from EAP Program
Milos Pesek, Charles University in Prague, Czech Republic

P1.04-013: Diagnostics and Treatment of ALK-Positive NSCLC Patients - A Single Center Experience
Milos Pesek, Charles University in Prague, Czech Republic

P1.04-014: Diagnostic Yield in Patients Undergoing Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Diagnosis of Lung Cancer
Sunkaru Touray, University of Massachusetts Medical School, USA

P1.04-015: Clinical Application of Virtual Navigated Bronchial Intervention
Naohiro Kajiwara, Tokyo Medical University, Japan

P1.04-016: EBUS plus Fluoroscopy-Guided Biopsy Compared to Fluoroscopy-Guided TBB for Obtaining Samples of Peripheral Pulmonary Lesions
Jian Ye, Affiliated Hangzhou Hospital of Nanjing Medical University, China

P1.04-017: The Survival of Our Patients Diagnosed with Lung Cancer in 2013
Sedat Altin, Yedikule Chest Diseases and Chest Surgery Hospital, Turkey

P1.04-018: Occurrence of Triple Multiple Malignancies with Last Lung Squamous Cell Carcinoma - Case Reports
Anna Romaszko, University of Warmia and Mazury, Poland

P1.04-019: Final Analysis of Lung Microbiome from Patients Undergoing Bronchoscopy
Glen Weiss, Western Regional Medical Center, Cancer Treatment Centers of America, USA

P1.04-020: Management of Lung Cancer in Patients with past Pulmonary Tuberculosis and Their Possible Causative Link
Fatmir Caushi, University Hospital of Lung Diseases, Albania

P1.04-021: Medical Thoracoscopy for the Diagnosis and Management of Pleural Effusions: Results of a Retrospective Analysis
Sofia Tsagouli, Medical School, University of Athens, Greece
P1.04-022: Use of Alternative Therapy in Patients with Lung Cancer
Kristina Krpina, KBC Rebro, Croatia

P1.04-023: Thrombomodulin Inhibits the Growth and Angiogenesis of Human Lung Cancer via Blocking VEGFR2-Mediated JAK/STAT3 Signaling Pathway
Shun Lu, Shanghai Chest Hospital, China

P1.04-024: Molecular Profiling and Survival of Primary Pulmonary Neuroendocrine Carcinoma with Completely Resection
Zhengbo Song, Zhejiang Cancer Hospital, China

P1.04-025: The Impact of Emergency Presentation on Survival of Lung Cancer Patients
Marko Jakopovic, University Hospital Center, Croatia

P1.04-026: Coexisting Lung Cancer and Interstitial Lung Disease: A Challenge in Clinical Practice
Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

P1.04-027: Changes in Pulmonary Function in Lung Cancer Patients after Thoracic Surgery
Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

P1.04-028: Collection of ICHOM-Defined Patient-Reported Outcome Measures (PROMs) during Routine Lung Cancer Treatment: A Pilot Study
Jan van Meerbeeck, Antwerp University Hospital, Belgium

P1.05 EARLY STAGE NSCLC

P1.05 EARLY STAGE NSCLC - TRANSLATIONAL RESEARCH & BIOMARKERS

P1.05-001: Creation and Early Validation of Prognostic miRNA Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium
David Harpole, Duke University Medical Center, USA

P1.05-002: The Prognostic Impact of EGFR Mutation Status and Mutation Subtypes in Patients with Surgically Resected Lung Adenocarcinomas
Kazuya Takamochi, Juntendo University School of Medicine, Japan

P1.05-003: Coexpression of CD8a and PD-L1 Frequently Observed in Resected NSCLC Tumors from Smokers
Aaron Lisberg, UCLA Medical Center, USA

P1.05-004: Surfactant Protein C is a Prognostic Marker in Resected Non-Small Cell Lung Cancer
Ivan Macía, Hospital Universitari de Bellvitge. IDIBELL, Institut d'Investigació Biomèdica de Bellvitge, Spain

P1.05-005: Programmed Death-Ligand 1 (PD-L1) in Resected Lung Adenocarcinomas (LA) in a University Hospital
Maria Álvarez, Hospital Universitario Miguel Servet, Spain

P1.05-006: Identification of miRNAs and mRNAs Associated with Metastasis in Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Shirley Tam, University Health Network, Canada
P1.05-007: Analysis of RNA Sequencing Data along with PET SUV-max Can Discover Novel Gene Sets Which Can Predict Surgical Outcome of NSCLC
Young Tae Kim, Seoul National University Hospital, South Korea

P1.05-008: Detection of EGFR Mutations in Pulmonary Vein and Peripheral Blood Plasma Cell-Free DNA for Analysis of Surgical Treatment in Early-Stage NSCLC
Chengliang Yang, Shenyang tenth People's Hospital & Shenyang Chest Hospital, China

P1.05-009: Clinical Value of Circulating Tumor Cell in the Differential Diagnosis of Solitary Pulmonary Nodule
Lin Wang, Shanghai Chest Hospital, China

P1.05-010: Aberrant Promoter Methylation of ESR1 and CDH13 Gene Are an Independent Prognostic Marker in Surgically Resected Non-Small Cell Lung Cancer
Milica Kontic, Clinical Centre of Serbia, Serbia

P1.05-011: Comparative Analysis of TTF-1 Copy Number Alterations and Protein Expression in Patients with Non-Small Cell Lung Cancer
Katsuhiro Yoshimura, Hamamatsu University School of Medicine, Japan

P1.05-012: The Impact of EGFR Mutations on the Prognosis of Patients with Resected Stage I Lung Adenocarcinoma
Jiro Kitamura, Massachusetts General Hospital, USA

P1.05-013: Lung Tumorspheres as a Platform for Testing New Therapeutic Strategies in Non-Small Cell Lung Cancer
Eloisa Jantus-Lewintre, Fundación Investigación Hospital General Universitario, Spain

P1.05-014: Stemness Gene Expression Profile of Tumorspheres from Non-Small Cell Lung Cancer
Eloisa Jantus-Lewintre, Fundación Investigación Hospital General Universitario, Spain

P1.05-015: Genomic Characterisation of Non-Small Cell Lung Cancer in an Australian Population
Brielle Parris, University of Queensland Thoracic Research Centre, The Prince Charles Hospital, Australia

P1.05-016: Circulating BARD1 Antibodies for Early Detection of Lung Cancer
Irmgard Irminger-Finger, University Hospitals Geneva, Switzerland

P1.05-017: The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas
Bonnie Gould Rothberg, Yale University School of Medicine, USA

P1.05-018: LncRNA16 is a Potential Biomarker for Early-Stage Lung Cancer That Promotes Cell Proliferation by Regulating the Cell Cycle
Xing Wang, Peking University Cancer Hospital & Institute, China

P1.05-019: Two Inflammatory Biomarkers MDC/CCL22 and BLC/CXCL13 Are Independently Associated with the Significant Risk of Early Stage Lung Adenocarcinoma
Baohui Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.05-020: Opposing Prognostic Roles of CD73 and A2A Adenosine Receptor in Non-Small-Cell Lung Cancer
Yusuke Inoue, Hamamatsu University School of Medicine, Japan
P1.05-021: circRNAs: Potential Novel Biomarkers for the Early Detection of Lung Cancer
Steven Gray, LabMed Directorate, Ireland

P1.05-022: Circulating Tumor Cell Isolation to Monitor NSCLC Patients over the Course of Treatment
Julia Herrmann, SRH Wald-Klinikum Gera, Germany

P1.05-023: Induction of Patient-Derived Xenograft Formation and Clinical Significance for PD-L1 in Lung Cancer Patients
Jiahui Si, Peking University Cancer Hospital & Institute, China

P1.05-024: Preoperative Neuron-Specific Enolase to Albumin Ratio is a Prognostic Biomarker for Patients with Operable Non-Small-Cell Lung Cancer
Hong Ren, The First Affiliated Hospital of Xi'an Jiaotong University, China

P1.05-025: Prognostic Significance of Hepatitis B Virus to Stage IB Non-Small Cell Lung Cancer Patients in China
Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.05-026: High Resolution Metabolomics on Exhaled Breath Condensate to Discover Lung Cancer's Biomarker
Sung Yong Lee, Korea University Medical Center, South Korea

P1.05-027: Novel Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma: A Study by the SPECS Lung Consortium
William Richards, Brigham and Women's Hospital, USA

P1.05-028: Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC)
Lorenzo Federico, MD Anderson Cancer Center, USA

**P1.05 EARLY STAGE NSCLC - SBRT**

P1.05-029: SABRTOOTH-A Feasibility Study of SABR Compared to Surgery in Patients with Peripheral Stage I NSCLC Considered to Be at Higher Risk from Surgery
Kevin Franks, Leeds Teaching Hospitals/University of Leeds, UK

P1.05-030: Lung SABR for Early Stage Lung Cancer: Outcomes and Toxicity of 803 Patients Treated at the Leeds Cancer Centre
Patrick Murray, St James’ University Hospital, UK

P1.05-031: Primary Results of Dose Escalated Stereotactic Body Radiotherapy for Stage IA Non-Small Cell Lung Cancer
Takafumi Komiyama, University of Yamanashi School of Medicine, Japan

P1.05-032: Quality of Life after Stereotactic Body Radiotherapy and Surgery in Patients with Early Stage Non-Small Cell Lung Cancer
Elisabeth Kastelijn, St. Antonius Hospital, Netherlands

P1.05-033: Comparison of Single- and Five-Fraction Schedules of Stereotactic Body Radiation Therapy for Central Lung Tumors
Sung Jun Ma, Roswell Park Cancer Institute, USA
P1.05-034: Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios as Prognostic Biomarkers in Early NSCLC Patients Treated with SABR
Stephen McKay, Beatson West of Scotland Cancer Centre, UK

P1.05-035: SABR for Medically Inoperable Early Stage NSCLC at the Beatson West of Scotland Cancer Centre: Outcomes and Toxicity
Stephen McKay, Beatson West of Scotland Cancer Centre, UK

P1.05 EARLY STAGE NSCLC - SURGERY

P1.05-036: A Propensity-Matched Study of Multi-Port versus Single-Port Video-Assisted Thoracoscopic Surgery for Early Lung Cancer
Kyoji Hirai, Nippon Medical School Chiba Hokusoh Hospital, Japan

P1.05-037: Histopathologic Results of Surgically Resected Pure Ground-Glass Opacity Lung Nodules
Geun Dong Lee, Gangnam Severance Hospital, Yonsei University College of Medicine, South Korea

P1.05-038: Patterns of Recurrence in Curatively Resected Stage I Lung Cancer
Kanghoon Lee, Asan Medical Center, University of Ulsan College of Medicine, South Korea

P1.05-039: Recurrence and Survival Outcome after Segmentectomy for Non-Small Cell Lung Cancer: A Long-Term Follow-Up Study at a Single Institute
Takamasa Koga, Kumamoto University Hospital, Japan

P1.05-040: Prognostic Factor of Node Involvement Pattern in Completely Resected pN1 Squamous Cell Carcinoma Patients
Kenta Tane, Hyogo Cancer Center, Japan

P1.05-041: Dynamics of Brain Metastasis for Curatively Resected Stage I or II Non-Small Cell Lung Cancer Patients
Sumin Shin, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

P1.05-042: Treatment Strategy of Limited Surgery for Early Lung Cancer
Katsuo Kojima, Musashino Red-Cross Hospital, Japan

P1.05-043: Survival Following Surgical Resection of Lung Adenocarcinoma Stratified According to Morphological Sub-Type
Haval Balata, University Hospitals of South Manchester, UK

P1.05-044: The Impact of IASLC 8th Edition Updates for T-Classification for Lung Cancer in a US Population-Based Surgical Resection Cohort
Matthew Smeltzer, University of Memphis School of Public Health, USA

P1.05 EARLY STAGE NSCLC - NEOADJUVANT AND ADJUVANT CHEMOTHERAPY

P1.05-045: Adjuvant Chemotherapy for Patients with Stage IB Non Small Cell Lung Cancer
Jia Wang, Beijing Cancer Hospital, China

P1.05-046: Randomized Study of Adjuvant Docetaxel vs. Observation for Completely Resected StageIIB-IIIA NSCLC with 11 Years' Median Follow-Up
Wen-zhao Zhong, Department of Pulmonary Oncology; Guangdong General Hospital & Guangdong Academy of Medical Sciences, China
P1.05-047: Early Mortality in Patients with Non-Small Cell Lung Cancer Undergoing Adjuvant Chemotherapy
Daniel Morgensztern, Washington University School of Medicine, USA

P1.05-048: Effect of Adjuvant Chemotherapy on the Patterns and Dynamics of Recurrences in Resected Stage II(N1) Lung Adenocarcinoma
Byung Jo Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

P1.05-049: Neoadjuvant Erlotinib Treatment in Patients with Resectable Non-Small Cell Lung Carcinoma
Matthijs Van Gool, NKI-AVL, Netherlands

P1.05-050: External Validation of a Prognostic Model for Squamous-Cell Lung Cancer and Impact of Adjuvant Treatment in >1,300 Patients
Emilio Bria, University Oncology Unit, Department of Medicine, Italy

P1.05-051: Safety and Compliance Data of the Phase III Study of Adjuvant Chemotherapy in Completely Resected P-Stage I Non Small Cell Lung Cancer: JCOG0707
Hiroyuki Sakurai, National Cancer Center Hospital, Japan

P1.05-052: An Exploratory Analysis of Postoperative Adjuvant Chemotherapy with Tegafur-Uracil on Survival for Lung Adenocarcinoma
Masahiro Tsuboi, National Cancer Center Hospital East, Japan

P1.05-053: Impact of Gender Difference on Adjuvant Chemotherapy after Radical Resection in Patients with Non-Small Cell Lung Cancer
Lu Yang, Peking Union Medical College, China

P1.05-054: Adjuvant Chemotherapy Uptake in Patients with NSCLC after Complete Resection: Single Institution/Single Area Experience
Vitezslav Kolek, University Hospital, Czech Republic

P1.05 - EARLY STAGE NSCLC - RECURRENCE

P1.05-055: Risk Factors of Postoperative Recurrence in Stage IA and IB Patients
Fumihiko Hoshi, Tohoku University Hospital, Japan

P1.05-056: Increased Risk of Postoperative Recurrence in EGFR-Positive Stage IA to IB Invasive Lung Adenocarcinoma
Masaoki Ito, Hiroshima University Hospital, Japan

P1.05-057: Prediction of Early Recurrence in Patients with Stage I and II Non-Small Cell Lung Cancer Using FDG PET Quantification
Sven Hillinger, University Hospital, Switzerland

P1.05-058: Prognostic Factors of Post-Recurrence Survival in Resected Stage I Non-Small Cell Lung Cancer
Yasuaki Kubouchi, Tottori University, Faculty of Medicine, Japan

P1.05-059: Factors Associated with Recurrence and Survival in Patients with Curatively Resected Stage IA Adenocarcinoma of the Lung
Masahiko Harada, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan
P1.05 EARLY STAGE NSCLC - MISCELLANEOUS

P1.05-060: Adherence to Surveillance Guidelines in Resected NSCLC: Physician Compliance and Impact on Outcomes
Cheryl Ho, BC Cancer Agency, Canada

P1.05-061: Increased Treatment-Related Toxicity in Patients with Early-Stage Non-Small Cell Lung Cancer and Co-Existing Interstitial Lung Disease
Hanbo Chen, London Health Sciences Centre, Canada

P1.05-062: Is Lung Microwave Thermoablation a Valid Alternative to Surgery in High Risk Patients? A Propensity Match Analysis
Paolo Mendogni, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Italy

P1.05-063: Multicenter Observational Study of Patients with Resected Early-Staged NSCLC, Who Were Excluded from an Adjuvant Chemotherapy Trial
Tomoyuki Hishida, National Cancer Center Hospital East, Japan

P1.05-064: Global Practice Patterns of Multifocal Lung Cancer
Aaron Mansfield, Mayo Clinic, USA

P1.05-065: Usage of Chest Radiography or Computed Tomography in Post-Treatment Surveillance for Stage I and II NSCLC: Influence on Survival
Leonie Alberts, St. Antonius hospital, Netherlands

P1.05-066: Impact of Micropapillary Pattern in Nodal Upstaging of Lung Adenocarcinoma 2cm or Less
Hirotsgu Yamazaki, Kitasato University School of Medicine, Japan

P1.05-067: Consultation with Medical Oncology Less Common in Elderly Patients with Resected Stage II Nonsmall Cell Lung Cancer
Gail Darling, Cancer Care Ontario, Canada

P1.05-068: Elderly Patients with Resected Stage II Nonsmall Cell Lung Cancer Are Less Likely to Have a Consultation with a Medical Oncologist
Gail Darling, University of Toronto, Canada

P1.05-069: Stage II NSCLC Treated with Non-Surgical Approaches: A Multi-Institution Report of Outcomes
Shaan Dudani, University of Ottawa, Canada

P1.05-070: Diagnostic Yield and Efficacy of EBUS TBNA in Molecular Testing for NSCLC Mutations
Shashank Nuguru, IU Health, USA

P1.05-071: A Review of Quality of Life Measures Used in Lung Cancer Surgical Outcomes
Rowena Yip, Icahn School of Medicine, USA

P1.05-072: Predictors and Patterns of Lymph Node Metastasis in Small Peripheral Non Small Cell Lung Cancer
Jun-tao Lin, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, China
P1.05-073: Evaluation of Stage 1 Sub-Solid Lung Nodules Using PET Imaging
Claudia Henschke, Icahn School of Medicine at Mount Sinai, USA

P1.05-074: Factors Predicting Discordance between Clinical and Surgical-Pathologic Staging in Operable Non-Small Cell Lung Cancer
Kostas Syrigos, Medical School, University of Athens, Greece

P1.05-075: The Correlation between the Prognoses of Patients with Non-Small Cell Lung Cancer and Preoperative Platelet- Lymphocyte Ratio
Shunta Ishihara, Ayabe City Hospital, Japan

P1.05-076: Risk Factors in Patients with Pathological Stage I Non-Small Cell Lung Cancer
Yoshimasa Tokunaga, Kochi Health Sciences Center, Japan

P1.05-077: Outcome of N2 Disease in NSCLC - A Single Institution Experience
Marko Jakopović, University hospital center Zagreb, Croatia

P1.05-078: The Relationship between IASLC/ATS/ERS Grading System of Adenocarcinoma of the Lung and Quantitive PET Parameters
Kyle Wang, University of North Carolina Hospitals, USA

P1.05-079: Lung Cancer in the Elderly: Factors Affecting Long-Term Survival Following Resection
Prakash Balakrishnan, Wellington Regional Hospital, New Zealand

1.06 ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY

P1.06-001: Sluga R, Roepman P, Kummer A, vd Bosch W, vd Borne BEEM, Schramel FMNH
Romina Sluga, St. Antonius Hospital, Netherlands

P1.06-002: Contralateral Axillary Lymph Node Metastasis of a Lung Cancer: A Case Report
Omer Giray Intepe, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Turkey

P1.06-003: Anamorelin in Cachectic Patients with Advanced NSCLC, a Post-Hoc Pooled Efficacy Data Analysis of Two Phase 3 Trials
David Currow, Flinders University, Australia

P1.06-004: Evaluating the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ): Preliminary Results from the Quantitative Pilot Study
Astra Liepa, Eli Lilly and Company, USA

P1.06-005: An International Cohort of Patients with Small Cell Lung Carcinoma Oncogene or Non-Oncogene Addicted
Matteo Giaj Levra, Michallon University Hospital, France

P1.06-006: Treatment beyond Progression in Patients with Advanced Squamous NSCLC Participating in the Expanded Access Programme (EAP)
Frederico Cappuzzo, AUSL Romagna, Italy
P1.06-007: Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Cancer (NSCLC)
Oscar Arrieta, Instituto Nacional de Cancerologia, Mexico

P1.06-008: Non-Small Cell Lung Cancer in Octogenarians: Real-Life Clinical Practice; Characteristics, Therapy and Survival
Hirsh Koyi, Gävle Hospital, Sweden

P1.06-009: Determining Optimal Array Layouts for Delivering TTFields to the Lungs Using Computer Simulations
Zeev Bomzon, Novocure Ltd., Israel

P1.06-010: Analysis of the Incidence of Cancer Cachexia in Patients with Advanced Lung Cancer at Referral to a Dietitian
Adele Hug, Royal Surrey County Hospital, UK

P1.06-011: Altered Body Composition and Fat Loss in Advanced Non-Small Cell Lung Cancer
Anant Mohan, All India Institute of Medical Sciences, India

P1.06-012: Central and Peripheral Lung Adenocarcinomas Exhibit Different Timing and Predilection for Distant Metastasis
Judit Moldvay, National Koranyi Institute of Pulmonology, Hungary

P1.06-013: Patient Characteristics and Survival: A Real-World Analysis of US Veterans With Stage IV Adenocarcinoma vs Squamous NSCLC
Monika Parisi, Celgene Corporation, USA

P1.06-014: What Factors Determine Treatment Satisfaction in Patients with Advanced NSCLC Receiving Chemotherapy?
Sabine Visser, Erasmus MC Cancer Institute, Netherlands

P1.06-015: Designing Transducer Arrays for the Delivery of TTFields Whilst Maximizing Patient Comfort and Field Intensity in the Thorax
Zeev Bomzon, Novocure Ltd., Israel

P1.06-016: Pulmonary Tuberculosis among Newly Diagnosed-Therapy Naive Advanced NSCLC in Persahabatan Hospital Jakarta Indonesia
Sita Laksmi Andarini, Faculty Of Medicine Universitas Indonesia, Indonesia

P1.06-017: Observational Study on Prolonged Disease Stabilization in Advanced NSCLC EGFR WT/Unknown Patients Treated with Erlotinib in Second Line
Francesco Grossi, IRCCS AOU San Martino - IST, Italy

P1.06-018: Treatment Patterns and Clinical Practices of Advanced (Stage IV) Non-Small Cell Lung Cancer (NSCLC) in Europe - A Structured Literature Review
Thomas Brodowicz, Medical University Vienna - General Hospital, Austria & Central European Cooperative Oncology Group, Austria

P1.06-019: The Possibility of the Additional Local Therapy to Systemic Chemotherapy in Advanced Lung Cancer Cases with Multiple Metastases
Takeshi Honda, Teikyo University, Japan
P1.06-020: Prevalence of Autoimmune Disease in US Veterans With Non-Small Cell Lung Cancer (NSCLC)
Monika Parisi, Celgene Corporation, USA

P1.06-021: Treatment Patterns and Healthcare Resource Use from a Retrospective Cohort of Japanese Patients with Advanced Non-Small Cell Lung Cancer
Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Japan

P1.06-022: Clinical Characteristics of Survival Outliers in Stage IV Adenocarcinoma Lung Cancer Patients
Andrea Fung, University of Calgary, Canada

P1.06-023: Clinicopathological Characteristics of Axillary Lymph Node Metastasis in Lung Cancer
Yue Kong, Zhejiang Cancer Hospital, China

P1.06-024: Distinctive Patterns of Primary Metastases and Clinical Outcomes According to the Histological Subtypes in Stage IV Non-Small Cell Lung Cancer
Dong Soo Lee, College of Medicine, The Catholic University of Korea, South Korea

P1.06-025: Analysis of Risk Factors for Development of Skeletal-Related Events in Women with Bone Metastases from NSCLC and Breast Cancer
Franco Lumachi, University of Padua, School of Medicine, Italy

P1.06-026: Adenosquamous Carcinoma of the Lung: A Single Institution Experience in the Era of Molecular Testing
Kamal Kishore Mandalapu, Merit Health Biloxi., USA

P1.06-027: Retrospective Study of Treatment for Postoperative Local Recurrence of Lung Cancer
Kenjiro Tsuruoka, Osaka Medical College Hospital, Japan

P1.06-028: Description of the Patients with Advanced Squamous NSCLC Treated in a Single Institution
Irene Torres, Hospital Universitario Miguel Servet, Spain

P1.06-029: Epidemiologic, Clinical Characteristics and Therapeutic Strategy of Elderly NSCLC Patients Treated in a Single Institution
Nektarios Alevizopoulos, Evaggelismos General Hospital, Greece

P1.06-030: Extended Lymph Node Dissection through Median Sternotomy in N3 Left NSCLC Surgical Results and Anatomical Findings
Shingo Ikeda, Mitsui Memorial Hospital, Japan

P1.06-031: A North Malaysia Pulmonology Center Experience in Management of Advanced Non-Small Cell Lung Cancer
Syazatul Syakirin Sirol Aflah, Hospital Sultanah Bahiyah, Malaysia

P1.06-032: The Humanistic Burden of Advanced Non-Small Cell Lung Cancer Patients in Europe - A Real World Survey
Oana Chirita, Bristol-Myers Squibb, UK

P1.06-033: Non-Small Cell Lung Cancer in Young Patients; Clinico-Pathologic Criteria and Prognostic Factors
Hala Aziz, National Cancer Institute, Egypt
P1.06-034: Outcomes after Pulmonary Metastasectomy for Metastatic Cancer
Prakash Balakrishnan, Wellington Regional Hospital, New Zealand

P1.06-035: Frequency and Clinical Relevance of EGFR-Mutations and EML4-ALK-Translocations in Octogenarians with NSCLC
Amanda Tufman, Ludwig Maximilian University of Munich, Germany

P1.06-036: Post-Recurrence Survival Analysis of Stage I Non-Small Cell Lung Cancer: Prognostic Significance of Local Treatment
Kanghoon Lee, Asan Medical Center, University of Ulsan College of Medicine, South Korea

P1.06-037: Non-Small Cell Lung Cancer Invading the Diaphragm: Outcome and Prognostic Factors
Domenico Galetta, European Institute of Oncology, Italy

P1.06-038: Survival and Prognostic Factors of Oligometastatic Non-Small Cell Lung Carcinoma: A Single Center Experience
Ugur Yilmaz, Ankara Atatürk Chest Disease and Thoracic Surgery Training and Research Hospital, Turkey

P1.06-039: Retrospective Study of the Incidence and Outcomes from Lung Cancer That Developed Following a Solid Organ Transplant
Kelvin Young, Princess Margaret Cancer Centre, Canada

P1.06-040: Home-Based Pulmonary Rehabilitation in Advanced Non Small Cell Lung Cancer Patients Treated by Oral Targeted Therapy: A Feasibility Study
Caroline Pagniez, Hospital of the University (CHRU) of Lille, France

P1.06-041: Overall Survival and Intermediate Outcomes among Scandinavian Non-Small Cell Lung Cancer Patients: The SCAN-LEAF Study
Maria Planck, Lund University, Sweden

P1.06-042: The Importance of Medication Related Osteonecrosis of the Jaws (MRONJ)
Mark Krasnik, Rigshospitalet, Denmark

P1.06-043: A Study to Select Rational Therapeutics in Subjects with Advanced Malignancies (WINHER) - The Sheba Experience in Lung Cancer Patients
Amir Onn, Sheba Medical Center, Israel

P1.06-044: Costs of Adverse Events (AE) Associated with Cancer Therapies in Non-Small Cell Lung Cancer (NSCLC) in France
Christos Chouaid, Centre Hospitalier Intercommunal Créteil, France

P1.06-045: Multiple Neoplasms Consist of Lung Cancer and Hematological Malignancies
Kazuhiko Natori, Toho University Medical Center Oomori Hospital, Japan

P1.06-046: Can We Better Manage Advanced NSCLC in the Elderly with the New Therapeutic Agents? Preliminary Analysis of a Real-Life Multicenter Study
Tindara Franchina, Department of Human Pathology, University of Messina and Medical Oncology Unit, A.O. Papardo, Italy
P1.06-047: Management of Patients Aged over 70 Years with Newly Diagnosed Lung Cancer
Haider Abbas, Birmingham Heartlands Hospital, UK

P1.07 SCLC/NEUROENDOCRINE TUMORS

P1.07 SCLC/NEUROENDOCRINE TUMORS - DRUG TREATMENT ALONE AND IN COMBINATION WITH RADIOTHERAPY

P1.07-001: A Phase II Study of Etirinotecan Pegol (NKTR-102), a Topoisomerase-I Inhibitor Polymer Conjugate, in Small Cell Lung Cancer
Hongbin Chen, Roswell Park Cancer Institute, USA

P1.07-002: GI1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results
Lowell Hart, Florida Cancer Specialists, USA

P1.07-003: A Phase II Study Evaluating the Combination of Everolimus with Carboplatin/Paclitaxel as 1st Line Treatment in Patients with Advanced LCNEC
Christian Grohé, Evangelische Lungenklinik, Germany

P1.07-004: Updated Analysis of Phase II Study of HA-Irinotecan, a CD44-Targeting Formulation of Hyaluronic Acid and Irinotecan, in Small Cell Lung Cancer
Muhammad Alamgeer, Monash Cancer Centre, Australia

P1.07-005: A Retrospective Study of Sequential Chemoradiotherapy for LD-SCLC Patients in Whom Concurrent Therapy is Not Indicated
Sayaka Ohara, NTT Medical Center Tokyo, Japan

Bart Hendriks, Merrimack Pharmaceuticals, Inc., USA

P1.07-007: Clinical Outcomes of Patients with LS-SCLC Treated with Chemoradiotherapy. Can We Find Candidates for Salvage Surgery?
Junichi Shimizu, Aichi Cancer Center Hospital, Japan

P1.07-008: Lomustine Endoxan VP16 as Second or Further Line for Recurrent or Progressive Brain Metastases from SCLC
Pascal Dô, Baclesse, France

P1.07-009: Outcomes of Patients with Relapsed Small-Cell Lung Cancer Treated with Paclitaxel plus Gemcitabine. 10 Year-Analysis
Ana Laura Ortega Granados, Complejo Hospitalario de Jaén, Spain

P1.07-010: Influence of Creatinine Clearance on Survival Parameters in Small Cell Lung Cancer Treated with Cisplatin-Based Chemotherapy Regimen
Fatih Kose, Baskent University, Turkey

P1.07-011: Extensive-Stage Small Cell Lung Cancer in a 13-Year-Old Male Patient Treated with Bevacizumab Followed by High-Dose Chemotherapy
Michihiro Yano, Akita University Hospital, Japan
P1.07-012: Efficacy of Immune Checkpoint Inhibitors in Large Cell Neuroendocrine Lung Cancer: Results from a French Retrospective Cohort
Matteo Giaj Levra, Michallon Hospital - University Hospital, France

P1.07-013: Treatment Related Side Effects of Oral Topotecan in Small Cell Lung Cancer
Marko Jakopovic, University Hospital Center, Croatia

P1.07-014: Impact of Chemotherapy for Small Cell Lung Cancer in the Third Line and beyond, a SEER-MEDICARE Analysis
Taofeek Owonikoko, Emory University Winship Cancer Institute, USA

P1.07-015: STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC
Penella Woll, University of Sheffield, UK

P1.07 SCLC/NEUROENDOCRINE TUMORS - LOCAL TREATMENT

P1.07-016: Trends, Practice Patterns and Underuse of Surgery in the Treatment of Early Stage Small Cell Lung Cancer
Elliot Wakeam, University of Toronto, Canada

P1.07-017: Indications for Adjuvant Mediastinal Radiation in Surgically Resected Small Cell Lung Cancer
Elliot Wakeam, University of Toronto, Canada

P1.07-018: Incidence of Brain Recurrence and Survival Outcomes in High-Grade Neuroendocrine Carcinomas of the Lung: Implications for Clinical Practice
Giannis Mountzios, University of Athens School of Medicine, Greece

P1.07-019: Large Cell Neuroendocrine Carcinoma of the Lung: Prognostic Factors of Survival and Recurrence after R0 Surgical Resection
Maria Cattoni, Swedish Cancer Institute, USA

P1.07-020: Surgical Resected Small Cell Lung Cancers (SCLCs): A Monocentric Retrospective Analysis
Laura Bonanno, Istituto Oncologico Veneto, Italy

P1.07-021: Impact on Survival of High Dose Consolidative Thoracic Radiotherapy in Extensive Stage Small Cell Lung Cancer
Josep Jové, Institut Catala Oncologia, Spain

P1.07-022: The Role of Surgery in Combination Treatment of Patients with Small Cell Lung Cancer
Aleksei Aksarin, Surgut District Clinical Hospital, Russia

P1.07 SCLC/NEUROENDOCRINE TUMORS - MOLECULAR CHANGES

P1.07-023: NGS May Discriminate Extreme Long-Term versus Short-Term Survival in Patients with Stage IV Small-Cell Lung Cancer (SCLC)
Zoltan Lohinai, Medical University Vienna, Austria

P1.07-024: EGFR Mutations in Small Cell Lung Cancer (SCLC): Genetic Heterogeneity and Prognostic Impact
Huarong Tang, Zhejiang Cancer Hospital, China
P1.07-025: MiR-495 Promotes Chemoresistance of SCLC through Epithelial-Mesenchymal Transition via Etk/BMX
Linlang Guo, Zhujiang Hospital, Southern Medical University, China

P1.07-026: Activin A is Associated with Poor Prognosis and Promotes Metastatic Growth in Small Cell Lung Cancer
Anita Rozsas, Medical University Vienna, Austria

P1.07-027: 13-Gene Signature of EMT Reveals Impact on Invasion and Metastasis of Neuroendocrine Carcinomas of the Lung: A Preliminary Study
Tabatha Prieto, Faculdade de Medicina da USP, Brazil

P1.07-028: Dual Role of the Focal Adhesion Kinase in Small-Cell Lung Cancer
Frank Aboubakar Nana, Université Catholique de Louvain, Belgium

P1.07-029: In Vitro Effects of Pegylated Arginase in Small Cell Lung Cancer
Shi Xu, The University of Hong Kong, Hong Kong

P1.07-030: Gene Signature of EMT in Neuroendocrine Lung Carcinoma: A Comparative Analysis with Adenocarcinoma and Squamous Cell Carcinoma
Tabatha Prieto, Faculdade de Medicina da USP, Brazil

P1.07-031: Clinical Evaluation of Folate Receptor-Positive Circulating Tumor Cells Detection in Patients with Small Cell Lung Cancer
Chunxia Su, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P1.07-032: Most Common Genomic Alterations in SCLC
Patricia Thompson, Cancer Treatment Centers of America, USA

P1.07-033: Trastuzumab Emtansine (T-DM1) Suppresses the Growth of HER2-Positive Small-Cell Lung Cancer in Preclinical Models
Osamu Morimura, Osaka University Graduate School of Medicine, Japan

P1.07-034: Somatostatin Receptors Expression in Small Cell Lung Cancer Patients
Konstantinos Zarogoulidis, Aristotle University of Thessaloniki, Greece

P1.07-035: Circulating Cell-Free Tumor DNA (cfDNA) Testing in Small Cell Lung Cancer
Daniel Morgensztern, Washington University School of Medicine in St. Louis, USA

P1.07  SCLC/NEUROENDOCRINE TUMORS - PATHOLOGY

P1.07-036: Large Cell Neuroendocrine Carcinoma of the Lung: The Mayo Clinic Experience
Kunlatida Maneenil, Rajavithi Hospital, College of Medicine, Rangsit University, Thailand

P1.07-037: Clinicopathological Significance of Cancer Stem-Like Cell Markers in High-Grade Neuroendocrine Carcinoma of the Lung
Masahiro Morise, Nagoya University Graduate School of Medicine, Japan

P1.07-038: Typical Morphological Features Revealed Unfavorable Survival Benefits in High-Grade Neuroendocrine Carcinomas
Hao-ran Zhai, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences; Southern Medical University, China
P1.07-039: Insulinoma-Associated 1 (INSM1) Immunohistochemical Expression in Lung Neuroendocrine Tumors
Yasuyuki Shigematsu, The Cancer Institute, Japan

P1.07  SCLC/NEUROENDOCRINE TUMORS - PROGNOSTIC FACTORS

P1.07-040: Prognostic Factors in Extensive Disease (ED) Small Cell Lung Cancer (SCLC): An ELCWP Phase III Randomised Trial
Thierry Berghmans, Institut Jules Bordet, Belgium

P1.07-041: Validation of Prognostic Scores in Small Cell Lung Cancer
Sacha Rothschild, University Hospital Basel, Switzerland

P1.07-042: Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios Predict Prognosis in Early-Stage Resected Small-Cell Lung Cancer Patients
Virag Hollosi, National Koranyi Institute of Pulmonology, Hungary

P1.07-043: Patterns of Failure and the Prognostic Factors of the Patients with LD SCLC according to the TNM Staging; TOG-TROD Study
H Fazilet Dinçbaş, Istanbul University, Cerrahpasa Medical Faculty, Turkey

P1.07  SCLC/NEUROENDOCRINE TUMORS - SCLC/NEUROENDOCRINE TUMORS IN GENERAL

P1.07-044: Educational Level and Management in Small-Cell Lung Cancer (SCLC): A Population-Based Study
Salomon Tendler, Karolinska University Hospital, Sweden

P1.07-045: Characteristics of Exceptional Long Term Survivors in Extensive Stage Small Cell Lung Cancer
Kunlatida Maneenil, Rajavithi Hospital, College of Medicine, Rangsit University, Thailand

P1.07-046: Uptake of Recommended Treatment in Small Cell Lung Cancer: Trend over the Last 15 Years and Risk Factors
KM Islam, University of Nebraska Medical Center, USA

P1.07-047: Refusal of Chemoradiotherapy and Chemotherapy among SCLC Patients: Analysis of US National Facility-Based Data
KM Islam, University of Nebraska Medical Center, USA

P1.07-048: Clinical Impact of the Relationship between Post-Progression Survival and Overall Survival in Extensive Disease Small Cell Lung Cancer Patients
Hisao Imai, Gunma Prefectural Cancer Center, Japan

P1.07-049: Limited Stage Small Cell Lung Cancer: Patterns of Care and Outcomes of a Single Institution over 15 Years
Eunji Hwang, Prince of Wales Hospital, Australia

P1.07-050: Patterns of Relapse in Small Cell Lung Cancer (SCLC): A Retrospective Analysis of Outcomes from a Single Canadian Center
Abdulaziz Al Farsi, Juravinski Cancer Center, Canada
P1.07-051: Incidence and Clinical Characteristics of Pulmonary Large-Cell Neuroendocrine Carcinoma: An Overview of Our Own Data
Gordana Drpa, Clinic for Respiratory Diseases "Jordanovac", University Hospital Centre Zagreb, Croatia

P1.07-052: Pulmonary Neuroendocrine Tumors: Single Institution Experience in Brazil
Maria Teresa Tsukazan, Universidade Federal do Rio Grande do Sul - UFRGS, Brazil

P1.07-053: Apatinib for Chemotherapy-Refractory Extensive Stage SCLC: Results from a Single-Center Retrospective Study
Wei Hong, Zhejiang Cancer Hospital, China

P1.07-054: Second Primary Small Cell Carcinoma of Lung in Previously Treated Carcinoma Breast
Prasanta Mohapatra, All India Institute of Medical Sciences, India

P1.07-055: Introducing the US National Cancer Institute's Small Cell Lung Cancer Consortium
Peter Ujhazy, National Cancer Institute, USA

P1.08 SURGERY

P1.08 SURGERY - RISK ASSESSMENT & PROGNOSTIC FACTORS

P1.08-001: Log Odds as a Novel Prognostic Indicator Superior to the Number-Based and Ratio-Based Category for Non-Small Cell Lung Cancer
Dariusz Dziedzic, National Institute of Chest Diseases, Poland

P1.08-002: The Prognostic Significance of Pleural Lavage Cytology before and after Lung Resection
Yohei Yurugi, Tottori University, Japan

P1.08-003: Survival of Lung Cancer Patients wasDepended on Tumor Characteristics, Blood Cell Circuit, Cell Ratio Factors, Hemostasis System
Oleg Kshivets, Saint-Petersburg Clinic, Russia

P1.08-004: Prediction of Surgical Outcome by Modeling Based on Risk Factors of Morbidity Following Pulmonary Resection for Lung Cancer in the Elderly
Yuzhao Wang, Peking University Cancer Hospital & Institute, China

P1.08-005: Stratification of pStage I Lung Adenocarcinoma by the Scoring System Based on Prognostic Factors
Naoya Kawakita, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan

P1.08-006: Prognostic Impact of Incompletely Lobulated Fissures in Non-Small-Cell Lung Cancer
Junichi Okamoto, Nippon Medical School Musashikosugi Hospital, Japan

P1.08-007: The Significant Improvement of Lung Function after Preoperative Rehabilitation in Patients with Thoracic Tumors and Abnormal Spirometry
Maciej Glogowski, The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology, Poland

P1.08-008: Impact of Perioperative Redox Balance on Long-Term Outcome in Patients Undergoing Lung Resection
Osamu Araki, Dokkyo Medical University, Japan
P1.08-009: Does Body Mass Index (BMI) Affect Outcomes Post Lung Resection Surgery?  
Tomoyo Fujiwara, NHS Golden Jubilee National Hospital, UK

P1.08-010: Octogenarians Perform Equally to Younger Patients in Lung Cancer Surgery  
Florian Kocher, Medical University Innsbruck, Austria

P1.08-011: Feasibility of Surgical Resection for Lung Cancer Patients Aged over 85 Years  
Takehiro Ouchi, Juntendo University, Japan

P1.08-012: Characterizing Time to Care for Lung Cancer Surgical Patients  
Michael Humer, Kelowna Thoracic Surgical Group, Canada

P1.08-013: Preoperative Managements for Pulmonary Complications Using Inhalations in Lung Cancer Patients with Chronic Obstructive Pulmonary Disease  
Kyoshiro Takegahara, Nippon Medical School Hospital, Japan

P1.08-014: Usefulness of Chest CT in Follow-Up of Patients with Completely Resected Lung Cancer  
Jefferson Gross, AC Camargo Cancer Center, Brazil

P1.08-015: Surgery of Stage I Non-Small Cell Lung Cancer in Patients Aged 80 Years or Older  
Osamu Kawamata, Onomichi Municipal Hospital, Japan

P1.08-016: BMI in Patients with Operated Lung Cancer in Comparison with the Scottish Health Survey 2014. Is There a Democracy in BMI?  
Tomoyo Fujiwara, Golden Jubilee National Hospital, UK

P1.08-017: Does Mediastinal Lymph Node Dissection Affect Prognosis of Early Stage NSCLC?  
Hye-seon Kim, Hanyang University Seoul Hospital, South Korea

P1.08-018: Positive N Stage is a Risk Factor for Survival in Five-Year Disease Free Survivors with Completely Resected Non-Small Cell Lung Cancer  
Jin Gu Lee, Yonsei University College of Medicine, South Korea

P1.08-019: Risk Factors and Survival of Occult N2 Lymph Node Metastasis in NSCLC Patients with Clinical N0-1 Diagnosed by Preoperative PET-CT  
KS Park, DCMC, South Korea

P1.08-020: The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)  
Nicholas Faris, Baptist Cancer Center, USA

P1.08-021: Predictors of Post-Operative Mortality in Non-Small Cell Lung Cancer (NSCLC) in a High Mortality Region of the US  
Matthew Smeltzer, University of Memphis School of Public Health, USA

P1.08-022: Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables  
Haval Balata, University Hospitals of South Manchester, UK

P1.08-023: Analysis of Prognostic Factors and Long-Term Results of Primary Pulmonary Pleomorphic Carcinoma  
Domenico Galetta, European Institute of Oncology, Italy
P1.08-024: Surgical Outcomes and Prognostic Factors in the Treatment of Adenosquamous Carcinoma of the Lung
Domenico Galetta, European Institute of Oncology, Italy

P1.08 SURGERY - EPIDEMIOLOGIC STUDIES IN SURGERY FOR NSCLC

P1.08-025: Long-Term Survival of Lung Cancer in Chile
Ruben Valenzuela, Clínica Santa María, Chile

P1.08-026: LUNG CANCER - Early and Late Outcomes of Surgical Patients of a New District Hospital
Paulo Calvinho, Hospital de Santa Marta, Portugal

P1.08-027: Evolution of Survival in a Regional Population-Based US Lung Cancer Resection Cohort
Raymond Osarogiagbon, Baptist Cancer Center, USA

P1.08-028: Nationwide Trends in Surgery for Lung Cancer in Finland from 2004 to 2014
Jarmo Gunn, Turku University Hospital, Finland

P1.08-029: Surgical Experience of Primary Salivary Gland Tumors of Lung: Experience from Tertiary Care Cancer Center in North India
Ashish Jakhetiya, All India Institute of Medical Sciences, India

P1.08-030: Female Lung Cancer and Our Five Year Experience
Fatmir Caushi, University Hospital of Lung Diseases, Albania

P1.08-031: Non-Small Cell Lung Cancer in Patients Aged 40 Years or Younger: Clinical, Surgical, and Long-Term Outcomes
Domenico Galetta, European Institute of Oncology, Italy

P1.08 SURGERY - TRANSLATIONAL STUDIES

P1.08-032: Impact of the Oncogenic Status on the Mode of Recurrence in Resected Non-Small Cell Lung Cancer
Tetsuya Mizuno, Aichi Cancer Center Hospital, Japan

P1.08-033: Effect of EGFR Mutations on Survival in Patients following Surgical Resection of Lung Adenocarcinoma
Grace Laidlaw, Stanford University School of Medicine, USA

P1.08-034: Prognostic Impact of EGFR Mutation in Patients with Surgically Resected Lung Adenocarcinoma; Analysis about Subtypes of EGFR Mutations
Yohei Kawaguchi, Tokyo Medical University Hospital, Japan

P1.08-035: Analysis of Post-Operative Recurrence in a Population with NSCLC Harboring an EGFR Mutation: A Single Institutional Retrospective Study
Hayashi Kosuke, Matusaka Municipal Hospital, Japan

P1.08 SURGERY - MINIMAL INVASIVE SURGERY

P1.08-036: Thoracotomy and VATS-Surgery in Local Non-Small Cell Lung Cancer: Differences in Long-Term Health Related Quality of Life
Ville Rauma, Heart and Lung Center, Helsinki University Central Hospital, Finland
P1.08-037: Thoracoscopic Segmentectomy of Pulmonary Nodules after Computed Tomography-Assisted Bronchoscopic Metallic Coil Marking (2nd Version)
Takanori Miyoshi, Tokushima Municipal Hospital, Japan

P1.08-038: VATS Sub-Lobar Anatomical Pulmonary Resections: Indications and Outcomes in Thoracic Oncological Practice
Bibhusal Thapa, Olivia Newton John Cancer Research Institute, Australia

P1.08-039: Systematic Review and Updated Meta-Analysis of Uniportal versus Multiportal Video-Assisted Thoracoscopic Surgery for Lung Cancer
Janusz Kowalewski, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland

P1.08-040: Lymph Node Sampling in 3-Port Video Assisted Thoracoscopic Surgery (VATS) vs Uniportal VATS
Michael Klimatsidas, Golden Jubilee National Hospital, UK

P1.08-041: Disease Free and Overall Survival is Equal in Open and VATS Resection for Early Lung Cancer in a Multivariate Analysis
Caecilia Ng, Medical University Innsbruck, Austria

P1.08-042: Overall Survival and Tumor Recurrence after VATS Lobectomy of N1 Positive NSCLC is Equal to Open Resection
Herbert Maier, Medical University Innsbruck, Austria

P1.08-043: Perioperative and Mid-Term Outcomes after Single Port versus Multi-Ports Thoracoscopic Lobectomy for Lung Cancer: A Propensity Matching Study
Bong Soo Son, Pusan National University Yangsan Hospital, South Korea

P1.08-044: Comparison of Peri-Operative Outcomes after Robotic-Assisted Video-Thoracoscopic Lobectomies versus Segmentectomies
Eric Toloza, Moffitt Cancer Center, USA

P1.08-045: Partial Lung Resection after Bronchoscopic Metallic Coil Marking Using Two Coins and C-Armed Shaped Fluoroscopic Guidance
Koh Uyama, Tokushima Municipal Hospital, Japan

P1.08-046: Survival Following Thoracoscopic Pulmonary Metastasectomy for Osteosarcoma
Takashi Tojo, Nara medical university, Japan

P1.08-047: Decreasing Use of Epidural Analgesia with Increasing Minimally Invasive Lobectomy: Impact on Postoperative Morbidity
Masha Zeltsman, Memorial Sloan Kettering Cancer Center, USA

P1.08-048: Comparison of Pulmonary Function after Robotic-Assisted Video-Thoracoscopic Lobectomies vs Segmentectomies
Eric Toloza, Moffitt Cancer Center, USA

P1.08-049: CT Guided Labeling with Indocyanine Green of Small Lung Nodules for Sublobar Resection Utilizing Robotic Assisted Thorascoscopic Surgery (RATS)
K Adam Lee, Jupiter Medical Center, USA

P1.08-050: VATS Lobectomy in Locally Advanced NSCLC: A Single Centre Experience
Davide Tosi, Fondazione IRCCS Ca’ Granda Policlinico, Italy
P1.08-051: VATS Lobectomy Combined with Limited Thoracotomy for Treatment of Superior Sulcus Tumors
Davide Tosi, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Italy

P1.08-052: Comparison Study of Perioperative Outcomes in Robotic, Video-Assisted Thoracic Surgery, and Thoracotomy Approaches for Lung Cancer
Hiroshige Nakamura, Tottori University Hospital, Japan

P1.08-053: Thoracoscopic Partial Resection for Peripheral Pulmonary Nodules without Using Stapler
Toshiya Toyazaki, Tenri Hospital, Japan

P1.08-054: Uniportal VATS Lobectomy in the Treatment of NSCLC
Nenad Ilic, University Surgical Hospital, Croatia

P1.08-055: Hand Assisted Thoracoscopic Surgery (HATS) for Metastatic Lung Tumors - Improved Technique for More Safety and Accuracy
Shozo Fujino, University Hospital Mizonokuchi, Teikyo University School of Medicine, Japan

P1.08-056: Surgical Results of Thoracoscopic Anatomical Sublobar Resections for Early-Stage Lung Cancer
Fumiaki Watanabe, Matsusaka Municipal Hospital, Japan

P1.08-057: Outcomes between Single Port, Two Port and Three Port VATS Pulmonary Resection
Jiwei Mu, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P1.08-058: VATS lung resection analysis from Brazilian Society of Thoracic Surgery Database
Maria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, Brazil

P1.08 - SURGERY - SURGERY FOR LOCALLY ADVANCED AND ADVANCED NSCLC

P1.08-059: Timing of Surgery after Induction Chemoradiation Therapy for Locally Advanced NSCLC
Huseyin Melek, Uludag University, Turkey

P1.08-060: Survival of Patients with Unsuspected N2 (Stage IIIA) Non-Small Cell Lung Cancer
Takashi Yamamichi, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

P1.08-061: Clinical Experience of Rib Resection for Lung Cancer with Chest Wall Invasion Using a Pneumatic High Speed Power Drill System
Yuichiro Ueda, Tenri Hospital, Japan

P1.08-062: The Short and Long-Term Outcomes of Completion Pneumonectomy Compared with Primary Pneumonectomy
Takuya Ueda, National Cancer Center Hospital East, Japan

P1.08-063: Double Primary Malignancies Involving Lung Cancer and Hepatocellular Carcinoma
Han Pil Lee, Asan Medical Center, University of Ulsan College of Medicine, South Korea

P1.08-064: Surgery for Malignant Pulmonary Tumor Invading Proximal Left Main Pulmonary Artery
Fumihiro Tanaka, University of Occupational and Environmental Health, Japan
P1.08-065: Resection of Isolated Brain Metastasis Improves Outcome of Non Small-Cell Lung Cancer (NSCLC) Patients: A Retrospective Multicenter Study
Julia Fuchs, University Hospital Basel, Switzerland

P1.08-066: Prognostic Factors of Post-Recurrence Survival in Patients with Completely Resected Stage III-N2 Non-Small Cell Lung Cancer
Kyung Wook Shin, Seoul National University Bundang Hospital, South Korea

P1.08-067: The Feasibility of Lung Second Surgery for 2nd Primary Lung Cancer
Kazunori Hata, Juntendo University School of Medicine, Japan

P1.08-068: Salvage Surgical Resection after Curative-Intent Concurrent Chemoradiotherapy for N2-Stage III Lung Cancer
Motohiro Yamashita, Shikoku Cancer Center, Japan

P1.08-069: One Surgeon’s 30-Year Experience of Surgical Treatment for Pancoast Tumor
Hiroshi Niwa, Seirei Mikatahara General Hospital, Japan

P1.08-070: Salvage Lung Surgery: Difficulties and Results
Berna Komurcuoglu, Izmir Suat Seren Education Hospital for Chest Disease, Turkey

P1.08-071: Surgery for Lung Cancer with Mediastinal Lymph Node Metastasis - Effectiveness of Extended Bilateral Mediastinal Lymphadenectomy
Toshiya Yokota, Mitsui Memorial Hospital, Japan

P1.08-072: The Result of Completion Pneumonectomy for the Local Recurrent Lung Cancer after Radical Lobectomy
Takeshi Shiraishi, Fukuoka University School of Medicine, Japan

P1.08-073: Experience of Third Primary Lung Tumors after Treatment of First and Second Primary Lung Cancer
Takehiro Watanabe, Nishi-Niigata Chuo National Hospital, Japan

P1.08-074: Effect of Intrapleural Perfusion Hyperthermic Chemotherapy in Non-Small Cell Lung Cancer with Pleural Seeding
Kyung Wook Shin, Seoul National University Bundang Hospital, South Korea

P1.08-075: Salvage Surgery for Stage IV Non-Small Cell Lung Cancer
Hideaki Kojima, Shizuoka Cancer Center, Japan

P1.08-076: Recurrence Patterns in Lung Cancer Patients Treated with Protocol Based Multimodality Treatment at a Tertiary Care Cancer Center in India
Ashish Jakhetiya, All India Institute of Medical Sciences, India

P1.08-077: Comparison of Pulmonary Resection for Lung Cancer after Radical Chemoradiation with That after Induction Chemoradiation
Yasuhiro Hida, Hokkaido University Hospital, Japan

P1.08-078: Does Surgery Have Real Benefit in Resectable Oligometastatic NSCLC?
Oleg Pikin, Hertzen Research Institute of Oncology, Russia

P1.08-079: Salvage Surgery after Definitive Radiotherapy or Chemoradiotherapy for Lung Cancer
Naoya Yamasaki, Nagasaki University, Japan
P1.08-080: Bilobectomy for Lung Cancer: Analysis of Indications, Postoperative Results and Long-term Outcomes
Domenico Galetta, European Institute of Oncology, Italy

P1.08-081: Resection of T4 Non-Small Cell Lung Cancer Invading the Spine
Domenico Galetta, European Institute of Oncology, Italy

P1.08-082: Surgical Techniques and Long-Term Results of the Pulmonary Artery Reconstruction in Patients with Lung Cancer
Domenico Galetta, European Institute of Oncology, Italy

P1.08-083: Hyperthermic Pleural Lavage for Pleural Metastases
Patricia Thompson, Cancer Treatment Centers of America, USA

P1.08  SURGERY - MISCELLANEOUS

P1.08-084: Treatment for Elderly Patients with Clinical Stage I Non-Small Cell Lung Cancer; Surgery or Stereotactic Body Radiotherapy?
Takuro Miyazaki, Nagasaki Graduate School of Medicine, Japan
TUESDAY, DECEMBER 6, 2016

P2.01 BIOLOGY/PATHOLOGY
ANALYSIS OF BODY FLUIDS IN CANCER
ANALYSIS OF RNA
PROTEINS IN LUNG CANCER AND PROTEOMICS
IMMUNE MECHANISMS IN THORACIC CANCER AND TARGETED THERAPY
MARKER FOR PROGNOSIS, PREDICTION
TARGETS FOR TREATMENT PREDICTION
MISCELLANEOUS

P2.02 LOCALLY ADVANCED NSCLC
BIOLOGY
CLINICAL OUTCOME
MULTIMODALITY TREATMENT
PROGNOSTIC FACTOR
RT TECHNIQUES
TOXICITIES

P2.03a ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
CLINICAL TRIALS

P2.03b ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
BRAIN META
BIOMARKERS

P2.04 MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES
THYMIC MALIGNANCIES CLINICAL & TRANSLATIONAL
ESOPHAGEAL CANCER AND OTHER MALIGNANCIES

P2.05 RADIOTHERAPY
BIOLOGY
CLINICAL OUTCOME
MULTIMODALITY TREATMENT
RT TECHNIQUES
TOXICITIES

P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS
PHASE I TRIALS
PHASE I/II TRIALS
PHASE II + NK
PHASE III
MESOTHELIOMA AND SCLC
SUPPORTIVE, PREVENTIVE
RADIOTHERAPY, TT FIELDS
LAB., OTHER

P2.07 NURSES
INFORMATION FOR PATIENTS
DIFFERENT ASPECTS OF SYMPTOMS
RESEARCH, AUDITS
P2.08  PATIENT SUPPORT AND ADVOCACY GROUPS
PATIENTS’ VOICE, PATIENTS INFORMATION
OTHER

P2.08-001 - P2.08-007
P2.08-008 - P2.08-015
Tuesday, December 6, 2016
Poster Setup Time: Tuesday, December 6, 08:30 - 10:15
Poster Takedown Time: Tuesday, December 6, 15:45 - 18:00
(Posters not taken down by 18:00 will be discarded by management)

POSTER SESSION WITH PRESENTERS PRESENT (PRESENTING AUTHOR STAND BY TIME)
Session in which Poster Presenters remains at his/her poster board and is available to discuss/present their research personally with interested delegates.
Tuesday, December 6, 14:30 - 15:45 (Hall B - Poster Area)

P2.01 BIOLOGY/PATHOLOGY

P2.01 BIOLOGY/PATHOLOGY - ANALYSIS OF BODY FLUIDS IN CANCER

P2.01-001: Enrichment-Free, Rapid Metabolic Assay for Detection of Tumor Cells in Pleural Effusion and Peripheral Blood
Qihui Shi, Shanghai Jiao Tong University, China

P2.01-002: Serum Protein Signature in Lung Cancer Patients and in Patients with Chronic Obstructive Pulmonary Disease
Janna Berg, Vestfold Hospital Trust, Norway

P2.01-003: Serum VEGF, MMP-7 and CYFRA 21-1 as Predictive Markers of Lung Metastases from Colorectal Cancer
Franco Lumachi, University of Padua, School of Medicine, Italy

P2.01-004: The Methylation Profiling of Multiple Tumor Suppressor Genes in Plasma Cell-Free DNA of Patients with NSCLC vs Benign Tumors
Mateusz Florczuk, National Institute of Tuberculosis and Lung Diseases, Poland

P2.01-005: Evaluation of Circulating Tumoral Microemboli (CTM) as a Prognostic Factor in Non-Small Cell Lung Cancer (NSCLC)
Marcelo Corassa, A.C.Camargo Cancer Center, Brazil

P2.01-006: Sensitive Detection of CTCs in Thoracic Malignant Tumors With "Universal" CTC-Chip
Kazue Yoneda, University of Occupational and Environmental Health, Japan

P2.01-007: Detection of Promoter DNA Methylation of APC, DAPK, and GSTP1 Genes in Tissue Biopsy and Matched Serum of Advanced Stage Lung Cancer Patients
Ashraf Ansari, All India Institute of Medical Sciences, India

P2.01-008: SiRe Next Generation Sequencing Panel: Effective Diagnostic Tool for Circulating Free DNA Analysis
Umberto Malapelle, University of Naples Federico II, Italy

P2.01-009: Serial Quantitative Assessment of Plasma Circulating Tumor DNA by Digital NGS in Patients with Lung Cancer
Yue Zhao, Fudan University Shanghai Cancer Center, China

P2.01 BIOLOGY/PATHOLOGY - ANALYSIS OF RNA
P2.01-010: Downregulation of PFTK1 by shRNA Inhibits Migration and Invasion of Human Non-Small Cell Lung Cancer Cell Lines
Xiaoting Zhao, Beijing TB and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, China

P2.01-011: Identification of Differentially Expressed Circulating miRNAs in the Serum of NSCLC Patients Using next Generation Sequencing
Sachin Kumar, Amity University Uttar Pradesh, India

P2.01-012: Acquired Chemotherapy Resistance in vitro: miRNA Profiles of Chemotherapy Resistant Squamous Lung Cancer Cell Lines
Simon Haefliger, University of Sydney, Australia

P2.01-013: HA-Liposome Nanocarrier Containing CD44 siRNA as a Targeted Chemotherapy to CD44 Related Chemoresistant Non-Small Cell Lung Cancer
Hyun Koo Kim, Korea University Guro Hospital, South Korea

P2.01-014: miR-3941: A Novel microRNA That Controls IGBP1 Expression and is Associated with Malignant Progression of Lung Adenocarcinoma
Taiki Sato, University of Tsukuba, Japan

P2.01-015: Differentially Expressed microRNAs in Lung Adenocarcinoma Invert Effects of Copy Number Aberrations of Prognostic Genes
Tomas Tokar, University Health Network, Canada

P2.01-016: Analysis of 5 Differential miRNA Expression in NSCLC Patients
Janusz Kowalewski, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland

P2.01-017: Circulating miRNAs in Lung Cancer Are Associated to Pro-Tumorigenic and Immunosuppressive Microenvironment
Orazio Fortunato, Fondazione IRCCS Istituto Nazionale dei Tumori INT, Italy

P2.01-018: Differential microRNA Expression Profile between Young and Old Lung Adenocarcinoma Patients
Mirella Giordano, University of Pisa, Italy

P2.01-019: Three microRNAs Associated with Poor Prognosis Are Up-Regulated in Amplified Regions of Squamous Cell Lung Carcinoma
Sana Yokoi, Chiba Cancer Center Research Institute, Japan

P2.01-020: Identification of a Three-IncRNA Signature for Lung Cancer Diagnosis and Prognosis
Changli Wang, Tianjin Medical University Cancer Institute and Hospital, China

P2.01-021: miRNA Deep Sequencing of Early-Stage Lung Cancer Patients to Evaluate the Dynamic Change of Circulating Biomarkers in Response to Surgery
Daniela Petriella, IRCCS, Istituto Tumori Giovanni Paolo II, Italy

P2.01-022: A PIWI-Interacting RNAs Co-Expression Networks as a Prognostic Factor in Lung Cancer
Brenda Minatel, British Columbia Cancer Research Centre, Canada

P2.01-023: Deregulation of Small Non-Coding RNAs at the DLK1-DIO3 Imprinted Locus Predicts Lung Adenocarcinoma Patient Outcome
John Enterina, BC Cancer Research Centre, Canada
P2.01-024: Expression of miR-106 Paralogs Improves Prognostic Value of Mesenchymal Signatures but Only miR-106b Promotes Invasiveness
Sonia Kung, British Columbia Cancer Research Centre, Canada

P2.01-025: MiR-146b Functions as a Suppressor miRNA and Prognosis Predictor in Non-Small Cell Lung Cancer
Jun Chen, Tianjin Medical University General Hospital, China

P2.01 BIOLOGY/PATHOLOGY - PROTEINS IN LUNG CANCER AND PROTEOMICS

P2.01-026: A Mass Spectrometry Based Stem Cell-Oriented Phylogeny of Intra-Tumoral NSCLC Subclones
Robert Downey, Memorial Sloan Kettering Cancer Center, USA

P2.01-027: A Comparison of Five Different Immunohistochemistry Assays for Programmed Death Ligand-1 Expression in Non-Small Cell Lung Cancer Samples
Joey Lim, National University of Singapore, Singapore

P2.01-028: Prognostic Significance of GLUT1 and CAIX Expression: Correlation with Volume-Based PET Parameters in Non-Small Cell Lung Cancer
Young Wha Koh, Ajou University School of Medicine, South Korea

P2.01-029: Tumor B7-H3 (CD276) Protein Expression, Smoking History, and Survival in Lung Adenocarcinoma Patients
Kentaro Inamura, The Cancer Institute, JFCR, Japan

P2.01-030: Prognostic Impact of Stathmin1 Expression in Patients with Non-Small Lung Cancer
Kimihiro Shimizu, Gunma University Graduate School of Medicine, Japan

P2.01-031: CCL Chemokines May Play an Important Role in Cisplatin Resistance
Sarah-Louise Ryan, Queensland University of Technology, Australia

P2.01-032: Impact of Preoperative Serum Anti-60S Ribosomal Protein L29 Levels on Prognosis in Patients Who Underwent Surgery for Non-Small Cell Lung Cancer
Hiromasa Yamamoto, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

P2.01-033: Exosomal Proteomics Analysis Reveal New Targets for Radiation-Induced Lung Toxicity Diagnosis
Xiance Jin, The 1st Affiliated Hospital of Wenzhou Medical University, China

P2.01-034: The Pregnancy Associated Endometrial Protein Glycodelin as a Biomarker for Malignant Pleural Mesothelioma
Marc Schneider, Thoraxklinik at Heidelberg University Hospital, Germany

P2.01-035: Protein and Molecular Alterations in EMT Pathways of Lung Cancer: A Comparative Analysis between NSCLCs
Vera Capelozzi, University of São Paulo, Brazil

P2.01-036: Identification of a Novel Oncogenic Ubiquitin Ligase from a Lung Cancer Epigenome-Wide Association Study (EWAS)
Christian Faltus, Division of Epigenomics and Cancer Risk Factors, DKFZ - German Cancer Research Center; University of Salzburg, Austria

P2.01-037: Molecular Biology Underlying COPD and Lung Cancer Converge on FOXM1 Network
Victor Martinez, British Columbia Cancer Research Centre, Canada

P2.01-038: Discrimination of NSCLC Cases from Cancer-Free Controls and Adenocarcinoma from Squamous Cell Carcinoma Using Plasma Metabolomics Profiles
Michael Abdalmassih, University of Manitoba, Canada

P2.01-039: Prognostic Significance of Claudin Protein Expression in Histological Subtypes of Non-Small Cell Lung Cancer
Judit Moldvay, National Korányi Institute of Pulmonology, Hungary

P2.01-040: CXC Chemokine Receptor 3 and ELR Motif Negative CXC Chemokine Ligand Axis in Non-Small Cell Lung Cancer
Artjoms Spaks, Pauls Stradins Clinical University Hospital, Latvia

P2.01-041: Integrated Proteo-Genomics Analyses Reveal Extensive Tumor Heterogeneity and Novel Somatic Variants in Lung Adenocarcinoma
Udayan Guha, Center for Cancer Research, NCI, NIH, USA

P2.01 BIOLOGY/PATHOLOGY - IMMUNE MECHANISMS IN THORACIC CANCER AND TARGETED THERAPY

P2.01-042: T Cells Subsets with INF-Gamma, TNF-Alpha and ADA in Distinguishing Tuberculous from Malignant Pleural Effusions
Abdellah Ali, Sohag University, Egypt

P2.01-043: Pathologist Agreement Rates of PD-L1 Tumor and Immune Cell Quantitation Using Digital Read, Field-Of-View, and Whole Tumor Image Analysis
Christoph Guetter, Roche Diagnostics, USA

P2.01-044: Baseline Peripheral Blood Cell Subsets Associated with Survival Outcomes in Advanced NSCLC Treated with Nivolumab in Second-Line Setting
Antonio Passaro, European Institute of Oncology, Italy

P2.01-045: Nintedanib Improves Anti-Tumor Efficacy in Combination with Anti PD-1 in Syngeneic Tumor Models Sensitive and Refractory to IO Inhibition
Frank Hilberg, Boehringer Ingelheim RCV, Austria

P2.01-046: Quantitative Measurement of B7-H3 Protein Expression and Its Association with B7-H4, PD-L1 and TILs in NSCLC
Mehmet Altan, Yale Cancer Center, USA

P2.01-047: Intra- and Inter-Observer Reproducibility Study of PD-L1 Biomarker in Non-Small Cell Lung Cancer (NSCLC) - The DREAM STUDY
Wendy Cooper, Royal Prince Alfred Hospital, Australia

P2.01-048: Paired Comparison of PDL1 Assessment on Cytology and Histology from Malignancies in the Lung
Birgit Skov, Copenhagen University Hospital, Rigshospitalet, Denmark
P2.01-049: A Comparative Study of PD-L1 IHC 28-8 pharmDx and PD-L1 IHC 22C3 pharmDx on Malignancies from the Lung
Birgit Skov, Copenhagen University Hospital, Rigshospitalet, Denmark

P2.01-050: Clinicopathological Characteristics of PD-L1 Expression in Lung Adenocarcinoma
Xuan Zeng, Peking Union Medical College Hospital, China

P2.01-051: Myeloid-Derived Suppressor Cell Expression within the Microenvironment of Lung Adenocarcinoma
Yasuto Jin, Hiratsuka Kyosai Hospital, Japan

P2.01-052: High PD-L1 Expression is Associated with Worse Prognosis in Primary Resected Squamous Cell Carcinomas of the Lung
Manuel Keller, Institute of Pathology, University of Bern, Switzerland

P2.01-053: PD-L1 Expression in Patients with Small Cell Lung Cancer
Haiyue Wang, Peking University Cancer Hospital, China

P2.01-054: Lung Cancer PD-L1 mRNA Expression Profile and Clinical Outcomes - An Analysis From The Cancer Genome Atlas and Cancer Cell Line Encyclopedia
Boris Sepesi, UT MD Anderson Cancer Center, USA

P2.01-055: Lymphocytes' Subtypes Differentiation after Stimulation with Synthetic Antigen-Pulsed Dendritic Cells in Lung Adenocarcinoma Patients
Pawel Krawczyk, Medical University, Poland

P2.01-056: Distinct PD-L1 Expression in Different Components of Pulmonary Sarcomatoid Carcinoma and Its Association with MET Mutation
Janaki Sharma, Albert Einstein College of Medicine/Montefiore Medical Center, USA

P2.01-057: Association of Tumor Infiltrating Lymphocytes Quantification with EGFR Mutations in Completely Resected Stage IIIA(N2) Lung Adenocarcinoma
Wen Feng, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P2.01-058: Mutational Features Associated with Immunoreactivity in Non-Small Cell Lung Cancer
Nicholas Syn, National University Cancer Institute, Singapore

P2.01-059: Regulation of Glycodelin Expression - An Immunomodulatory and Pregnancy Associated Protein in NSCLC
Rebecca Weber, Thoraxklinik at Heidelberg University Hospital, Germany

P2.01-060: Comparative Analysis of PD-L1 Expression between Circulating Tumor Cells and Tumor Tissues in Patients with Lung Cancer
Yasuhiro Koh, Wakayama Medical University, Japan

P2.01-061: Image Analysis-Based Expression of Nine Immune Checkpoints Identifies Distinct Immunoprofiling Patterns in Non-Small Cell Lung Carcinomas
Jaime Rodrigues-Canales, U.T.-M.D. Anderson Cancer Center, Translational Molecular Pathology, USA

P2.01-062: Impact of the Tissue Distribution of Subpopulations of TILs and PD-L1 Expression on the Clinical Outcome of NSCLC
Giovanni Bocchialini, University of Parma, Italy
P2.01-063: PDL1, JAK2 and PTEN Copy Number Alterations Synergistically Upregulate PD-L1 Expression in NSCLC
Sergi Clavé, Hospital del Mar, Spain

P2.01-064: Molecular Context of Immune Microenvironment in Early-Stage Lung Squamous Cell Carcinoma
Esther Conde, Hospital Universitario HM Sanchinarro, Spain

P2.01-065: Quantification of Tumour-Immune Cell Spatial Relationships in the Lung Tumour Microenvironment Using Single Cell Profiling
Katey Enfield, BC Cancer Research Centre, Canada

P2.01-066: PD-L1 Tumor Expression and Its Effect on Overall Survival among Patients with Resected Non-Small Cell Lung Cancer (NSCLC)
Jane Sui, St. James's Hospital, Ireland

P2.01-067: The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Giulia Barletta, San Martino Hospital - National Institute for Cancer Research, Italy

P2.01-068: Analysis of Epithelial-Stromal Interactions and their Relevance to Lung Cancer
César Márquez, Stanford University School of Medicine, USA

P2.01 BIOLOGY/PATHOLOGY - MARKER FOR PROGNOSIS, PREDICTION

P2.01-069: Erythron Reaction Shows High Malignant Tumor Process in Lung Cancer Patients
Yury Ragulin, Medical Radiological Research Center, Russia

P2.01-070: Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Alastair Greystoke, Newcastle University, UK

P2.01-071: Biological Implication of Cytoplasmic ECT2 in Malignant Progression of Lung Adenocarcinoma
Zeinab Kosibaty, University of Tsukuba, Japan

P2.01-072: Clinical Associations of MUC1 Expression in Human Lung Cancer and Precancerous Lesions
Andreas Saltos, Moffitt Cancer Center, USA

P2.01-073: The Diagnostic Value of Carcinoembryonic Antigen and Squamous Cell Carcinoma Antigen in Lung Adenosquamous Carcinoma
Hongyang Lu, Zhejiang Cancer Hospital, China

P2.01-074: Increased AIMP2-DX2/AIMP2 Autoantibody Ratio is Associated with Poor Prognosis in Lung Cancer
Eun Young Kim, Yonsei University College of Medicine, South Korea

P2.01-075: Prognostic Value of Angiogenesis and Cell Adhesion Biomarkers in Non-small Cell Lung Cancer
Kostas Syrigos, Medical School, University of Athens, Greece

P2.01-076: Drebrin: A New Targetable Molecular Marker of Lung Adenocarcinoma
Shinji Iyama, University of Tsukuba, Japan
P2.01-077: Serum CYFRA 21-1 and CEA Level as a Predicting Marker for Advanced Non-Small Cell Lung Cancer
Busyamas Chewaskulyong, Faculty of Medicine, Chiangmai university, Thailand

P2.01-078: Frequent High TIM-3 (HAVCR2) Expression in Resected NSCLC Specimens, Most Notably in Adenocarcinoma Histology
Aaron Lisberg, UCLA Medical Center, USA

P2.01-079: The Serum Levels of Alpha-1 Antitrypsin Are Strongly Associated with Its Local Production by Tumor Cells in NSCLC Patients
Adam Szpechcinski, National Institute of Tuberculosis and Lung Diseases, Poland

P2.01-080: Mitosis Count of Lung Adenocarcinomas: Correlation between the Phosphorylated Histone 3, Number of Cancer Cells, Nuclear Grade, and Prognosis
Takashi Inoue, Dokkyo Medical University, Japan

P2.01-081: CDCA3 is a Novel Prognostic Cell Cycle Protein and Target for Therapy in Non-Small Cell Lung Cancer
Mark Adams, Institute of Health and Biomedical Innovation, Australia

P2.01-082: Transcriptional Profiling Identified the Anti-Proliferative Effect of Mitofusin-2 Deficiency and Its Risk in Lung Adenocarcinoma
Yuqing Lou, Shanghai Chest Hospital, Shanghai Jiaotong University, China

P2.01-083: Prognostic Factors of Overall Survival in 150 Resected Lung Adenocarcinoma Patients
Yue Cheng, West China School of Medicine, West China Hospital, Sichuan University, China

P2.01-084: Linker-Phosphorylated Smad2 and STAT3 Induce Resistance to Tyrosine Kinase Inhibition in Lung Cancer
Yojiro Makino, Tokyo Medical University Hospital, Japan

P2.01-085: Epigenetic Profile of Oligoprotgressive versus Widespread Non-Small Cell Lung Cancer Patients
Carolina Gabay, Instituto Angel H Roffo, Argentina

P2.01 - BIOLOGY/PATHOLOGY - TARGETS FOR TREATMENT PREDICTION

P2.01-086: Luteolin is a Novel Target of Axl Receptor Tyrosine Kinase to Inhibit Cell Proliferation and Circumvent Chemoresistance in Lung Cancer Cells
Kyungchan Kim, Catholic University of Daegu Hospital, South Korea

P2.01-087: Prognostic Significance of CA IX Overexpression in Stage III NSCLC Patients Received Neoadjuvant Treatment
Sezer Saglam, Istanbul Bilim University, Turkey

P2.01-088: Prenylation Inhibitors in Lung Adenocarcinoma: Comparison of Zoledronic Acid and a Novel Lipophilic Bisphosphonate
Balazs Hegedus, Medical University of Vienna, Austria

P2.01-089: Predictive Value of AEG-1 Expression on Tumor Response by Liquid Biopsy in NSCLC Patients Treated with Chemotherapy
Chung-Yu Chen, National Taiwan University Hospital Yunlin Branch, Taiwan
P2.01-090: Platin Induced Phosphorylation of ATM and ATM-Deficiency as a Predictive Marker of Platin Sensitivity in Non-Small Cell Lung Cancer
Jarrett Moore, University of Calgary, Canada

P2.01-091: The Anticancer Effect of Techoic Acids on Lewis Lung Carcinoma Model
Viktoriia Nikulina, Taras Shevchenko National University of Kyiv, Ukraine

P2.01-092: PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy
Meng Welliver, The Ohio State University CCC, USA

P2.01-093: Exo-ALK Proof of Concept: Exosomal Analysis of ALK Alterations in Advanced NSCLC Patients
Christian Rolfo, Antwerp University Hospital & Antwerp University, Belgium

P2.01 BIOLOGY/PATHOLOGY - MISCELLANEOUS

P2.01-094: Stromal Antigen 1 (SA-1), a Cohesin, is a Novel Proto-Oncogene Regulating Chromatin in Non-Small Cell Lung Cancer (NSCLC)
Hemant Roy, Boston University Medical Center, USA

P2.02 LOCALLY ADVANCED NSCLC

P2.02-001: Advanced Large Cell Lung Cancer; Biological Behavior and Prognostic Factors
Hala Aziz, National Cancer Institute, Egypt

P2.02-002: Association between VEGF Gene Functional Polymorphisms and Clinical and Pathological Characteristics of Non-Small Cell Lung Cancer
Anna Shchayuk, National Academy of Sciences of Belarus, Belarus

P2.02-003: Increased Circulating Cytokeratin-19 (Cyfra 21-1) is Predictive of Poor Outcome of Locally Advanced Squamous Cell Carcinoma in Lung
Jingbo Wang, Cancer Hospital, Chinese Academy of Medical Sciences, China

P2.02-004: Real-time Monitoring of Circulating Tumor Cells to Evaluate Response of Neoadjuvant Chemotherapy in Locally Advanced NSCLC
Miao Huang, Peking University Cancer Hospital and Institute, China

P2.02-005: A Rare Clinical Presentation Of EGFR-Mutant Non-Small Cell Lung Cancer With Oligo-Acrmostasis
Ugur Yilmaz, Ankara Atatürk Chest Disease and Thoracic Surgery Training and Research Hospital, Turkey

P2.02-006: Targeted Next Generation Sequencing Reveals Prognostic Recurrent Somatic Mutations in the GNAQ Oncogene in NSCLC
Norma Hernández-Pedro, Instituto Nacional de Cancerología, Mexico

P2.02 LOCALLY ADVANCED NSCLC - CLINICAL OUTCOME
P2.02-007: Treatment Outcomes of Combine Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer: A Single Institution Study
Pitchayaponne Klunklin, Chiangmai University, Thailand

P2.02-008: How Do We Really Treat Patients with Stage III Non-Small Cell Lung Cancer (NSCLC)?
Allan Price, Western General Hospital, UK

P2.02-009: Clinical Outcomes of Induction Chemoradiotherapy with High Dose Chest Radiation for Locally Advanced Non-Small Cell Lung Cancer Patients
Hidejiro Torigoe, Okayama University Hospital, Japan

P2.02-010: Prognosis Impact of Oligoprogression Following Definitive Chemo-Radiotherapy in Stage III Non-Small Cell Lung Cancer
Maria Saigi, Department of Medical Oncology, Catalan Institute of Oncology, Hospitalet, Spain

P2.02-011: Management of Non-Small-Cell Lung Cancer (NSCLC) Stage III Patients in Central European Countries
Milada Zemanová, Faculty of Medicine of Charles University in Prague, Czech Republic

P2.02-012: Long-Term Survival of Phase II of Full-Dose Oral Vinorelbine Combined with Cisplatin & Radiotherapy in Locally Advanced NSCLC
Óscar Juan, Hospital Universitari i Politècnic La Fe, Spain

P2.02-013: Costing Analysis of PROCLAIM Non-Small Cell Lung Cancer Trial Data
Katherine Winfree, Eli Lilly and Company, USA

P2.02-014: Perioperative Outcomes and Downstaging Following Neoadjuvant Therapy For Lung Cancer - Analysis of the National Cancer Database
Boris Sepesi, MD Anderson Cancer Center, USA

P2.02-015: Guideline Concordant Care is Associated with Better Survival for Patients with Stage III Non-Small Cell Lung Cancer
Hiba Ahmed, Winship Cancer Institute, Emory University, USA

P2.02-016: Real World Experience with Chemoradiotherapy in Locally Advanced NSCLC
Irene Torres, Hospital Universitario Miguel Servet, Spain

P2.02-017: A Clinical Outcome of Resected Small-Sized Non-Small Cell Lung Cancer 1 cm or Less in Diameter with N2 Lymph Node Metastasis
Yasufumi Kato, Tokyo Medical University Ibaraki Medical Center, Japan

P2.02-018: Chemoradiotherapy in Elderly Patients with Locally Advanced Non-Small Cell Lung Cancer
Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

P2.02-019: Lung Cancer in Young Adults (Age Group 18-50 yrs): Presentation, Clinical Features and Treatment
Balaji Varadhan, Leicester Royal Infirmary, UK

P2.02-020: Pattern of Care of Inoperable Locally Advanced (LA) NSCLC in Elderly Patients: Analysis of the Experience of Two Academic Italian Hospitals
Marco Perna, Radiation Oncology Unit, Italy
P2.02-021: Extracranial Progression (ePD) after Chemoradiotherapy (CRT) for Stage III NSCLC: Does the Chemotherapy Regimen Matter?
Anne-Marie Dingemans, Maastricht University Medical Center, Netherlands

P2.02-022: For down Staged Clinical N3 M0 Non-Small Cell Lung Cancer Patients Chemo-Radiotherapy Followed by Surgery Can Improve Survival
Jitian Zhang, University of Hong Kong Shenzhen Hospital, China

P2.02  LOCALLY ADVANCED NSCLC - MULTIMODALITY TREATMENT

P2.02-023: Neoadjuvant Chemotherapy and Concurrent Full-Dose Radiation Therapy Followed by Surgery for Stage IIIIB Non-Small Cell Carcinoma of the Lung
Sherry Yan, Columbia University Medical Center, USA

P2.02-024: Phase I and II Trial of Intrapleural Paclitaxel Injection for Non-Small-Cell Lung Cancer Patients with Malignant Pleural Effusions
Masato Sasaki, University of Fukui, Japan

P2.02-025: Continuous Intravenous Pumping Endostar Combined with Radiochemotherapy in Unresectable Stage ? Non-Small-Cell Lung Cancer
Hong Lian Ma, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation Oncology, China

P2.02-026: Individualized Adjuvant Chemotherapy for Resected Lung Cancer According to Collagen Gel Droplet-Embedded Culture Drug Sensitivity Test
Masayoshi Inoue, Kyoto Prefectural University of Medicine, Japan

P2.02-027: A Randomized Phase II Trial of S-1 plus Cisplatin or Docetaxel plus Cisplatin with Concurrent Thoracic Radiotherapy for Stage III NSCLC: TORG1018
Kazuhiko Yamada, Kurume University School of Medicine, Japan

P2.02-028: A Phase I/II Study of Carboplatin, Pemetrexed, and Concurrent Radiation Therapy for Patients with Locally Advanced NSCLC, CJLSG0912
Naohiko Murata, Japanese Red Cross Nagoya Daini hospital, Japan

P2.02-029: Concomitant ChemoRadiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Phase II Study from the Galician Lung Cancer Group
Joaquin Casal Rubio, Complejo Hospitalario Universitario de Vigo, Spain

P2.02-030: Consolidation Chemotherapy Following Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: A Brazilian Multicentric Cohort
Vladmir Cordeiro De Lima, A.C. Camargo Cancer Center, Brazil

P2.02-031: Survival Data of Postoperative Adjuvant Chemotherapy of Cisplatin plus Vinorelbine for Completely Resected NSCLC: A Retrospective Study
Hirotsugu Kenmotsu, Shizuoka Cancer Center, Japan

P2.02-032: Induction Histology-Based Combination Chemotherapy for Elderly Patients with Inoperable Non-Small Cell Lung Cancer (NSCLC)
Giuseppe Banna, Cannizzaro Hospital, Italy

P2.02-033: The Role of Surgery for Treating Occult N2 Non-Small Cell Lung Cancer
Masashi Yanada, Japanese Red Cross Kyoto Daini Hospital, Japan
P2.02-034: Both Induction and Adjuvant Treatment Improve Outcomes of Surgically-Resected IIIA(N2) NSCLC When Compared to Definitive Chemoradiotherapy
Patrick Villeneuve, The Ottawa Hospital, Canada

P2.02-035: The Advantage of Induction Chemoradiotherapy in Bronchoplastic Procedure for Non Small Cell Lung Cancer Accompanied with Central Disease Region
Hiroki Sato, Okayama University Graduate School of Medicine, Japan

P2.02-036: Double Plasty Operation; A Procedure with Pulmonary Arterioplasty and Bronchoplasty against Centrally Located Non-Small Cell Lung Cancer
Koji Takahashi, Graduate School of Medicine, Kyoto University, Japan

P2.02-037: Final Results of Prospective Phase II Study of Adding Erlotinib to Chemoradiation for patients with Stage III Non-Small-Cell Lung Cancer
Ritsuko Komaki, MD Anderson Cancer Center, USA

P2.02-038: Surgical Outcome of Stage III A-cN2/pN2 Non-Small Cell Lung Cancer
Ryotaro Kamohara, Nagasaki University Graduate School of Biomedical Sciences, Japan

P2.02-039: Intercalated EGFR and Chemotherapy in Locally Advanced NSCLC with EGFR Mutations: Data on 5 Patients and Clinical Study
Frank Griesinger, Pius Hospital Oldenburg, Germany

P2.02-040: Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer
Yuhchyau Chen, University of Rochester, USA

P2.02-041: The Impact of Surgical Resection after Concurrent Chemotherapy and High Dose (61 Gy) Radiation in Stage IIIA/N2 Non-Small Cell Lung Cancer
Akif Turna, Istanbul University, Cerrahpasa Medical Faculty, Turkey

P2.02-042: Surgical Management of Squamous Cell Carcinoma of the Lung: Survival and Functional Outcomes
Jun Chen, Tianjin Medical University General Hospital, China

P2.02-043: Randomized Ph II Trial of Allogeneic DPV-001 Cancer Vaccine Alone or with Adjuvant for Curatively-Treated Stage III NSCLC
Rachel Sanborn, Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, USA

P2.02-044: Impact of N2 Extent and Nodal Response on Survival after Trimodal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer
Hong Kwan Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

P2.02-045: Prognostic Value of Metabolic FDG-PET Response in Locally Advanced NSCLC: A Literature Review
Charlotte Van De Kerkhove, University Hospital KU Leuven, Belgium

P2.02-046: Prognostic Value of Early Tumor Regression during Chemo-Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer
Alexander Sun, University of Toronto, Canada
P2.02-047: Association of FDG PET, Complete Pathological Response and Overall Survival in Patients with Pancoast Tumours Treated with Trimodality Therapy
Bibhusal Thapa, Austin Health, Australia

P2.02-048: Predictive Factors of Outcome in Locally Advanced NSCLC Patients Treated with Neo-Adjuvant Chemotherapy in Resource-Constrained Settings
VinayaKumar J R, IRCH, All India institute of Medical Sciences(AIIMS), India

P2.02-049: Gender and Risk of Cessation of Oral Vinorelbine in a Randomized Trial of Concurrent Chemoradiation of Locally Advanced NSCLC
Olfrid Hansen, Odense University Hospital, Denmark

P2.02-050: Gender and Smoking Influence on Non Small Cell Lung Cancer Histology and Tnm Stage in a Brazilian Population
Ricardo Terra, University of Sao Paulo Medical School, Brazil

P2.02-051: Prognostic Value of the Pretreatment Peripheral Blood Markers in Patients with Non-Small Cell Lung Cancer
Marko Jakopovic, University Clinical Hospital Center Zagreb, Croatia

P2.02-052: Does Delay from Diagnosis to Start of Radiotherapy, or Modified Comorbidity Score Impact Survival in Curatively Treated Non Small Cell Lung Cancer
Jeremy Ruben, William Buckland Radiotherapy Centre and Monash University, Australia

P2.02-053: Does the Method of Mediastinal Staging Cause the Mediastinal Nodal Clearance Following Trimodality Therapy?
Jong Ho Cho, Sungkyunkwan University School of Medicine, Samsung Medical Center, South Korea

P2.02-054: Impact of Prognostic Nutrition Index for Induction Chemoradiotherapy Followed by Surgery in Locally Advanced Non-Small Lung Cancers
Junichi Soh, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

P2.02-055: Pathologic Mediastinal Nodal and Metabolic Tumor Response to Predict Overall Survival in Stage IIIA-N2 NSCLC after Neoadjuvant Chemotherapy
Christophe Dooms, University Hospitals KU Leuven, Belgium

P2.02-056: FGFR Gene Mutation is an Independent Prognostic Factor in Squamous Non-Small Cell Lung Cancer, and Associated with Lymph Node Metastasis
Wu Nan, Peking University Cancer Hospital & Institute, China

P2.02-057: The Importance of Adaptive Radiotherapy in the Radical Treatment of Locally Advanced Non Small Cell Lung Cancer
Slavica Maric, International Medical Centers Banja Luka, Bosnia and Herzegovina

P2.02-058: Moderately Hypofractionated Radiotherapy in Locally Advanced Non Small Cell Lung Cancer: A Single Institution Retrospective Analysis
Alessio Bruni, Aou Policlinico Of Modena, Italy
P2.02-059: New Treatment Strategy in Inoperable Locoregionally Advanced NSCLC: C Arm Cone Beam CT -GuıDed Selective Intraarterial Chemotherapy
Mustafa Ozdogan, Mediterranean Integrative Oncology Group, Turkey

P2.02-060: SBRT and Sequential Chemotherapy for Stage IIA to IIAA Non-Small Cell Lung Cancer - A Phase I Dose Escalation Study
Andreas Rimner, Memorial Sloan Kettering Cancer Center, USA

P2.02 - LOCALLY ADVANCED NSCLC - TOXICITIES

P2.02-061: Role of MMP-2-1306C/T in Onset of Hematological Toxicity in Lung Cancer Patients Receiving First Line Platinum Based Therapy
Annamaria Catino, National Cancer Research Centre, Istituto Tumori "Giovanni Paolo II" Bari, Italy, Italy

P2.02-062: Alterations in Pulmonary Function Tests Predict the Development of Radiation-Induced Pneumonitis in Advanced NSCLC
Oscar Arrieta, National Cancer Institute, Mexico

P2.03a - ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY

P2.03a - ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - CLINICAL TRIALS

P2.03a-001: A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Baohui Han, Shanghai Chest Hospital, China

P2.03a-002: Patterns of Chemotherapy Use and Overall Survival (OS) of Patients with Stage IV Squamous Lung Cancer (SCC)
Daniel Morgensztern, Washington University School of Medicine, USA

P2.03a-003: Belinostat in Combination with Carboplatin and Paclitaxel in Patients with Chemotherapy-Naıve Metastatic Lung Cancer (NSCLC)
Ramawamy Govindan, Washington University School of Medicine, USA

P2.03a-004: Second-line Therapy Improves Overall Survival in Primary Refractory Non Small-Cell Lung Cancer (NSCLC) Patients
Sacha Rothschild, University Hospital Basel, Switzerland

P2.03a-005: A Study of Endostar Combined with Gemcitabine in the First-Line Treatment of the Elderly Patients with Advanced Non-Small Cell Lung Cancer
Qun Chen, Fuzhou Pulmonary Hospital of Fujian, China

P2.03a-006: Frequency of 2 Year PFS Milestone in Stage IV NSCLC Patients Treated with First Line Pemetrexed/Platinum and Pemetrexed Maintenance
Marta Batus, Rush University Medical Center, USA

P2.03a-007: Pem/CBP/Bev Followed by Pem/Bev in Hispanic Patients with NSCLC: Outcomes According to Combined Score of TS, ERCC1 and VEGF Expression
Andrés Cardona, Clinical and Traslational Oncology Group, Institute of Oncology, Clinica del Country, Colombia
P2.03a-008: Relative Dose Intensity of First-Line Chemotherapy and Overall Survival in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)
Jeffrey Crawford, Duke University School of Medicine, USA

P2.03a-009: Clinical Outcome of Node-Negative Oligometastatic Non-Small Cell Lung Cancer
Masayuki Takeda, Kinki University Faculty of Medicine, Japan

P2.03a-010: A Randomized Phase II Study of Platinum-Based Chemotherapy +/- Metformin in Chemotherapy-Naïve Advanced Non-Squamous NSCLC
David Ettinger, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA

P2.03a-011: Population Pharmacokinetic/Pharmacodynamic Monitoring of Pemetrexed to Predict Survival in Patients with Advanced NSCLC
Sabine Visser, Erasmus MC Cancer Institute, Netherlands

P2.03a-012: Nephrotoxicity in Patients with Advanced NSCLC Receiving Pemetrexed-Based Chemotherapy
Sabine Visser, Erasmus MC Cancer Institute, Netherlands

P2.03a-013: Chemotherapy is Beneficial for Octogenarians with Non-Small Cell Lung Cancer (NSCLC)
Hirsh Koyi, Gävle Hospital, Sweden

P2.03a-014: A Dose-Finding and Phase 2 Study of Ruxolitinib plus Pemetrexed/Cisplatin for Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Giuseppe Giaccone, Georgetown University, USA

P2.03a-015: Systemic Inflammation Alters Carboplatin Pharmacokinetics Explaining Poor Survival in Advanced Lung Cancer Patients
Benjamin Harris, University of Sydney, Australia

P2.03a-016: Weekly Paclitaxel with 4 Weekly Carboplatin as Salvage Treatment in Advanced Non-Small Cell Lung Cancer- HCG Centre Experience
Satheesh Thungappa, HCG Bangalore Institute of Oncology Speciality Centre, India

P2.03a-017: Chemotherapy-Induced Nausea and Vomiting (CINV) in Italian Lung Cancer Patients: Assessment by Physician, Nurse and Patient
Silvia Novello, Thoracic Oncology Unit, Italy

P2.03a-018: A Phase I/II Study of Alisertib, an Oral Aurora Kinase Inhibitor, in Combination with Erlotinib in Patients with Recurrent or Metastatic NSCLC
Hossein Borghaei, Fox Chase Cancer Center, USA

P2.03a-019: A Retrospective Analysis Of Nanoparticle Albumin Bound Paclitaxel In Chinese Patients With Recurrent Advanced Non-small Cell Lung Cancer In A Single Center
Yixiang Zhu, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China

P2.03a-020: Metronomic Oral Vinorelbine Monotherapy in Elderly Patients with Advanced NCSLC
Angeliki Rapti, Hospital of Chest Diseases of Athens, Greece

P2.03a-021: Vinorelbine/Carboplatin vs Gemcitabine/Carboplatin in Advanced Squamous Cell Lung Cancer
Ali Hasan, Damascus University, Syria
P2.03a-022: QOL and Febrile Neutropenia: Japanese Phase 2 Trial of Docetaxel with/out Antiangiogenic Agent in 2nd Line NSCLC
Yukie Omori, Eli Lilly Japan K.K., Japan

P2.03a-023: Induction-Maintenance Treatment Sequence in Non-Squamous Non-Small Cell Lung Cancer (neNSCLC): Pemetrexed vs Vinorelbine-Based Induction
Xabier Mielgo Rubio, Hospital Universitario Fundación Alcorcón, Spain

P2.03a-024: The Clinical Efficacy and Safety of Paclitaxel Liposome on the Patients with Non-Small Cell Lung Cancer: A Meta-Analysis
Xingsheng Hu, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China

P2.03a-025: Randomized, Double-Blind, Phase 3 Study Comparing Biosimilar Candidate ABP 215 with Bevacizumab in Patients with Non-Squamous NSCLC
Vladimir Hanes, Amgen, USA

P2.03a-026: Pemetrexed (Alimta) in Maintenance Therapy of 194 Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Jana Skrickova, University Hospital and Masaryk University Brno, Czech Republic

P2.03a-027: A Phase I Study of the Non-Receptor Tyrosine Kinase Inhibitor (NKI) Bosutinib in Combination with Pemetrexed in Patients with Advanced Solid Tumors
Nagla Karim, The University of Cincinnati, USA

P2.03a-028: Phase I/II Trial of Carboplatin, nab-Paclitaxel and Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of Phase I Part
Satoshi Ikeo, Kurashiki Central Hospital, Japan

P2.03a-029: Efficacy and Safety of Combined Carboplatin, Paclitaxel and Bevacizumab for Patients with Stage IIIb and IV Non-Squamous NSCLC
Nektarios Alevizopoulos, Evangelismos General Hospital, Greece

P2.03a-030: nab-Paclitaxel/Carboplatin Induction Therapy in Squamous (SCC) NSCLC: Interim Quality of Life (QoL) Results From ABOUND.sqm
Michael Thomas, Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Germany

P2.03a-031: Metronomic Oral Vinorelbine as First-Line Treatment in Elderly (>65 Year) Patients with Advanced NSCLC
Franco Lumachi, University of Padua, School of Medicine, Italy

P2.03a-032: Palliative Chemotherapy with Oral Metronomic Vinorelbine in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unsuitable for Chemotherapy
Giuseppe Banna, Cannizzaro Hospital, Italy

P2.03a-033: Prediction of Response to First Line Treatment for Metastatic Non-Small Cell Lung Cancer
Ahmed Badawy, Alexandria University, Egypt
P2.03a-034: RRM1 - A Prognostic Marker in Advanced NSCLC among Male Smokers Receiving Chemotherapy
Maha Yehia, National Cancer Institute, Egypt

P2.03a-035: Down-Regulation of βIII-Tubulin and bFGF Sensitizes Non-Small Cell Lung Carcinoma A549/Taxol Cells Lines to Taxol
Qisen Guo, Shandong Cancer Hospital, China

P2.03a-036: Response of Additional Chemotherapy, since First Line Chemotherapy in Non-Small Cell Lung Cancer
Jung Hyun Chang, Ewha Womans University, South Korea

P2.03a-037: Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy
Hee Kyung Ahn, Gachon University Gil Medical Center, South Korea

P2.03a-038: Phase III Trial of Pemetrexed/Carboplatin vs Pemetrexed Only in Chemo-Naïve Elderly Non-SQCC NSCLC Patients Aged ≥ 70
Dae Ho Lee, University of Ulsan College of Medicine, Asan Medical Center, South Korea

P2.03a-039: ABOUND.70+: Interim Quality of Life (QoL) Results of nab-Paclitaxel/Carboplatin Treatment of Elderly Patients With NSCLC
Jared Weiss, Lineberger Comprehensive Cancer Center, USA

P2.03a-040: Safety and Efficacy of Nab-Paclitaxel for 2nd Line Treatment of Elderly Patients with Stage IV Non-Small Cell Lung Cancer
Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, USA

P2.03a-041: Comparison between Combination and Mono Chemotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Population-Based Study
Joung Soon Jang, Chung-Ang University College of Medicine, South Korea

P2.03a-042: Comorbidity as a Prognostic Factor in Elderly Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
Danica Sazdanic-Velikic, Institute for pulmonary Diseases of Vojvodina, Serbia

P2.03a-043: A Retrospective Analysis of the Chemotherapy for 'Very Old' Patients Aged 80 Years and Order with Advanced Lung Cancer
Yosuke Tamura, Osaka Medical College Hospital, Japan

P2.03a-044: Severe Adverse Events Impact Overall Survival (OS) and Costs in Elderly Patients with Advanced NSCLC on Second-Line Therapy
Hossein Borghaei, Fox Chase Cancer Center, USA

P2.03a-045: Safety of Bevacizumab (B) in Elderly Stage IV Non-Squamous NSCLC Patients Selected by Geriatric Assessment: A Phase II Study
Óscar Juan, Hospital Universitari i Politècnic La Fe, Spain

P2.03a-046: Safety and Efficacy Results From ABOUND.70+: nab-Paclitaxel/Carboplatin in Elderly Patients With Advanced NSCLC
Corey Langer, Abramson Cancer Center, University of Pennsylvania, USA
P2.03a-047: Clinical Trial Participation and Outcomes in Non-Small Cell Lung Cancer: Case-Control Study
Ana Laura Ortega Granados, Complejo Hospitalario de Jaén, Spain

P2.03a-048: The CDK4/6 Inhibitor G1T28 Protects Immune Cells from Cisplatin-Induced Toxicity in vivo and Inhibits SCLC Tumor Growth
John Heymach, The University of Texas M.D. Anderson Cancer Center, USA

P2.03a-049: Response to Salvage Chemotherapy Following Exposure to PD-1 Inhibitors in Patients with Non-Small Cell Lung Cancer
Paul Leger, Vanderbilt University Medical Center, USA

P2.03a-050: Elevated Expression of CCP Genes is Associated with Absolute Chemotherapy Benefit in Early Stage Lung Adenocarcinoma Patients
Prasad Adusumilli, Memorial Sloan Kettering Cancer Center, USA

P2.03a-051: CMTM1_v17 Promotes Chemotherapy Resistance and is Associated with Poor Prognosis in Non-Small Cell Lung Cancer
Jiahui Si, Peking University Cancer Hospital & Institute, China

P2.03a-052: Phase I Study and Pharmacokinetics of Paclitaxel Micelles for Injection in Chinese Patients with Advanced-Stage Malignancies
Meiqi Shi, Jiangsu Cancer Hospital, China

P2.03a-053: Immuno-Inflammatory Markers in Advanced NSCLC Patients Undergone Fractioned Cisplatin, Oral Etoposide and Bevacizumab
Pierpaolo Correale, Azienda Ospedaliera Universitaria Senese, Italy

P2.03a-054: A Single-Arm Phase II Study of Nab-Paclitaxel for Patients with Chemorefractory Non-Small Cell Lung Cancer
Hisashi Tanaka, Hirosaki University, Japan

P2.03a-055: Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Lung Patients: A Pooled Analysis of US Cooperative Group Trials
Herbert Pang, The University of Hong Kong, China

P2.03a-056: Phase II Trial of Weekly Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: KTOSG Trial 1301
Shinya Sakata, Kumamoto University Hospital, Japan

P2.03a-057: Ligand Mediated Solid Lipid Nanoparticle of Paclitaxel for Effective Management of Bronchogenic Carcinoma
Saurabh Bhargava, Manav Bharti University, India

P2.03a-058: Is There a Place for Pemetrexed Rechallenge in Advanced Lung Adenocarcinoma?
Shun Lu, Shanghai Chest Hospital, China

P2.03a-059: LCL161 Increases Paclitaxel-Induced Apoptosis by Degrading cIAP1 and cIAP2 in NSCLC
Chengcheng Yang, The First Affiliated Hospital of Xi'an Jiaotong University, China

P2.03a-060: Favorable Survival of TTF-1 Expression in Pemetrexed Based Treated NSCLC Patients
Claus Steppert, Klinikum Bayreuth, Germany
P2.03a-061: Randomized Phase II Trial Comparing Intercala
tion of Afatinib to Pemetrexed with Pemetrexed Alone after Failure of Platinum Doublet Therapy
Shinkyo Yoon, Bundang Jesaeng General Hospital, South Korea

P2.03a-062: Characterisation and Targeting of the DNA Repair Gene, XRCC6BP1, in Cisplatin Resistant NSCLC
Martin Barr, St. James's Hospital & Trinity College Dublin, Ireland

P2.03a-063: Small Molecule Cancer Stemness Inhibitor, BBI608, Restores Cisplatin Sensitivity in Resistant NSCLC
Martin Barr, Trinity College Dublin/St. James's Hospital, Ireland

P2.03a-064: Inhibition and Exploitation of Aldehyde Dehydrogenase 1 as a Cancer Stem Cell Marker to Overcome Cisplatin Resistant NSCLC
Martin Barr, Trinity College Dublin/St. James's Hospital, Ireland

P2.03a-065: Lack of Drug-Drug Interaction (DDI) between Necitumumab and Gemcitabine or Cisplatin: A Phase 2, Open-Label, Nonrandomized Study
James Lee, University of Pittsburgh Cancer Institute, USA

P2.03a-066: Pemetrexed(P) in Third and Fourth Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (Non-Squamous)-aNSCLCs
Alexandru Calin Grigorescu, Institute of Oncology Bucharest, Romania

P2.03a-067: Therapy-Related Leukemia after Lung Cancer Chemotherapy
Kazuhiro Natori, Toho University Medical Center Oomori Hospital, Japan

P2.03a-068: Impact of Platinum/Pemetrexed versus Other Platinum-Based Regimens on Adjuvant Chemotherapy in Resected Adenocarcinoma Lung Cancer
Wang Ziping, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P2.03a-069: Effectiveness of Adjuvant Carboplatin-Based Chemotherapy Compared to Cisplatin in Resected Non-Small Cell Lung Cancer
Pierre-Yves Gagnon, IUCPQ, Canada

P2.03a-070: A Feasibility Study of Adjuvant Chemotherapy with Modified Weekly Nab-Paclitaxel and Carboplatin for Completely Resected NSCLC
Hisashi Saji, St. Marianna University School of Medicine, Japan

P2.03a-071: Adjuvant Chemotherapy Following Resection of NSCLC: An Audit of 5 Years of Practice and Outcomes in South West Wales
Amy Case, Singleton Hospital, UK

P2.03b ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY

P2.03b-001: A Phase I Dose Expansion Study of Epitinib to Evaluate Efficacy and Safety in EGFR Mutation Positive (EGFRm+) NSCLC Patients with Brain Metastasis
Qing Zhou, Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, China

P2.03b-002: Efficacy and Safety of WBRT Combined with Endostar in Patients with Advanced Non-Small Cell Lung Cancer  
Ruiguang Zhang, Union Hospital, China

P2.03b-003: Mutation Profile & Histology According to ERS/ATC/IASCL Associated with IPFS to WBI in BM Patients with Recent Adenocarcinoma Lung Cancer  
Oscar Arrieta, National Cancer Institute, Mexico

P2.03b-004: Factors Associated with Brain Metastasis in Patients with Lung Adenocarcinoma after Surgical Resection  
Jung-Jyh Hung, Taipei Veterans General Hospital and National Yang-Ming University, Taiwan

P2.03b-005: Correlation between Primary Tumor Location and Brain Metastasis Development or Peritumoral Brain Edema in Lung Cancer  
Katalin Fabian, Semmelweis University Department of Pulmonology, Hungary

P2.03b-006: Distinct MR Imaging Features of Metastatic Lesions in Brain with Non-Small Cell Lung Cancer According to EGFR Mutation Status  
Yan Cheng, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P2.03b-007: Palliative Whole Brain Radiotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC), the University College London Hospital Experience  
Amy Ward, University College London, UK

P2.03b-008: The Impact of Brain Metastases and Their Treatment on Health Utility Scores in Molecular Subsets of Lung Cancer Patients  
Grainne O’Kane, Princess Margaret Cancer Centre, Canada

P2.03b-009: Brain Metastasis and Epidermal Growth Factor Receptor Mutations in Croatian Caucasians with Lung Adenocarcinoma  
Katherina Sreter, University Hospital Centre “Sestre Milosrdnice”, Croatia

P2.03b-010: EGFR Mutation Status Analysis in Cerebrospinal Fluid and Plasma of Advanced Lung Adenocarcinoma with Brain Metastases  
Zhe Liu, Beijing Chest Hospital, Capital Medical University, China

P2.03b-011: Screening for ALK Abnormalities in Central Nervous System Metastases of Non-Small-Cell Lung Cancer  
Pawel Krawczyk, Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland

P2.03b-012: A Phase II Study of Etirolinatagon Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer  
Joel Neal, Stanford Cancer Institute, USA

P2.03b-013: Outcome of Patients with ALK+ NSCLC and Brain Metastases in Relation to Disease Burden and Clinical Management  
Luigi De Petris, Karolinska University Hospital, Sweden
P2.03b-014: Atezolizumab in Advanced NSCLC Patients with Baseline Brain Metastases: A Pooled Cohort Safety Analysis
Rimas Lukas, The University of Chicago Medicine, USA

P2.03b-015: Efficacy of the Irreversible ErbB Family Blocker Afatinib in Treatment of an Intracerebral Non-Small Cell Lung Cancer in Mice
Shirong Zhang, Hangzhou First People's Hospital, Nanjing Medical University, China

P2.03b-016: Tesevatinib in NSCLC Patients with EGFR Activating Mutations and Brain Metastases (BM) or Leptomeningeal Metastases (LM)
Davic Berz, Beverly Hills Cancer Center, USA

P2.03b-017: Differences of Central Nerve System Metastasis during Gefitinib or Erlotinib Therapy in Patients with EGFR-Mutated Lung Adenocarcinoma
Kazushi Yoshida, National Cancer Center Hospital, Japan

P2.03b-018: Clinical Data from the Real World: Efficacy of Crizotinib in Chinese Patients with Advanced ALK+ Non-Small Cell Lung Cancer and Brain Metastases
Shouzheng Wang, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), China

P2.03b-019: Comparison of the Efficacy of First-Generation EGFR-TKIs in Brain Metastasis
Naoto Aiko, Yokohama Municipal Citizen's Hospital, Japan

P2.03b-020: EGFR Exon 19 Deletion Mutation Patients Obtain Optimal Survival in Icotinib Treated Non-Small-Cell Lung Cancer Patient with Brain Metastases
Xiao-Ling Xu, Zhejiang Province Cancer Hospital, China

P2.03b-021: Screening for Major Oncogene Alterations in Adenosquamous Lung Carcinoma Using PCR Coupled with Next-Generation and Sanger Sequencing Methods
Xiaohua Shi, Peking Union Medical College Hospital, China

P2.03b-022: Outcome in Molecularly Defined NSCLC within the NOWEL Network: The Influence of Sequential 2nd and 3rd Generation TKI in EGFR mt+ and ALK+ pts
Julia Roeper, Pius Hospital Oldenburg, Germany

P2.03b-023: Circulating Tumor DNA (ctDNA)-Based Genomic Profiling of Known Cancer Genes in Lung Squamous Cell Carcinoma (LUSC)
Vincent Lam, The University of Texas M.D. Anderson Cancer Center, USA

P2.03b-024: microRNA-330-3p Promotes Brain Metastasis of Non-Small Cell Lung Cancer (NSCLC) by Activating MAPK/MEK/ERK Signaling Pathway
Rui guang Zhang, Union Hospital, China

P2.03b-025: Mutation Profile and Histology Subtype According to IASLC/ERS/ATC as Risk Factors for Brain Metastases in Lung Adenocarcinoma
Oscar Arrieta, Instituto Nacional de Cancerología, Mexico
<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.03b-026</td>
<td>Next-Generation Sequencing for Molecular Diagnosis of Tumour Specimens from Patients with Advanced Lung Adenocarcinoma</td>
<td>Maria Gabriela Fernandes, Centro Hospitalar São João, Portugal</td>
<td></td>
</tr>
<tr>
<td>P2.03b-027</td>
<td>Circulating Free DNA (cfDNA) Analysis from Patients with Advanced Lung Adenocarcinoma</td>
<td>Maria Gabriela Fernandes, Centro Hospitalar São João, Portugal</td>
<td></td>
</tr>
<tr>
<td>P2.03b-028</td>
<td>Improved Overall Survival Following Implementation of NGS in Routine Diagnostics of Advanced Lung Cancer in Germany: Results of the NGM</td>
<td>Anna Kostenko, University Hospital of Cologne, Germany</td>
<td></td>
</tr>
<tr>
<td>P2.03b-029</td>
<td>Analysis of Genomic Alterations and Heterogeneity in Pulmonary Adenoid Cystic Carcinoma by Next-Generation Sequencing</td>
<td>Min Li, Xiangya Hospital, Central South University, China</td>
<td></td>
</tr>
<tr>
<td>P2.03b-030</td>
<td>Retrospective Review Clinical Use of a cfDNA Blood Test for Identification of Targetable Molecular Alterations in Patients with Lung Cancer</td>
<td>Hai Tran, University of Texas M.D. Anderson Cancer Center, USA</td>
<td></td>
</tr>
<tr>
<td>P2.03b-031</td>
<td>Impact of PD-L1 Status on Clinical Response in SELECT-1: Selumetinib + Docetaxel in KRASm Advanced NSCLC</td>
<td>Pasi Jänne, Dana-Farber Cancer Institute, USA</td>
<td></td>
</tr>
<tr>
<td>P2.03b-032</td>
<td>The Peculiar Changing Pattern of Serum NSE Acts as an Indicator of Transformation from Adenocarcinoma to SCLC</td>
<td>Jie Zhang, Shanghai Pulmonary Hospital, China</td>
<td></td>
</tr>
<tr>
<td>P2.03b-033</td>
<td>Clinical Effectiveness of Hybrid Capture-Based Massive Parallel Sequencing in Therapeutic Strategy Planning in Lung Cancer</td>
<td>Smadar Geva, Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Israel</td>
<td></td>
</tr>
<tr>
<td>P2.03b-034</td>
<td>Clinical Relevant Oncogenic Drivers in Advanced Adenocarcinoma Discloses New Therapeutic Targets in Negative EGFR/ALK/KRAS Patients</td>
<td>Vera Capelozzi, University of São Paulo, Brazil</td>
<td></td>
</tr>
<tr>
<td>P2.03b-035</td>
<td>EGFR FISH as Potential Predictor of Necitumumab Benefit with Chemotherapy in Squamous NSCLC: Subgroup Analyses from SQUIRE</td>
<td>Carlo Genova, IRCCS AOU San Martino - IST, Italy</td>
<td></td>
</tr>
<tr>
<td>P2.03b-036</td>
<td>Analysis of Potentially Targetable Mutations in 821 Patients with Squamouscell Lung Cancer Undergoing Routine NGS-Based Molecular Diagnostics</td>
<td>Sophia Koleczko, Lung Cancer Group Cologne, Germany</td>
<td></td>
</tr>
<tr>
<td>P2.03b-037</td>
<td>Prognostic Impact of 1st-Line Treatment and Molecular Testing in Advanced NSCLC in France - Results of the IFCT-PREDICT.amm Study</td>
<td>Jacques Cadranel, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, France</td>
<td></td>
</tr>
<tr>
<td>P2.03b-038</td>
<td>The Diagnostic and Prognostic Value of CSF Cyfra 21-1 in Patients with Leptomeningeal Metastasis of Non-Small Cell Lung Cancer</td>
<td>Jae-Won Hyun, National Cancer Center, South Korea</td>
<td></td>
</tr>
</tbody>
</table>
P2.03b-039: Cell-Free (cf) DNA and cfRNA levels in Plasma of Lung Cancer Patients Indicate Disease Status and Predict Progression
Luis Raez, Memorial Cancer Institute, USA

P2.03b-040: NANOG Predicts Poor Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
Seung Hyeun Lee, Kyung Hee University Medical Center, South Korea

P2.03b-041: Cerebrospinal Fluid Tumor Cells for Diagnosis of Leptomeningeal Metastases in Non-Small Cell Lung Cancer
Yang-si Li, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P2.03b-042: MET exon 14 Mutations Encode a Hyperactive Kinase and Therapeutic Target in Lung Adenocarcinoma
Nir Peled, Rabin Medical Center, Israel

P2.03b-043: Peripheral Blood CD45RA+ CCR7+ Naive T Cells Were Correlated with Prognosis in Non-Small Cell Lung Cancer Patients
Shu-Mei Huang, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P2.03b-044: Treatment Outcome and the Role of Primary Tumor Therapy in a Cohort of Patients with Synchronous Oligometastatic NSCLC
Jose Carlos Ruffinelli, Medical Oncology Dept Catalan Institute of Oncology - ICO Hospitalet, Spain

P2.03b-045: Assessment of microRNAs in FFPE Tissue for Prediction of the Effect of Palliative Chemotherapy for Squamous Cell Carcinoma of the Lung
Martin Svaton, Charles University in Prague, Czech Republic

P2.03b-046: Clinicopathologic Characteristics, Genetic Variability and Therapeutic Options of RET Rearrangement Patients in Lung Adenocarcinoma
Zhengbo Song, Zhejiang Cancer Hospital, China

P2.03b-047: The Clinical Impact of Multiplex ctDNA Gene Analysis in Lung Cancer
Smadar Geva, Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Israel

P2.03b-048: Access to Biomarker Testing in Patients with Advanced Non-Small Cell Lung Cancer
Apar Ganti, Veteran's Affairs Nebraska-Western Iowa Health Care System, University of Nebraska Medical Center, USA

P2.03b-049: Molecular & Clinical Status of Current Biomarkers: EGFR, ALK, ROS, MET of Lung Cancer in North Indian Patients
Moushumi Suryavanshi, Rajiv Gandhi Cancer Institute and Research Center, India

P2.03b-050: Prognostic Value of HLA-A2 Status in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Laura Mezquita, Gustave Roussy, France

P2.03b-051: TrxR1: A Novel Biomarker Proved to Be Prognostic Factor and Evidence to Provide Newly Treatment Strategies in Metastatic EGFR Wild-Type NSCLC
Yongchang Zhang, Hunan Cancer Hospital, China
P2.03b-052: XRCC1 Arg399Gln and Rad51 G135C Gene Polymorphisms in Advanced Lung Adenocarcinoma in Serbia
Jelena Spasic, Institute for Oncology and Radiology of Serbia, Serbia

P2.03b-053: Role of KRAS Mutation Status in NSCLC Patients Treated on SWOG S0819, a Phase III Trial of Chemotherapy with or without Cetuximab
Philipp Mack, UC Davis Comprehensive Cancer Center, USA

P2.03b-054: Biomarker Predictors in NSCLC
Maha Yahia, National Cancer Institute, Egypt

P2.03b-055: Survival in Non-Small Cell Lung Cancer (NSCLC) Patients (pts) with Driver Mutations at Sandton Oncology Centre, South Africa
Sze Wai Chan, Sandton Oncology Centre, South Africa

P2.03b-056: Prognostic Value of Neutrophil to Lymphocyte Ratio Was Influenced by Albumin Level
Zhen-Yu Ding, West China Hospital, China

P2.03b-057: Diagnostic Value of Tumor Markers in Lung Adenocarcinoma-Associated Cytologically Positive and Negative Pleural Effusions
Cheng-Chuan Su, Buddhist Dalin Tzu Chi Hospital, Taiwan

P2.03b-058: Blood Cell Count Ratios at Diagnosis as Prognostic Markers in Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Eliza Ricardo, A.C. Camargo Cancer Center, Brazil

P2.03b-059: Detection of Circulating Tumor Cells Using Multiple mRNA in Situ Hybridization Predicts Metastasis in Non-Small Cell Lung Cancer
Shirong Zhang, Hangzhou First People's Hospital, Nanjing Medical University, China

P2.03b-060: Baseline Skeletal Muscle Index (SMI) Values Are Associated with Biomarkers of Insulin Resistance in Stage IV Non-Small Cell Lung Cancer
Marta Batus, Rush University Medical Center, USA

P2.03b-061: Baseline Neutrophil-Lymphocyte Ratio is Related to Baseline Presence of Brain Metastases and Subsequent Brain Metastases in Stage IV NSCLC
Young Wha Koh, Ajou University School of Medicine, South Korea

P2.03b-062: Association of the FAACT Total Score and Subscales with Clinical Characteristics and Survival in Advanced Lung Cancer
Oscar Arrieta, National Cancer Institute, Mexico

P2.03b-063: Molecular Profiling in Advanced Non-Small-Cell Lung Cancer: Preliminary Data of an Italian Observational Prospective Study
Silvia Novello, Department of Oncology, University of Turin, AOU San Luigi, Italy

P2.03b-064: Genomic Profiling in Non Small Cell Lung Cancer: New Hope for Personalized Medicine
Satheesh Thungappa, HCG Bangalore Institute of Oncology Speciality Centre, India

P2.03b-065: Serum and Bronchoalveolar Lavage Levels of Adiponectin in Advanced Non-Small Cell Lung Cancer: Results of a Prospective Study
Kostas Syrigos, Medical School, University of Athens, Greece
P2.03b-066: Diagnostic Value of Pleural Cytology Together with Pleural CEA and VEGF in Patients with NSCLC and Lung Metastases from Breast Cancer
Franco Lumachi, University of Padua, School of Medicine, Italy

P2.03b-067: Predictors of Advanced Squamous Cell Lung Cancer Prior to Biopsy; Biological Behavior and Prognostic Factors
Hala Aziz, National Cancer Institute, Egypt

P2.03b-068: The Druggable Mutation Landscape of Lung Adenocarcinoma
Siraj Ali, Foundation Medicine, USA

P2.03b-069: LKB1 Loss is a Novel Determinant of MEK Sensitivity Due to Alterations in AKT/FOXO3 Signaling
Tadaaki Yamada, Kanazawa University, Japan

P2.03b-070: Establishment of Organoid Cell Lines from Lung Squamous Cell Carcinoma
Ruoshi Shi, Ontario Cancer Institute, Canada

P2.03b-071: Therapeutic Targeting of the Phosphatidylinositol-3 Kinase Pathway in Lung Squamous Cell Carcinoma
Ruoshi Shi, Ontario Cancer Institute, Canada

P2.03b-072: Resistance to BET Inhibitors in Lung Adenocarcinoma is Mediated through a MYC Independent Mechanism
Jack Calder, BC Cancer Research Center, Canada

P2.03b-073: High Concordance of Somatic SNVs between Tumor-Only and Tumor-Normal Testing: Implications for Clinical Practice
Dongmei Lin, Peking University Cancer Hospital, China

P2.03b-074: NSCLC Homing Nanoparticles Selectively Transfect Lung Cancer
Gregory Holt, University of Miami, USA

P2.03b-075: PD-1 Protein Expression Predicts Survival in Resected Adenocarcinomas of the Lung
Martin Filipits, Medical University of Vienna, Austria

P2.03b-076: MAP2K1 Mutations in NSCLC: Clinical Presentation and Co-Occurrence of Additional Genetic Aberrations
Alessandra Holzem, Department I of Internal medicine University Hospital of Cologne, Germany

P2.03b-077: EGFR/ALK+ Patient-Derived Xenografts from Advanced NSCLC for TKI Drug Selection & Resistance Development: The REAL-PDX Study
Michael Cabanero, University of Toronto, University Health Network, Canada

P2.03b-078: MET Gene Amplification and Overexpression in Chinese NSCLC Patients without EGFR Mutations
Zhengbo Song, Zhejiang Cancer Hospital, China

P2.03b-079: Decreased Expression of miR-125a-3p is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients
Likun Hou, Tongji University School of Medicine, China
P2.03b-080: A Comprehensive Test of Cancer Treatment-Related Genes for the Clinical Samples of Non-Small Cell Lung Cancer (NSCLC)
Yoshiaki Inoue, Saitama Medical University Saitama Medical Center, Japan

P2.03b-081: Comparison of Genomic Alterations Derived from Matched Tumor Tissue and Liquid Biopsy
Judith Müller-Eisert, NEO New Oncology, Germany

P2.03b-082: AQP11 as a Novel Factor of Lung Cancer Cell Resistance to Cisplatin
David Carbone, The Ohio State University, USA

P2.03b-083: Soluble Angiogenic Factors as Predictive Biomarkers of Response to Docetaxel plus Nintedanib as Second Line Therapy in NSCLC
Denisse Lee-Cervantes, Instituto Nacional de Cancerologa, Mexico

P2.03b-084: Profiling of Eph Signaling in Malignant Pleural Effusions- Identification of Therapy Approaches and Associated Biomarkers
Metka Novak, Karolinska Institutet, Sweden

P2.03b-085: Programmed Cell Death Ligand 1 (PD-L1) Expression in Stage II and III Lung Adenocarcinomas
Hironori Uruga, Toranomon Hospital, Japan

P2.03b-086: High Expression of PDL-1 Correlates with Pleomorphic Features in Non-Small Cell Lung Carcinomas
Francois Kwong, Royal Brompton and Harefield NHS Foundation Trust, UK

P2.03b-087: PD-L1 Expression in Adenosquamous Lung Carcinoma and the Comparison with the Other Common Variants of Non-Small Cell Lung Cancer
Xiaohua Shi, Peking Union Medical College Hospital, China

P2.03b-088: PET-CT with 68Ga-RGD as Biomarker of Response to Nintedanib plus Docetaxel as Second Line Therapy in NSCLC
Denisse Lee-Cervantes, Instituto Nacional de Cancerologa, Mexico

P2.03b-089: CD1C in Lung Adenocarcinoma: Prognosis and Cellular Origin
Chang-Qi Zhu, University Health Network, Canada

P2.03b-090: A CTLA-4 Antagonizing DNA Aptamer with Anti-Tumor Effect
Bo-Tsang Huang, Institute of Biomedical Science, Academia Sinica, Taiwan

P2.03b-091: CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer
Hui Zhao, The Second Affiliated Hospital, Dalian Medical University, China

P2.03b-092: Predictive and Prognostic Effect of Circulating Tumor Cells in Non-Small Cell Lung Cancer Treated with Targeted Therapy
Chunxia Su, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P2.03b-093: Validation and Performance of a Standardized ctDNA NGS Assay across Two Laboratories
Emma Green, Inivata Ltd., UK
P2.03b-094: Prognostic Value of Serum Carcinoembryonic Antigen during Conventional Chemotherapy in Advanced (Non-)Small Cell Lung Cancer
C. De Jong, St Antonius Hospital, Netherlands

P2.03b-095: Retrospective Analysis of Correlation between ACEIs/ARBs and Clinical Outcome in Lung Cancer Patients with Bevacizumab-Based Chemotherapy
Sachi Okawa, Kobe Red-Cross Hospital, Japan

P2.03b-096: Utilisation of a Novel 3D Culture Technology for the Assessment of Chemo-Resistance in Non-Small Cell Lung Cancer
Sarah-Louise Ryan, Queensland University of Technology, Australia

P2.03b-097: Prognostic Factors for Overall Survival among Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Katharina Verleger, Pharmerit International, Germany

P2.03b-098: Comparison of Digital PCR, Ion Proton with ARMS-PCR in Tumor Tissue and Plasma of NSCLC Patients
WanChun Zang, Novogene Bioinformatics Institute, China

P2.04 - MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES

P2.04 - MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES - THYMIC MALIGNANCIES CLINICAL & TRANSLATIONAL

P2.04-001: A Comparative Analysis of Long-Term Outcome of Thymoma between Video-Assisted Surgery and Open Resection from Multi-Center Study Data
Su Kyung Hwang, Asan Medical Center, University of Ulsan College of Medicine, South Korea

P2.04-002: The Efficacy of Postoperative Radiotherapy against Thymic Epithelial Tumors According to Masaoka Staging and WHO Classification
Kai Obayashi, Gunma University Hospital, Japan

P2.04-003: Chemotherapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort
Nicolas Girard, Hospices Civils de Lyon, France

P2.04-004: Thymectomy without Definitive Diagnosis Could Be Feasible in Patients with Suspicious of Thymic Epithelial Tumor
Shuhei Hakiri, Nagoya University, Japan

P2.04-005: WHO Classification and IASLC/ITMIG Staging Proposal in Thymic Tumors: Real-Life Assessment
Nicolas Girard, Hospices Civils de Lyon, France

P2.04-006: Updated Incidence of Thymic Epithelial Tumors (TET) in France and Clinical Presentation at Diagnosis
Nicolas Girard, Louis Pradel Hospital, France

P2.04-007: Role of F-18-Choline Petscan in Recurrence of Thymic Epithelial Tumors (TET)
Benjamin Besse, Gustave Roussy, France
P2.04-008: Diagnostic Performance of PET-CT for Anterior Mediastinal Lesions - The DECiMaL Study
Chiara Proli, Royal Brompton & Harefield NHS Foundation Trust, UK

P2.04-009: Tumor Size Did Not Affect Masaoka Staging as Predictors of Recurrence in Thymoma
Yen-Chiang Tseng, Kaohsiung Veterans General Hospital, Taiwan

P2.04-010: Survival after Surgery and Radiotherapy for Thymic Epithelial Tumours: A Single-Centre Experience from the United Kingdom
Hemal Ariyaratne, University College London Hospital, UK

P2.04-011: Tumours of the Thymus: Northern Ireland 11 Year Experience
Lynn Campbell, Belfast City Hospital, UK

P2.04-012: A Risk of Death from a Second Cancer Following Complete Resection of Thymoma
Masatsugu Hamaji, Kyoto University, Japan

P2.04-013: Prognosis Factors and Survival Analysis in Thymic Epithelial Tumors
Margarita Majem, Hopital de la Santa Creu i Sant Pau, Spain

P2.04-014: Retrospective Study of Pleuropneumonectomy for Thymoma with Dissemination
Shiaki Oh, Juntendo University School of Medicine, Japan

P2.04-015: Thymoma and Thymic Carcinoma - Our Experience
Jana Kulísková, University hospital Olomouc, Czech Republic

P2.04-016: Is FDG-PET Useful for Distinguishing between Thymic Epithelial Tumors and Malignant Lymphoma?
Hiroyuki Sakamaki, Keio University School of Medicine, Japan

P2.04-017: Prognostic Relevance of PD-1/PD-L1 Pathway in Thymic Malignancies with Combined Immunohistochemical and Biomolecular Approach
Rossana Berardi, Università Politecnica delle Marche - AOU Ospedali Riuniti, Italy

P2.04-018: Comprehensive Copy Number Alteration and Gene Expression Analysis of Surgically Resected Thymic Carcinoma
Takao Nakanishi, Graduate School of Medicine, Kyoto University, Japan

P2.04-019: A Peripheral Immune Signature Associated with Clinical Activity of Sunitinib in Thymic Carcinoma
Arun Rajan, Center for Cancer Research, NCI, NIH, USA

P2.04-020: Expression Patterns and Prognostic Value of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma
Dwight Owen, Ohio State University Comprehensive Cancer Center, USA

P2.04-021: Role of Adjuvant Radiotherapy and Prognostic Factor Analysis in Thymic Malignancies: A Retrospective Analysis of 129 Consecutive Patients
Alessio Bruni, Aou Policlinico Of Modena, Italy

P2.04-022: Impact of Metastasis Site for Survival of Patients with Advanced Thymic Epithelial Tumors
Zhengbo Song, Zhejiang Cancer Hospital, China
P2.04-023: Rare Frequency of Gene Variation and Survival Analysis in Thymic Epithelial Tumors
Zhengbo Song, Zhejiang Cancer Hospital, China

P2.04-024: Thymic Epithelial Tumors and Radiotherapy Results
Sureyya Sarihan, Uludag University, Turkey

P2.04: MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES - ESOPHAGEAL CANCER AND OTHER MALIGNANCIES

P2.04-025: Recombinant Human Endostatin and/or Cisplatin in Treatment of Malignant Hydrothorax and Ascites: A Multicenter Randomized Study
Jun Liang, Beijing Cancer Hospital, China

P2.04-026: Expression Patterns of PD-L1 in Esophageal Adenocarcinomas: Comparison between Primary Tumors and Metastases
Rupert Langer, Institute of Pathology, University of Bern, Switzerland

P2.04-027: Targeting Adenosine A2B Receptor for Modulation of Tumor Microenvironment, Primary Tumor Growth, and Lung Metastasis
David Carbone, The Ohio State University, USA

P2.04-028: Cone-Beam CT Virtual Navigation-Guided Percutaneous Needle Biopsy of Suspicious Pleural Metastasis: Initial Experience
Hyun-Ju Lim, Seoul National University Hospital, South Korea

P2.04-029: Primary Pulmonary Sarcoma: Risks and Optimal Surgical Treatment Options
Yoshito Yamada, Zurich University Hospital, Switzerland

P2.04-030: Airway Intervention in the Management of Low Grade Malignant Bronchogenic Neoplasms
Anne Hsu, Singapore General Hospital, Singapore

P2.04-031: Predictors of Pathological Complete Response (TRG=1) among Esophageal Cancer Cases; NCI Pooled Data
Fatma Abou Elkassem, National Cancer Institute, Egypt

P2.04-032: Pulmonary Sarcomatoid Carcinoma (PSC): Experience of 45 Patients at a Comprehensive Cancer Center
Nabeela Khan, State University of New York Downstate, USA

P2.04-033: Primary Salivary Gland Tumors of the Lung: A Systematic Review and Pooled Analysis
Pankaj Garg, University College of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi, India

P2.04-034: SPARC/β-Tubulin III Expressions for Clinical Outcomes of ESCC Patients Receiving Nab-Paclitaxel plus DDP Neoadjuvant Chemotherapy
Yun Fan, Zhejiang Cancer Hospital, China

P2.04-035: Surgical Perplexities in a Rare Case of Symptomatic Mediastinal Lymphangioma
Kingsfield Ong, Tan Tock Seng Hospital, Singapore

P2.04-036: Giant Primary Dedifferentiated Liposarcoma of the Anterior Mediastinum: An Extremely Rare Occurrence
Luigi Ventura, Thoracic Surgery, University Hospital of Parma, Italy
P2.04-037: Solitary Fibrous Tumor of the Pleura Associated with Severe Hypoglicemia: The Doege-Potter Syndrome
Luigi Ventura, Thoracic Surgery, University Hospital of Parma, Italy

P2.04-038: Primary Pulmonary Meningioma: Rare Tumour with Malignant Potential
Kingsfield Ong, Tan Tock Seng Hospital, Singapore

P2.04-039: Long-Term Risk of Recurrence in Benign Pleural Solitary Fibrous Tumors: A Single Institution Review
Gavitt Woodard, UCSF, USA

P2.04-040: Pleural Effusion Characteristics and Relationship with Outcomes in Cancer Patients
Patricia Thompson, Cancer Treatment Centers of America, USA

P2.04-041: Two Cases of Pulmonary Schwanoma
Tsunehiro Ii, Otsu Municipal Hospital, Japan

P2.04-042: Epithelial-Myoepithelial Tumour of Unknown Origin: An Interesting Case Report with Unexpected Outcome
Nektarios Alevizopoulos, Evaggelismos General Hospital, Greece

P2.04-043: Squamous Cell Carcinoma Arising from the Pleura. An Interesting Case Report
Nektarios Alevizopoulos, Evaggelismos General Hospital, Greece

P2.04-044: Mediastinal Neurogenic Tumors: Histopathological Characteristics and Surgical Treatment in a Single-Institutional Experience
Fatmir Caushi, University Hospital of Lung Diseases, Albania

P2.04-045: Management of Malignant Pleural Effusions: Ten Years Experience of a Single Center
Fatmir Caushi, University Hospital of Lung Diseases, Albania

P2.04-046: A Rare Case of Pleuro-Pulmonary Epithelioid Hemangioendothelioma
Giulia Pacella, Ospedali Riuniti di Foggia, Italy

P2.04-047: A Rare Case of Extramedullary Plasmacytoma Occurring in the Posterior Mediastinum
Giulia Pacella, Ospedali Riuniti di Foggia, Italy

P2.04-048: Sarcomatoid Carcinoma of Lung
Berna Komurcuoglu, Izmir Suat Seren Education Hospital for Chest Disease, Turkey

P2.04-049: Treatment for Three Cases Tracheal Carcinoma of Low-Grade Malignancy
Yutaka Oshima, Showa University Hospital, Japan

P2.04-050: Giant Solitary Fibrous Tumor of the Pleura Saved by Biopsy and Following Extended Resection: A Long Term Surviving Case
Jun Zhang, China Medical University Lung Cancer Center, The First Hospital of China Medical University, China

P2.04-051: Palliative Treatment of Dysphagia Syndrome in Patients with Gastroesophageal Cancer
Irina Schetkina, Ministry of Healthcare of Perm region State Budget Health Care Establishment “Ordena “Znak Pocheta” Perm Regional Clinical Hospital”, Russia
P2.04-052: Promoter Hypermethylation of DNA Mismatch Repair Gene hMLH1 of Lung Cancer in Chromate-Exposed Workers  
Mitsuhiro Tsuboi, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan

P2.04-053: Surgery of Multiple Lung Metastases in Patients with Sarcomas and Epithelial Tumors  
Yury Ragulin, Medical Radiological Research Center, Russia

P2.04-054: Pleural CEA and C-Reactive Protein in Patients with Lung Metastases and Malignant Pleural Effusion. A Prospective Case-Control Study  
Franco Lumachi, University of Padua, School of Medicine, Italy

P2.05 RADIOTherapy

P2.05 RADIOTherapy - BIOLOGY

P2.05-001: α7-nAChR Agonist GTS-21 Reduces Radiation-Induced Lung Injury by Inhibiting HMGB1/TLR-4/NF-κB Pathway  
Conghua Xie, Zhongnan Hospital of Wuhan University, China

P2.05-002: CACNA2D1 Enhances Radio-Resistance in Cancer Stem-Like Cells in NSCLC  
Siyuan Zhang, Peking University Cancer Hospital and Institute, China

P2.05-003: PIK3CA Mutation is Associated with Increased Local Failure in Lung Stereotactic Body Radiation Therapy (SBRT)  
Abraham Wu, Memorial Sloan Kettering Cancer Center, USA

P2.05-004: ABT-737, a BH3 Mimetic, Enhances Therapeutic Effect of Ionizing Radiation in Murine Lung Cancer Model  
Jung Mo Lee, Yonsei University College of Medicine, South Korea

P2.05-005: Mechanism of Radiotherapy in Reduction/Delay of T790M-Mediated EGFR TKI Resistance  
Shirong Zhang, Hangzhou First People's Hospital, Nanjing Medical University, China

P2.05 RADIOTherapy - CLINICAL OUTCOME

P2.05-006: Radiotherapy as Definitive Treatment in Patients Aged 70 Years and Older with Non-Small Cell Lung Cancer  
Sureyya Sarihan, Uludag University, Turkey

P2.05-007: Outcomes after Stereotactic Body Radiotherapy/Proton Beam Therapy or Wedge Resection for Stage I Non-Small-Cell Lung Cancer  
Yasuhisa Ohde, Shizuoka Cancer Center, Japan

P2.05-008: Can Stereotactic Body Radiation Therapy (SBRT) Be an Effective Treatment for Lung Metastases From “Radioresistant” Histologies?  
Davide Franceschini, Humanitas Clinical and Research Center, Italy

P2.05-009: The Outcome and Adverse Event of Chemoradiation ± Surgery for Stage III Non-Small Cell Lung Cancer  
Shigehiro Kudo, Saitama Cancer Center, Japan
P2.05-010: Stereotactic Radioterapy (SBRT) for Primary and Metastatic Lung Tumors in Elderly Patients
Luis Larrea, Hospital NISA Virgen del Consuelo, Spain

P2.05-011: The Current Status of Radiotherapy in the Definitive Treatment of Lung Cancer in a Developing Country: Turkey
Deniz Yalman, Ege University Faculty of Medicine, Turkey

P2.05-012: Definitive Radiotherapy and Survival in Lung Cancer: Results from a Brazilian Cohort Study
Matheus Leal, UFRGS, Brazil

Wai Kong Tsang, Prince of Wales Hospital, Hong Kong

P2.05-014: Sites of Recurrent Disease in SCLC Patients Treated with Radiochemotherapy - Is Selective Nodal Irradiation Safe?
Calogero Gumina, Medical Faculty and University Hospital Carl Gustav Carus, Germany

P2.05-015: Long-Term Outcomes of Prospective Phase II Clinical Trial for Stereotactic Ablation Radiotherapy in Recurrent NSCLC
Joe Chang, The University of Texas MD Anderson Cancer Center, USA

P2.05-016: Higher Dose of Radiotherapy Better for Outcome of Patients with Locally Advanced Non-Small Lung Cancer
Martina Vrankar, Institute of Oncology Ljubljana, Slovenia

P2.05-017: Tumor Regression Gradient Predicts Disease Free Survival
Yolande Lievens, Ghent University Hospital, Belgium

P2.05-018: Re-Irradiation Using SBRT: A Good Option as a Salvage Treatment in Pulmonary Lesions
Arturo Navarro-Martín, Catalan Institute of Oncology - ICO Hospitalet, Spain

P2.05-019: Stereotactic Body Radiotherapy (SBRT) for Central Lung Tumors: The Experience of Florence University-Careggi Hospital Radiotherapy
Vieri Scotti, Radiation Oncology Unit, Italy

P2.05-020: Survival Outcomes in Stage 1 NSCLC Following Stereotactic Ablative Radiotherapy or Conventional Radiotherapy
Gerard Hanna, Queen's University of Belfast, UK

P2.05-021: Stereotactic Radiosurgery for Brain Metastasis in Non-Small Cell Lung Cancer: Predictor of Intracranial Progression
Yeon Sil Kim, Seoul St. Mary's Hospital, The Catholic University of Korea, South Korea

P2.05-022: Is Post-Chemotherapy Tumor Volume Sufficient RT Target Volume in Patients with LD-SCLC?
Jae Myoung Noh, Samsung Medical Center, South Korea

P2.05-023: Patterns of Failure after Adjuvant Radiation Therapy Based On "Tumor Bed with Margin" for Stage III Thymic Epithelial Tumor
Jae Myoung Noh, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea
P2.05-024: Current Status of Stereotactic Body Radiation Therapy (SBRT) in Japan
Yasushi Nagata, Hiroshima University, Japan

P2.05-025: 9-Year Experience: Prophylactic Cranial Irradiation in Extensive Disease Small-Cell Lung Cancer
Denise Bernhardt, Heidelberg Institute of Radiation Oncology (HIRO), Germany

P2.05: RADIOTherapy - MULTIMODALITY TREATMENT

P2.05-026: Postoperative Radiotherapy in Non-Small Cell Lung Cancer: 20 Years' Experience in a Single Centre
Deniz Yalman, Ege University Faculty of Medicine, Turkey

P2.05-027: Effects of Thermo-Chemotherapy for Lung Cancer Induced by Nano-Paclitaxel Magnetic Fluid
Runlei Hu, Hangzhou First People's Hospital, China

P2.05-028: Comparison of Adjuvant Chemotherapy with or without Radiotherapy in NSCLC Patients with Stage IIIA-Single Station N2
Jian Ni, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P2.05-029: Microwave Thermal Therapy Enhances Radiosensitivity of Highly Invasive Human Non-Small Cell Lung Cancer H460 Cells via Inhibiting DNA Repair
Shirong Zhang, Hangzhou First People's Hospital, Nanjing Medical University, China

P2.05-030: WBRT Prior EGFR TKIs is Effective Treatment Option for NSCLC Patients with CNS Metastases Harboring EGFR Mutation
Pawel Krawczyk, Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland

P2.05-031: The Clinical Impact of Different Chemotherapy Regimen Combined with Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer
Jiancheng Li, Fujian Cancer Hospital, China

P2.05-032: CT-Based Surrogates of Pulmonary Ventilation in Lung Cancer: A Voxel-Level Comparison with HP Gas MRI
Matthew Hatton, Weston Park Hospital, UK

P2.05: RADIOTherapy - RT TECHNIQUES

P2.05-033: Predictors of Survival after Whole Brain Radiotherapy for Patients with Brain Metastasized Lung Cancer
Georgios Tsakonas, Karolinska Institute, Sweden

P2.05-034: New 3D «All in 1» Device for Fiducial Tumor Marking: A Pilot Animal Study
Bruno Escarguel, Hopital Saint Joseph, France

P2.05-035: Interim Analysis of the Phase II Trial Dose Risk Adapted FFF Using SBRT in Stage I NSCLC and Lung Metastases (NCT01823003)
Arturo Navarro-Martin, Catalan Institute of Oncology - ICO Hospitalet, Spain

P2.05-036: Single Fraction of SBRT for Pulmonary Lesions
Arturo Navarro-Martin, Catalan Institute of Oncology - ICO Hospitalet, Spain
P2.05-037: Higher Radiation Dose is Still Promising in Patients with Complete Response to 50 Gy of Early Thoracic Radiotherapy with Chemotherapy?
Sung-Ja Ahn, Chonnam National University Hwasun Hospital, South Korea

P2.05-038: Initial Clinical Experience of VMAT-SBRT with Flattening-Filter-Free Techniques in the University of Tokyo Hospital
Shuri Aoki, University of Tokyo Hospital, Japan

P2.05-039: Assessment of Lung Tumour Motion Comparing 4DCT, 4DCBCT and Motion of Implanted Beacons during Imaging and Irradiation
Elisabeth Steiner, University of Sydney, Australia

P2.05-040: Interobserver Variability in the Definition of the Primary Lung Cancer and Lymph Nodes on Different 4DCT Reconstructions
Susan Mercieca, University of Malta, Malta

P2.05-041: Accelerated Radical Radiotherapy for Non Small Cell Lung Cancer: Single Centre Experience of Two Fractionations
Stephen Robinson, Sheffield Teaching Hospitals, UK

P2.05-042: Development of Thoracic Magnetic Resonance Imaging (MRI) for Radiotherapy Planning
Fiona McDonald, Institute of Cancer Research & Royal Marsden Hospital, UK

P2.05-043: Lung Tumour Motion Kilovoltage Intrafraction Monitoring (KIM): First Clinical Results
Fiona Hegi-Johnson, University of Sydney, Australia

P2.05-044: Influence of Technological Advances and Institutional Experience on Outcome of Stereotactic Body Radiotherapy for Lung Metastases
Juliane Hoerner-Rieber, Universitätsklinikum Heidelberg, Germany

P2.05-045: Accelerated Radical Radiotherapy for Non Small Cell Lung Cancer: Single Centre Experience of Two Schedules in the Treatment of Elderly Patients
Stephen Robinson, Sheffield Teaching Hospitals, UK

P2.05-046: Is Delineating Clinical Target Volume a Must for Medium and Late Stages of Non-Small Cell Lung Cancer?
Jiancheng Li, Fujian Cancer Hospital, China

P2.05-047: Feasibility Study: Assessment of RT Dose Using Cardiac MRI Contouring Methodology on Retrospective Lung Planning CT Scans
Nazia Mohammed, Beatson West of Scotland Cancer Centre, UK

P2.05-048: Directional Characteristics of Motion Marker in CBCT for Target Localization for Lung Stereotactic Body Radiotherapy (SBRT)
Kaile Li, Associates in Medical Physics, USA

P2.05 - RADIOTHERAPY - TOXICITIES

P2.05-049: Radical Treated NSCLC Radiotherapy Patients: A Prospective Study of Toxicities and Outcomes
Nathaniel Hatton, University of Glasgow, UK
P2.05-050: Impact of Inflammation and Sarcopenia on Outcomes after Stereotactic Body Radiotherapy for T1N0M0 Non-Small Cell Lung Cancer
Yukinori Matsuo, Kyoto University, Japan

P2.05-051: Safety of Lung Stereotactic Body Radiotherapy (SBRT): A Single Institution Prospective Study Based on RTOG 0915 Protocol Constraints
Christine Seebacher, S. Maurizio Hospital, Italy

P2.05-052: A Systematic Review and Meta-Analysis of Pneumonitis in Radically Treated NSCLC Patients: SABR vs. Non-SABR Treatment
Fiona Hegi-Johnson, University of Sydney, Australia

P2.05-053: Discussion and Analysis of Pneumonitis Related to Stereotactic Radiotherapy in Our Hospital
Keisuke Imasaka, Saiseikai Yokohamashi Tobu Hospital, Japan

P2.05-054: Radiation Pneumonitis; Early Diagnosis and Protein Expression Profile in NSCLC Patients
Samantha Aso, Bellvitge Hospital, Spain

P2.05-055: 90 Day Mortality and Survival Following Radical Radiotherapy for Non-Small Cell Lung Cancer Treated in the Dorset Cancer Centre, UK
Matthew Roberts, Poole Hospital, UK

P2.05-056: Safety of Stereotactic Body Radiotherapy for Central, Ultracentral, and Paramediastinal Lung Tumors
Megan Daly, University of California Davis Comprehensive Cancer Center, USA

P2.05-057: Baseline Inflammatory and Immunological Profile Predict the Survival of NSCLC Patients Undergone Palliative Radiotherapy
Pierpaolo Pastina, Azienda Ospedaliera Universitaria Senese, Italy

P2.05-058: Blood Biomarkers of Inflammation, Tumour Burden and Proliferation Predict Radiotherapy Response and Toxicity in Lung Cancer
Ahmed Salem, University of Manchester, UK

P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS

P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - PHASE I TRIALS

P2.06-001: A Study of MGCD516, a Receptor Tyrosine Kinase (RTK) Inhibitor, in Molecularly Selected Patients with NSCLC or Other Advanced Solid Tumors
Matteo Levisetti, Mirati Therapeutics, USA

P2.06-002: Phase I Study of DS-6051b, a ROS1/NTRK Inhibitor, in Japanese Subjects with Advanced Solid Tumors Harboring Either a ROS1 or NTRK Fusion Gene
Kaname Nosaki, National Kyusyu Cancer Center, Japan

P2.06-003: A Phase Ib Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant Non-Small Cell Lung Cancer (NSCLC) Progressed on EGFR-TKI
Ji Soo Park, Yonsei Cancer Center, South Korea
**P2.06-004**: A Phase 1b Study of Erlotinib and Momelotinib for EGFR TKI Naive EGFR Mutated Metastatic Non-Small Cell Lung Cancer
Sukhmani Padda, Stanford Cancer Institute/Stanford University School of Medicine, USA

**P2.06-005**: Phase 1 Study of Ramucirumab or Necitumumab in Combination with Osimertinib (AZD9291) in Advanced T790M-Positive EGFR-Mutant NSCLC
David Planchard, Gustave Roussy, France

**P2.06**  SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - PHASE I/II TRIALS

**P2.06-006**: Phase I/II Dose Escalation Study of L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients
Heman Chao, Helix BioPharma Corp., Canada

**P2.06-007**: A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC)
Robert Doebele, University of Colorado Cancer Center, USA

**P2.06-008**: Phase 1/2 Study of Mocetinostat and Durvalumab (MEDI4736) in Patients with Advanced Solid Tumors and Non Small Cell Lung Cancer (NSCLC)
Matteo Levisetti, Mirati Therapeutics, USA

**P2.06-009**: Combined PKCι and mTOR Inhibition in Advanced or Recurrent Lung Cancer, Preliminary Report of an Ongoing Phase I/II Trial
Helen Ross, Mayo Clinic Arizona, USA

**P2.06**  SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - PHASE II + NK

**P2.06-010**: AZD9291 as 1st-Line Therapy for EGFR Mutant NSCLC Patients with Concomitant Pretreatment EGFR T790M Mutation. The AZENT Study
Niki Karachaliou, Instituto Oncológico Dr Rosell (IOR), Hospital Universitario Quirón-Dexeus, Spain

**P2.06-011**: Phase 2 Study of MM-121 plus Chemotherapy vs. Chemotherapy Alone in Heregulin-Positive, Locally Advanced or Metastatic NSCLC
Arthur Kudla, Merrimack Pharmaceuticals, Inc., USA

**P2.06-012**: Phase 2 Study of Abemaciclib + Pembrolizumab in KRAS Mutation, PD-L1+, Stage IV Non-Small Cell or Squamous Cell Lung Cancer
Julien Mazieres, Hôpital Rangueil, France

**P2.06-013**: Afatinib in Patients with Advanced HER2 Mutation-Positive (M+) NSCLC Previously Treated with Chemotherapy
Caicun Zhou, Shanghai Pulmonary Hospital, China

**P2.06-014**: Phase 2 Study of Glesatinib or Sitravatinib with Nivolumab in Non-Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy
Matteo Levisetti, Mirati Therapeutics, USA

**P2.06-015**: The NICE Salvage Study: A Phase II Trial of Weekly Nab-Paclitaxel in the Salvage Setting for Advanced Non-Small Cell Lung Cancer
Takashi Niwa, Kurashiki Central Hospital, Japan
P2.06-016: Phase 2 Study of Ramucirumab plus Weekly Docetaxel in Stage IV NSCLC Following Progression after Platinum-Based Chemotherapy
Martin Sebastian, University Hospital Frankfurt, Goethe University, Germany

P2.06-017: Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET
Lyudmila Bazhenova, University of California San Diego, USA

P2.06-018: Multicenter, Single-Arm Phase II Study of Nab-Paclitaxel/Carboplatin in Untreated PS2 Patients with Advanced NSCLC: TORG1426
Yasuko Ichikawa, Teikyo University School of Medicine, Japan

P2.06-019: A Phase II Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients (pts) with Resectable Non-Small Cell Lung Cancer (NSCLC)
Dwight Owen, Ohio State University Comprehensive Cancer Center, USA

P2.06-020: A Open-Label Randomised Controlled Trial of First-Line Genexol-PM/ CrEL-Based Paclitaxel plus Cisplatin in Advanced NSCLC Patients
Baohui Han, Shanghai Chest Hospital, China

P2.06 - SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - PHASE III

P2.06-021: Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment in Subjects with EGFRMut+ NSCLC
Ronan Kelly, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, USA

P2.06-022: First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study
Tony Mok, Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong

P2.06-023: A Phase III Study Comparing Gefitinib and Inserted Cisplatin plus Pemetrexed with Gefitinib for EGFR-Mutated Advanced Non-Squamous NSCLC
Shintaro Kanda, National Cancer Center Hospital, Japan

P2.06-024: Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE-1
Benjamin Besse, Gustave Roussy, France

P2.06 - SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - MESOTHELIOMA AND SCLC

P2.06-025: DREAM - A Phase 2 Trial of DuRvalumab with First Line chEmotherApy in Mesothelioma with a Safety Run In
Anna Nowak, Sir Charles Gairdner Hospital, Australia

P2.06-026: A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma - Trial in Progress
Anna Nowak, University of Western Australia, Australia

P2.06-027: Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma
Raffit Hassan, National Cancer Institute, USA
P2.06-028: A Phase 2 Study of Prexasertib in Patients with Extensive Stage Small Cell Lung Cancer
Lauren Averett Byers, The University of Texas MD Anderson Cancer Center, USA

P2.06-029: Pilot Window-Of-Opportunity Study of Pembrolizumab in Patients with Resectable Malignant Pleural Mesothelioma (MPM)
Hedy Kindler, University of Chicago, USA

P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - SUPPORTIVE, PREVENTIVE

P2.06-030: Optimum Duration of Vitamin B12/Folate Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy: The PEMVITASTART Randomized Trial
Navneet Singh, Postgraduate Institute of Medical Education and Research (PGIMER), India

P2.06-031: QUADRUPLE THREAT: A Pilot Phase 2 Study of RRx-001 in Advanced Lung Cancer Prior to Re-Administration of Platinum Doublets
Karen Zeman, Walter Reed National Military Medical Center, USA

P2.06-032: Oral Pioglitazone for the Chemoprevention of Lung Cancer in Current and Former Smokers
Robert Keith, Denver Veteran Affairs Medical Center, USA

P2.06-033: Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects with Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy
Jesús Cárdenas Sánchez, Centro Medico de Colima, Mexico

P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - RADIOTHERAPY, TT FIELDS

P2.06-034: METIS: A Phase 3 Study of Radiosurgery with TTFields for 1-10 Brain Metastases from NSCLC
Minesh Mehta, Miami Cancer Institute, USA

P2.06-035: Exploring Recruitment Factors in a Feasibility Trial of SABR versus Surgery
Janine Bestall, Leeds institute of Health Sciences, UK

P2.06-036: LUNAR - A Phase 3 Trial of TTFields in Combination with PD-1 Inhibitors or Docetaxel for 2nd Line Treatment of Non-Small-Cell Lung Cancer (NSCLC)
Uri Weinberg, Novocure GmbH, Switzerland

P2.06-037: A Feasibility Study of Concurrent Chemoradiation Followed by Surgery for Pathologically-Proven Clinical IIIA-N2 Non-Small Cell Lung Cancer
Hiroyasu Yokomise, Kagawa University Hospital, Japan

P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - LAB., OTHER

P2.06-038: An RCT of the Detection of Autoantibodies to Tumour Antigens in Lung Cancer Using the EarlyCDT-Lung Test in Scotland (ECLS) in 12 208 Study Subjects
Alistair Dorward, NHS Greater Glasgow & Clyde, UK

P2.06-039: Searching for Standards: Multicenter Ring Trials to Evaluate Technologies for the Enrichment of Circulating Tumor Cells
Sebastian Bender, Bayer AG, Germany
P2.06-040: WINNERS Study: Does a Formal Interactive Patient Education Program Positively Impact Patient Outcomes and Satisfaction after Thoracic Surgery
Melissa Culligan, University of Maryland Medical Center, USA

P2.06-041: TeleNursing: A Thoracic Surgery Nursing Initiative Aimed at Decreasing Hospital Readmissions and Increasing Patient Satisfaction
Melissa Culligan, University of Maryland Medical Center, USA

P2.06-042: Evaluate the Utility of the Computed Bioconductance Measurement in the Diagnosis of Lung Cancer
Dawei Yang, Zhongshan Hospital Fudan University, China

P2.06-043: 3-Dimensional High Throughput Multi-Drug Screening Using Patient-Derived Tumor Cells (PDC) Established from Surgical Specimens of NSCLC
Sumin Shin, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

P2.06-044: Frequency of Mutations and Related Factors in Lung Adenocarcinoma Cases in Turkey
Senay Yilmaz, Eskisehir Osmangazi University, Turkey

P2.06-045: Initiative for Early Lung Cancer Research on Treatment (IELCART)
Claudia Henschke, Icahn School of Medicine at Mount Sinai, USA

P2.06-046: Shaping and Optimization of the Non-Small Cell Lung Cancer (NSCLC) Diagnostic Landscape in Australia and New Zealand (ANZ)
Anchit Khanna, Pfizer Oncology, Australia

P2.06-047: LRRK2-In-1 Inhibit Proliferation of Doublecortin and CaM Kinase-Like-1 (DCLK1)-Positive Lung Cancer Cells
Hiroyuki Tao, Yamaguchi Ube Medical Center, Japan

P2.07 NURSES

P2.07 NURSES - INFORMATION FOR PATIENTS

P2.07-001: Non-Negotiated Companion Influence on Information Exchange at Lung Cancer Clinic Consultations
Allison Smith, Greater Glasgow and Clyde Health Board, UK

P2.07-002: Evaluation of Providing Healthcare Information for Lung Mass Patients after Surgery
Daowan Khunyotying, Chiang Mai University, Thailand

P2.07-003: What Do People Living with and Surviving Lung Cancer and Mesothelioma Want and Need from a Recovery Care Package?
Josianne Roberts, The Rotherham NHS Foundation Trust, UK

P2.07 NURSES - DIFFERENT ASPECTS OF SYMPTOMS

P2.07-004: Social Support and Number of Symptoms One Month after Lung Cancer Surgery
Trine Oksholm, VID Specialized University, Norway
P2.07-005: Narratives from High Risk Respiratory Patients Who Had Bronchoscopy with Limited Sedation and Analgesia
Catherine Saxon, University of Queensland Thoracic Research Centre, Australia

P2.07-006: Combined Application of Two Biological Medicines with Healthcare and Health Education in Systemic Therapy Clinic
Irena Tominc, University Clinical Centre Maribor, Slovenia

P2.07 - NURSES - RESEARCH, AUDITS

P2.07-007: Thoracic Oncology Research from Concept to Home-run (TORCH): Building Research Capacity in Lung Cancer Nursing
Mary Grace Coates, Barts Health NHS Trust, UK

P2.07-008: Victorian Comprehensive Cancer Centre Lung Cancer Clinical Audit: Collecting the UK National Lung Cancer Audit data from hospitals in Australia
Mark Shaw, Peter MacCallum Cancer Centre, Australia

P2.07-009: Lung Function after Pulmonary Resection in Lung Cancer
Pernille Mikkelsen, Odense University Hospital, Denmark

P2.07-010: Hospital Readmission Rates within 30 Days Following Thoracic Oncology Surgery
Maureen King, Papworth Hospital, UK

P2.08 - PATIENT SUPPORT AND ADVOCACY GROUPS

P2.08-001: Giving a Voice to Patients and Caregivers through the Lung Cancer Canada ‘Faces of Lung Cancer’ Survey
Mark Doherty, Princess Margaret Cancer Centre, Canada

P2.08-002: Online Patient Education in Advanced Lung Cancer: Effect on Patient/Caregiver Knowledge
Elaine Hamarstrom, Medscape Education, USA

P2.08-003: Quality of Life and Patient Reported Outcome Measures for Lung Cancer Patients; Treatment Outcomes, and Patient Management
Maureen Rigney, Lung Cancer Alliance, USA

P2.08-004: The Importance of Patient Recall within Cancer Survivorship Care for Improved Post-Treatment Surveillance in Lung Cancer Survivors
Leah Backhus, Stanford University, USA

P2.08-005: Treating Cachexia-Anorexia in Lung Cancer Patients: Understanding the Patient Perspective on Novel Treatment Approaches
Upal Basu Roy, LUNGevity Foundation, USA

P2.08-006: Attempts to Improve the Patient Literacy in Japan
Tetsuya Yamaoka, Nikkei Business Publications, Inc., Japan
P2.08-007: Listen Advocate Voice - Web-Survey for the Japanese Model of Lung Cancer Advocacy by Society
Toshiyuki Sawa, Gifu Municipal Hospital, Japan

P2.08 PATIENT SUPPORT AND ADVOCACY GROUPS - OTHER

P2.08-008: Regional Clinical Pathway for Lung Cancer in Kumamoto University Hospital
Takeshi Mori, Kumamoto University Hospital, Japan

P2.08-009: Need for Consistent Language around Biomarker Testing in the Diagnosis and Treatment of Lung Cancer
Andrea Ferris, LUNGevity Foundation, USA

P2.08-010: The Reach and Adoption of a Multidisciplinary Thoracic Oncology Program within a U.S. Community Healthcare System
Fedoria Rugless, Baptist Cancer Center, USA

P2.08-011: Fashion Forward: Stigma Busting in Style in Egypt
Esraa Elsayed, CanSurvive, Egypt

P2.08-012: Evaluation of Lung Cancer Support Group Participation: Preliminary Results
Maureen Rigney, Lung Cancer Alliance, USA

Patricia Swann, East and North Herts NHS Trust, UK

P2.08-014: Lung Cancer Awareness and Barriers to Primary Care in Ireland
Aoife McNamara, Irish Cancer Society, Ireland

P2.08-015: Promoting Lung Cancer Awareness in Ireland - Balancing Traditional and Digital Platforms
Aoife McNamara, Irish Cancer Society, Ireland
WEDNESDAY, DECEMBER 7, 2016

P3.01 BIOLOGY/PATHOLOGY
   MORPHOLOGY
   FUNCTIONAL BIOLOGY IN LUNG CANCER
   MODELS OF LUNG CANCER
   STEM CELLS IN LUNG CANCER
   APOPTOSIS IN LUNG CANCER
   P3.01-001 - P3.01-033
   P3.01-034 - P3.01-051
   P3.01-052 - P3.01-054
   P3.01-055 - P3.01-062
   P3.01-063 - P3.01-064

P3.02a ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
   ALK
   ALK BIOMARKERS
   ALK CLINICAL
   ROS1
   MISCELLANEOUS
   P3.02a-001 - P3.02a-004
   P3.02a-005 - P3.02a-011
   P3.02a-012 - P3.02a-028
   P3.02a-029 - P3.02a-031
   P3.02a-032 - P3.02a-036

P3.02b ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
   EGFR
   EGFR BIOMARKERS
   EGFR CLINICAL
   EGFR RES
   P3.02b-001 - P3.02b-005
   P3.02b-006 - P3.02b-043
   P3.02b-044 - P3.02b-093
   P3.02b-094 - P3.02b-127

P3.02c ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
   TARGETED THERAPY
   IT
   IT BIOMARKERS
   IT CLINICAL
   P3.02c-001 - P3.02c-025
   P3.02c-026 - P3.02c-057
   P3.02c-058 - P3.02c-090
   P3.02c-091 - P3.02c-102

P3.03 MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES
   MESOTHELIOMA TRANSLATIONAL
   MESOTHELIOMA CLINICAL
   P3.03-001 - P3.03-027
   P3.03-028 - P3.03-063

P3.04 SURGERY
   MISCELLANEOUS I
   MISCELLANEOUS II
   P3.04-001 - P3.04-028
   P3.04-029 - P3.04-047

P3.05 PALLIATIVE CARE/ETHICS
   SYMPTOMS, THERAPEUTIC INTERVENTIONS
   QOL, OTHERS
   P3.05-001 - P3.05-009
   P3.05-010 - P3.05-020

P3.06 TRIAL DESIGN/STATISTICS
   CLINICAL STUDIES
   OTHERS
   P3.06-001 - P3.06-004
   P3.06-005 - P3.06-009

P3.07 REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH
   THERAPY AND ECONOMICS
   OTHER- GEOGRAPHICAL DIFFERENCES
   P3.07-001 - P3.07-010
   P3.07-011 - P3.07-022
**Wednesday, December 7, 2016**

Poster Setup Time: Wednesday, December 7, 08:30 - 10:15  
Poster Takedown Time: Wednesday, December 7, 15:45 - 18:00  
(Posters not taken down by 18:00 will be discarded by management)

**POSTER SESSION WITH PRESENTERS PRESENT (PRESENTING AUTHOR STAND BY TIME)**  
Session in which Poster Presenters remains at his/her poster board and is available to discuss/present their research personally with interested delegates.  
**Wednesday, December 7, 14:30 - 15:45 (Hall B - Poster Area)**

**P3.01**  
**BIOLOGY/PATHOLOGY**

**P3.01**  
**BIOLOGY/PATHOLOGY - MORPHOLOGY**

**P3.01-001:** Cancer Cell Invasion Driven by Extracellular Matrix Remodeling is Dependent on the Properties of Cancer-Associated Fibroblasts  
Shinya Neri, Kyoto University Graduate School of Medicine, Japan

**P3.01-002:** The Clinical Impact of Spread through Air Spaces (STAS) in Surgically Resected pStage I Lung Squamous Cell Carcinoma  
Naoki Yanagawa, Yamagata Prefectural Central Hospital, Japan

**P3.01-003:** Thyroid Transcription Factor-1 (TTF-1) Expression for Intraoperative Diagnosis Using the Rapid-Immunohistochemistry (IHC) in Lung Tumors  
Hayato Konno, Akita University Graduate School of Medicine, Japan

**P3.01-004:** Exceptional Evolution of Benign Metastasizing Leiomyomas of the Lung  
Luigi Ventura, Thoracic Surgery, University Hospital of Parma, Italy

**P3.01-005:** 9 Year’s in Oncopathology at a Latin American Country: Demographic and Pathology Characterization of Lung Cancer at National Cancer Institute  
Silvia Josefina Ayala Leon, National Cancer Institute Prof.Manuel Riveros, Paraguay

**P3.01-006:** Prognostic Impact of Tumor Spread through Air Spaces in Limited Resection for pStage I Lung Cancer  
Kyohei Masai, National Cancer Center Hospital, Japan

**P3.01-007:** A Pulmonary Glomus Timor  
Satoshi Yamamoto, Medical Kouhoukai Takagi Hospital, Japan

**P3.01-008:** Clinicopathological and Immunohistochemical Features in Lung Invasive Mucinous Adenocarcinoma According to Computed Tomography Findings  
Yuji Nojima, Kawasaki Medical School, Japan

**P3.01-009:** A Prospective Study of 'Spread through a Knife Surface' (STAKS) in Non-Small Cell Lung Cancer Resection Specimens  
Hans Blaauwgeers, Onze Lieve Vrouwe Gasthuis, Netherlands

**P3.01-010:** Primary Giant Cell Carcinomas of the Lung: Study of Seven Cases  
Lourdes Gutierrez Sanz, Hospital Universitario Puerta de Hierro, Spain
P3.01-011: Clinocopathological Profile and Role of Immunohistochemistry in the Diagnosis of Primary Lung Cancer - A Prospective Study from Eastern India
Pritinanda Mishra, All India Institute of Medical Sciences, India

P3.01-012: P40 in Metastatic Pulmonary Trophoblastic Tumour: Potential Diagnostic Pitfall with Pulmonary Squamous Cell Carcinoma
Deepali Jain, All India Institute of Medical Sciences, India

Sue Wang, University of California San Francisco, USA

P3.01-014: Differential Gene Expression of Lung Adenocarcinoma Histology Subtypes According to the IASLC/ATS/ERS Classification
Oscar Arrieta, National Cancer Institute, Mexico

P3.01-015: Prognostic Impact of Histologic Invasion Factors in Pulmonary Adenocarcinoma, with Particular Focus on the Pattern of Architectural Remodeling
Masaya Yotsukura, National Cancer Center Hospital, Japan

P3.01-016: Factors Influencing the Concordance of Histological Subtype Diagnosis by Biopsy and Resected Specimens of Lung Adenocarcinoma
Reiko Matsuzawa, National Cancer Center Hospital East, Japan

P3.01-017: Primary Lung Adenocarcinomas with Enteric Differentiation: A Retrospective Analysis
Laura Bonanno, Istituto Oncologico Veneto, Italy

P3.01-018: Reproducibility in Classification of Small Lung Adenocarcinomas: An International Interobserver Study
Mari Mino-Kenudson, Massachusetts General Hospital, USA

P3.01-019: Desmoplasia is Associated with Poor Prognosis and Carcinoma-Associated Fibroblast Heterogeneity in Non-Small Cell Lung Cancer
Roya Navab, Princess Margaret Hospital and Ontario Cancer Institute, Canada

P3.01-020: Evolving Trends in Lung Cancer Pathology
Karen Ege Olsen, Odense University Hospital, Denmark

P3.01-021: Reproducibility of Comprehensive Histologic Assessment and Refining Histologic Criteria in P Staging of Multiple Tumour Nodules
Andrew Nicholson, Royal Brompton and Harefield NHS Foundation Trust and National heart and Lung Institute, UK

P3.01-022: Impact of Histologic Subtype and Spread through Air Spaces (STAS) in Stage III (N2) Lung Adenocarcinoma
Yuriko Terada, The University of Tokyo, Japan

P3.01-023: Quality Assessment of Resampling Specimens in Primary Lung Cancers with Acquired Resistance to the Initial Therapy
Masashi Mikubo, Aichi Cancer Center Hospital, Japan
P3.01-024: Drastic Morphological and Molecular Differences between Lymph Node Micrometastatic Tumors and Macrometastatic Tumors of Lung Adenocarcinoma
Nao Aramaki, Tokyo Medical University, Japan

P3.01-025: Primary Pulmonary Sarcomas: An Entity Lost in Misdiagnosis
Kavneet Kaur, All India Institute of Medical Sciences, India

P3.01-026: Clinical and Pathological Reappraisal of Primary Lung Cancer with Lymphoepithelioma-Like Carcinoma Morphology
Yasufumi Goda, Kyoto University, Japan

P3.01-027: 3D Telomere Nuclear Organization to Distinguish Multiple Synchronous Lung Adenocarcinoma from Metastatic Lung Adenocarcinoma
Nathalie Bastien, Quebec Heart and Lung Institute, Canada

P3.01-028: Comparison of Touch Imprint Cytology and Section Histopathology in the Diagnostic of the Small Peripheral Lung Tumors
Masatoshi Kakihana, Tokyo Medical University, Japan

P3.01-029: Cases Demonstrating Spread Through Air Spaces (STAS) Reflects Invasive Growth and Not an Artifact
Shaohua Lu, Memorial Sloan Kettering Cancer Center, USA

P3.01-030: Correlation of Preoperative CT Characteristics and Histologic Patterns of Pulmonary Adenocarcinoma
Yue Cheng, West China School of Medicine, West China Hospital, Sichuan University, China

P3.01-031: Impact of a Novel Lung Gross Dissection Method on Intrapulmonary Lymph Node Yield
G Spencer, Trumbull Laboratories, USA

P3.01-032: PELP1 Expression in Molecularly Classified Lung Adenocarcinomas
Charuhas Deshpande, University of Pennsylvania, USA

P3.01-033: Changes in the Tumor Microenvironment during Lymphatic Metastasis of Lung Squamous Cell Carcinoma
Shinnosuke Ikemura, Tokyo Dental Collage Ichikawa General Hospital, Japan

P3.01 BIOLOGY/PATHOLOGY - FUNCTIONAL BIOLOGY IN LUNG CANCER

P3.01-034: Migration and Epithelial to Mesenchymal Transition of Lung Cancer Can Be Targeted via Translation Initiation Factors eIF4E and eIF4GI
Oshrat Attar-Schneider, Meir Medical Center, Israel

P3.01-035: Nicotine Enhances Hepatocyte Growth Factor-Mediated Lung Cancer Cell Migration
Remi Yoneyama, Tokyo Medical University, Japan

P3.01-036: Eukaryotic Translation Initiation Factors impact Non Small Cell Lung Cancer
Nadine Gantenbein, Medical University of Graz, Austria

P3.01-037: The Role of HIF3A Polymorphism in Lung Cancer Patients
Andika Putra, Faculty of Medicine, Universitas Indonesia-Persahabatan Hospital, Indonesia
P3.01-038: STAT3 and Src-YAP1 Inhibition Results in Greater Necitumumab Sensitivity in Lung Squamous Cell Carcinoma
Chiara Lazzari, Istituto Europeo di Oncologia - IEO, Italy

P3.01-039: JAK2 Participates in Lung Cancer Cells Proliferation, Migration and Invasion
Yun Fan, Zhejiang Cancer Hospital, China

P3.01-040: Difference of Graphene Oxide-Induced Autophagy between Adenocarcinoma and Macrophage Cell Line
Jong Wook Shin, Chung-Ang University Hospital, South Korea

P3.01-041: Anti-Cancer Effect of Hyperoxia on Human Lung Cancer Cells through Oxidative Stress Mediated ERK Signaling
Jin Young Mo, The Catholic University of Korea, South Korea

P3.01-042: Lung Cancer Cells Can Stimulate Functional and Genotypic Modifications in Normal Bronchial Epithelial Cells
Anne-Marie Baird, St. James’s Hospital & Queensland University of Technology, Ireland

P3.01-043: Inhibition of Ornithine Decarboxylase Facilitates Pegylated Arginase Treatment in Lung Adenocarcinoma Xenograft Models
James Chung-Man Ho, The University of Hong Kong, Hong Kong

P3.01-044: Splicing Variant of Estrogen Receptor Alpha is Associated with Pathological Invasiveness in Smoking Independent Lung Cancer
Ayumi Suzuki, Nagoya City University Graduate School of Medical Sciences, Japan

P3.01-045: Sex Differences in CXCR4-Dependent Motility of NSCLC Cells
D. Gwyn Bebb, University of Calgary, Canada

P3.01-046: Klotho Regulates Epithelial-Mesenchymal Transition in Lung Squamous Cell Carcinoma
Takayuki Ibi, Nippon Medical School Hospital, Japan

P3.01-047: Food for Thought: Should We Analyze a Cancer Cell as a Biological Mechanism or as a Biological Computer?
Zarko Vrbića, University of Dubrovnik, Croatia

P3.01-048: Cigarette Smoking is Associated with Epithelio-Mesenchymal Transition in Human Adenocarcinoma
Toshi Menju, Kyoto University Graduate School of Medicine, Japan

P3.01-049: ELF3 Overexpression Leads to Oncogenic Reprogramming of Protein Interactions Exposing Therapeutically Actionable Targets
Katey Enfield, BC Cancer Research Centre, Canada

P3.01-050: Isolation and Characterization of Lymphatic Endothelial Cells from Neoplastic and Normal Human Lung
Giulia Mazzaschi, University of Parma, Italy

P3.01-051: Analysis of Molecular Aberrations Associated with COPD in Patients with Lung Cancer
Tomas Tokar, University Health Network, Canada
P3.01-052: DNA Adductomics to Identify the Role of Inflammation in NNK-Induced Lung Carcinogenesis  
Silvia Balbo, Masonic Cancer Center, USA

P3.01-053: Mouse Models of Primary Lung Cancer - A Thorough Evaluation  
Jae-Hwi Jang, University Hospital Zürich, Switzerland

P3.01-054: Antagonism of a Novel Kinase, MAP3K19, By Specific Small Molecule Inhibitors Blocks Human Primary NSCLC Tumor Growth in Murine Xenograft Models  
Stefen Boehme, Axikin Pharmaceuticals, Inc., USA

P3.01 BIOLOGY/PATHOLOGY - STEM CELLS IN LUNG CANCER

P3.01-055: In vitro Construction of Lung Cancer Organoids from Induced Lung Cancer Stem Like Cells  
Hiroyuki Ogawa, Kobe University Hospital, Japan

P3.01-056: Association of Angiogenesis, EMT and Stem Cell Characteristics Using Hypoxic Stress in Lung Cancer  
ChanKwon Park, The Catholic University of Korea, South Korea

P3.01-057: TGF-β Induced EMT and Stemness Characteristics in Lung Cancer  
Seung Joon Kim, The Catholic University of Korea, South Korea

P3.01-058: Demethylation of CXCR4 and Stemness Acquisition in Lung Cancer  
Seung Joon Kim, The Catholic University of Korea, South Korea

P3.01-059: A Stem-Cell Oriented Phylogeny of Non-Small Cell Lung Cancers  
Robert Downey, Memorial Sloan Kettering Cancer Center, USA

P3.01-060: Aptamers as a Tool to Detect Lung Cancer Stem Cells  
Isis Nascimento, University of São Paulo, Brazil

P3.01-061: Prognostic Significance of Stem Cell-Related Marker Expression and Its Correlation with Histologic Subtypes in Lung Adenocarcinoma  
Hyojin Kim, Seoul National University Bundang Hospital, South Korea

P3.01-062: Profiling DNA Methylation and Gene Expression on Cancer Stemness Reprogramming in Lung Adenocarcinoma  
Sheng-Fang Su, Academia Sinica, Taiwan

P3.01 BIOLOGY/PATHOLOGY - APOPTOSIS IN LUNG CANCER

P3.01-063: XIAP Inhibits Mature Smac Induced Apoptosis by Degrading It through Ubiquitination in NSCLC  
Sida Qin, The First Affiliated Hospital of Xi'an Jiaotong University, China

P3.01-064: The Overexpression and Cleavage of SASH1 by Caspase-3 Stimulates Cell Death in Lung Cancer Cells  
Kenneth O'Byrne, Queensland University of Technology, Australia

P3.02a ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
P3.02a ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - ALK

P3.02a-001: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC
Leora Horn, Vanderbilt University, USA

P3.02a-002: Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor
Likun Chen, Sun Yat-Sen University Cancer Center, China

P3.02a-003: ALK and ROS1 Rearrangements, Coexistence and Treatment in EGFR-Wild Type Lung Adenocarcinoma - A Multicentre Study of 732 Cases
Zhengbo Song, Zhejiang Cancer Hospital, China

P3.02a-004: NSCLC Patients Harboring ALK Translocation: Clinical Characteristics and Management in Real World Setting. EXPLORE GFPC 02-14
Christos Chouaid, CHI Créteil, France

P3.02a ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - ALK BIOMARKERS

P3.02a-005: The Association between the Percentage of Anaplastic Lymphoma Kinase(ALK)-Positive Cells and Efficacy of ALK Inhibitor
Tae Tanaka, Kurashiki Central Hospital, Japan

P3.02a-006: Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer
Mark Awad, Dana-Farber Cancer Institute, USA

P3.02a-007: Monitoring for and Characteristics of Crizotinib Progression: A Chart Review of ALK+ Non-Small Cell Lung Cancer Patients
Gero Struebbe, Novartis Pharmaceuticals Corporation, USA

P3.02a-008: EML4-ALK in Plasma Exosomes from a Cohort of NSCLC Patients
Kay Brinkmann, Exosome Diagnostics GmbH, Germany

P3.02a-009: TPX-0005: A Multi-Faceted Approach to Overcoming Clinical Resistances from Current ALK or ROS1 Inhibitor Treatment in Lung Cancer
J. Jean Cui, TP Therapeutics, Inc., USA

P3.02a-010: Evaluation of Aberrant ALK Expression in Lung Cancer by RT-PCR and Comparison with FISH and Immunohistochemistry
Mirella Giordano, University of Pisa, Italy

P3.02a-011: Analysis of ALK Status in Peripheral Blood to Predict the Clinical Activity of Alk Inhibitors and Assess Prognosis in Patients with Lung Cancer
Zhen Zhou, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P3.02a ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - ALK CLINICAL
P3.02a-012: Patient-Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK+ NSCLC Treated with Crizotinib vs Chemotherapy
Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital, China

P3.02a-013: Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial
Marcello Tiseo, University Hospital of Parma, Italy

P3.02a-014: Patient Reported General Health Status in a Study of Crizotinib Versus Chemotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC)
Elizabeth Masters, Pfizer Oncology, USA

P3.02a-015: Ceritinib as First-Line Therapy in Patients with ALK-Rearranged Non-Small Cell Lung Cancer: ASCEND-1 Subgroup Analysis
Daniel Shao-Weng Tan, National Cancer Center, Singapore

P3.02a-016: Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC)
James Chih-Hsin Yang, National Taiwan University, Taiwan

P3.02a-017: Indirect Naive Comparison of Post-Crizotinib Treatments for ALK+ Non-Small-Cell Lung Cancer (NSCLC)
Karen Reckamp, City of Hope Comprehensive Cancer Center, USA

P3.02a-018: Efficacy of Pemetrexed Based Chemotherapy Compared with Non-Pemetrexed Based Chemotherapy in Advanced, ALK-Positive NSCLC
Jaemin Jo, Seoul National University Bundang Hospital, South Korea

P3.02a-019: Real World Utilization and Outcomes of ALK-Positive Crizotinib Treated Metastatic NSCLC Patients in US Community Oncology Practice
Craig Reynolds, McKesson Specialty Health/The US Oncology Network, USA

P3.02a-020: Clinical Failure to Crizotinib in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancers
Jin Kang, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P3.02a-021: Clinical Benefit of Continuing Crizotinib Therapy after Initial Disease Progression in Chinese Patients with Advanced ALK-Rearranged NSCLC
Xiangchan Hong, Sun Yat-Sen University Cancer Center, China

P3.02a-022: Experiences of Patients Receiving Treatment with Ceritinib to Treat ALK+ Non-Small Cell Lung Cancer: A Qualitative Study
Kenneth Culver, Novartis, USA

P3.02a-023: Treatment Patterns and Early Outcomes of ALK+ Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study
Gero Struebbe, Novartis Pharmaceuticals Corporation, USA

P3.02a-024: Response to Crizotinib in a Lung Adenocarcinoma Patient Harbouring EML4-ALK Translocation with Adnexal Metastasis
Wenxian Wang, Zhejiang Cancer Hospital, China
P3.02a-025: PROs With Ceritinib Versus Chemotherapy in Patients With Previously Untreated ALK-rearranged Nonsquamous NSCLC (ASCEND-4)  
Daniel Shao-Weng Tan, National Cancer Centre Singapore, Singapore

P3.02a-026: Crizotinib in Clinical Practice and in Clinical Trials - How Much the Results Differ?  
Peter Berzinec, Specialised Hospital of St Zoerardus Zobor, Slovakia

P3.02a-027: A Retrospective Analysis of the Efficacy and Safety of ALK Inhibitors in ALK-Positive Lung Cancer Patients  
Kazutoshi Komiya, Saga University, Japan

P3.02a-028: Anaplastic Lymphoma Kinase Fusion Oncogene Positive Non-Small Cell Lung Cancer - The Experience of an Institution  
Sérgio Azevedo, Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Porto, Portugal

P3.02a-029: Patients with ROS1 Rearrangement Positive Non-Small Cell Lung Cancer Benefit from Pemetrexed-Based Chemotherapy  
Zhengbo Song, Zhejiang Cancer Hospital, China

P3.02a-030: ROS1 Fusion Chinese Lung Adenocarcinoma Patients Treated with Crizotinib Detected Using Next-Generation Genotyping from ctDNA  
Xiaomin Niu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P3.02a-031: Non-Small Cell Lung Cancer Targeted Therapy in Case of ROS1 Rearrangement  
Elena Reutova, Russian Cancer Research Center, Russia

P3.02a-032: Multicenter Trial of Nintedanib in Combination with Docetaxel in Metastatic Lung Adenocarcinoma: Expertise in the Real-Life Setting  
Jeronimo Rodriguez Cid, Instituto Nacional de Enfermedades Respiratorias, Mexico

P3.02a-033: The Humanistic Burden Associated with Caring for Advanced NSCLC Patients in Europe - A Real World Survey of Caregivers  
Oana Chirita, Bristol-Myers Squibb, UK

P3.02a-034: Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSé Trial  
Julien Mazieres, CHU de Toulouse Hôpital Larrey, France

P3.02a-035: Can Airway Stenting Avoid Suffocation Deaths Caused by Malignant Airway Obstruction?  
Naofumi Miyahara, Fukuoka University Hospital, Japan
P3.02a-036: Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC
Rafal Dziadziusko, Medical University of Gdansk, Poland

P3.02b-001: Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/−T790M) NSCLC
Hatim Husain, UC San Diego Moores Cancer Center, USA

P3.02b-002: Treatment Outcome Comparison between Exon 19 and 21 EGFR Mutations after Second-Line TKIs in Advanced NSCLC Patients
Xiance Jin, The 1st Affiliated Hospital of Wenzhou Medical University, China

P3.02b-003: Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumour and Serum Biomarkers
Enriqueta Felip, Vall d’Hebron University Hospital, Spain

P3.02b-004: EGFR Mutation in Squamous Cell Advanced NSCLC in Persahabatan Hospital, Jakarta Indonesia
Sita Laksmi Andarini, Faculty Of Medicine Universitas Indonesia, Indonesia

P3.02b-005: Phase Ib Trial of Afatinib and BI 836845 in Advanced NSCLC: Dose Escalation and Safety Results
Byoung Chul Cho, Yonsei University Medical Center, South Korea

P3.02b - ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - EGFR BIOMARKERS

P3.02b-006: Role of TP53 Mutations in Determining Primary Resistance to First-Line Tyrosine Kinase Inhibitors in EGFR-Mutated NSCLC Patients
Paola Ulivi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy

P3.02b-007: Differential Efficacy of Gefitinib in Exon 19 or Exon 21 Mutated Adenocarcinoma Lung
Alok Goel, Tata Memorial Hospital, India

P3.02b-008: Quantification and Monitoring of Treatment Response in EGFR Mutant NSCLC Patients by Digital-PCR in Plasma cftDNA
Vienna Ludovini, Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Italy

P3.02b-009: Plasma and Tissue Inflammatory and Angiogenic Biomarkers to Explore Resistance to EGFR-TKIs and Association with VeriStrat Status
Chiara Lazzari, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale San Raffaele, Italy

P3.02b-010: Urine Detection of EGFR T790M Mutation in Non-Small-Cell Lung Cancer: An Outcomes and Total Cost of Care Analysis
Jacob Sands, Lahey Hospital & Medical Center, USA

P3.02b-011: Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Patients with Non-Small Cell Lung Carcinoma
Xiaozheng Kang, Peking University Cancer Hospital and Institute, China
P3.02b-012: Longitudinal Monitoring of ctDNA EGFR Mutation Burden from Urine Correlates with Patient Response to EGFR TKIs: A Case Series
David Berz, Beverly Hills Cancer Center, USA

P3.02b-013: Evaluation of Lung Specific GPA Score in Adenocarcinoma Patients with Brain Metastasis and EGFR Activating Mutation
Pascal Dô, Baclesse, France

P3.02b-014: Monitoring of T790M Mutation in Serum for Prediction of Response to Third Generation Inhibitors
Teresa Morán, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Spain

P3.02b-015: Impact of Metastatic Status on the Prognosis of Patients Treated with First Generation EGFR-TKIs
Yoshihiko Taniguchi, National Hospital Organization Kinki-chuo Chest Medical Center, Japan

P3.02b-016: An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR-TKIs in Patients Harboring TKI-Sensitive EGFR Mutations
Ee Ke, Guangdong Lung Cancer Institute; Guangdong General Hospital(GGH) & Guangdong Academy of Medical Sciences, China

P3.02b-017: Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC
Chanchai Charonpongsuntorn, Ramathibodi Hospital, Thailand

P3.02b-018: Detection of Epidermal Growth Factor Receptor Mutations in Circulating Cell-Free DNA versus Tumor Biopsy
In-Jae Oh, Chonnam National University Hwasun Hospital, South Korea

P3.02b-019: TTF-1 Expression as a Predictor of Response to EGFR-TKIs in Patients with Lung Adenocarcinoma
Kostas Syrigos, Medical School, University of Athens, Greece

P3.02b-020: Gender and Ethnicity Influence on Outcome in EGFRmut+ NSCLC Patients Treated at a Single Canadian Institution
Roxana Tudor, University of Calgary, Canada

P3.02b-021: Comparing T790M Identification across Testing Strategies in Advanced EGFR NSCLC: A Diagnostic Outcomes and Cost Analysis
Carolyn Bodnar, AstraZeneca, UK

P3.02b-022: Early Experience of Detecting EGFR Activating Mutations in Cell Free DNA Using Droplet Digital PCR
Moushumi Suryavanshi, Rajiv Gandhi Cancer Institute and Research Center, India

P3.02b-023: Physician Patterns of Care in Patients with EGFR Mutation+ NSCLC: An International Survey into Testing and Treatment Choice
Bernd Tischer, Kantar Health, Germany

P3.02b-024: Dynamics of EGFR Mutational Load in Urine and Plasma Correlates with Treatment Response in Advanced NSCLC
Jhanelle Gray, Moffitt Cancer Center, USA
P3.02b-025: Rapid and Highly Sensitive EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA Specimen of Lung Adenocarcinoma
Filiz Oezkan, Ruhrlandklinik, West German Lung Center, University Duisburg-Essen, Germany

P3.02b-026: Association of EGFR Exon 19 Deletion and EGFR-TKI treatment duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
Norikazu Matsuo, Kurume University School of Medicine, Japan

P3.02b-027: Detection of EGFR Mutations in Plasma of Lung Adenocarcinoma Patients Using Real-Time PCR and Mass Spectrometry
Rossella Bruno, University of Pisa, Italy

P3.02b-028: Characterizing Residual Erlotinib-Tolerant Population Using EGFR-Mutated NSCLC Primary Derived Xenografts: The Last Holdouts
Erin Stewart, University of Toronto, Canada

P3.02b-029: Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 - Prevalence and Treatment Results in Slovakian NSCLC Patients
Peter Berzinec, Specialised Hospital of St Zoerardus Zobor, Slovakia

P3.02b-030: Single Institution Experience with EGFR Gene Mutation Analysis and Treatment of EGFR Positive Patients in the Years 2010 to 2015
Ondřej Venclíček, University Hospital Brno, Czech Republic

P3.02b-031: T790M: A Favorable Mutation?
Hong Jian, Shanghai Chest Hospital, China

P3.02b-032: Association between EGFR T790M Mutation Copy Numbers in Cell-Free Plasma DNA and Response to Osimertinib in Advanced NSCLC
Anna Buder, Medical University of Vienna, Austria

P3.02b-033: Filter Paper as Specimen Storage and Transport Medium of EGFR Mutation Testing Collected from Lung Cancer Patients in Remote Areas of Indonesia
Najmiatul Masykura, Stem-cell and Cancer Institute, Indonesia

P3.02b-034: Clinical Impact of Pretreatment EGFR T790M Mutation in Lung Adenocarcinoma Patients
Elisabetta Macerola, University of Pisa, Italy

P3.02b-035: Cell Free Tumor DNA to Monitor Response to Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Paola Ulivi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy

P3.02b-036: The Predictive Factors for Post-Progression Survival after EGFR-TKI Failure in Advanced EGFR-Mutant Lung Cancer Patients
Toshiki Ebisudani, Kameda Medical Center, Japan

P3.02b-037: Does Tissue EGFR Mutation Status Predict Treatment Response and Mortality in Adenocarcinoma Lung?
Anant Mohan, All India Institute of Medical Sciences, India

P3.02b-038: Molecular Dynamics Simulation of EGFRL844V Mutant Sensitive to AZD9291 in Non-Small Cell Lung Cancer
Vahideh Assadollahi, Student Research Committee, Kurdistan University of Medical Sciences, Iran
P3.02b-039: Analysis of Prognostic Factor for Afatinib Treated Patients with EGFR Mutation Positive NSCLC
Masafumi Sata, Kanagawa Cancer Center, Japan

P3.02b-040: A Comparison of ddPCR and ARMS for Detecting EGFR T790M Status from Advanced NSCLC Patients with Acquired EGFR-TKI Resistance
Wenxian Wang, Zhejiang Cancer Hospital, China

P3.02b-041: Genome-Wide Screen of DNA Methylation Changes Reveals GABBR2 as a Novel Potential Target for EGFR 19 Deletion Adenocarcinoma with Erlotinib
Xiaomin Niu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P3.02b-042: Reduction in Peripheral Blood Cytokine Levels Observed in EGFR Mutant (EGFRm) Patients Treated with Erlotinib
Aaron Lisberg, UCLA Medical Center, USA

P3.02b-043: Inter-Laboratory Comparison of the Roche Cobas EGFR Mutation Test v2 in Plasma
Cleo Keppens, KULeuven, Belgium

**ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY -EGF CLINICAL**

P3.02b-044: Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged ≥75 Years: Subgroup Analysis of LUX-Lung 7
Ken O’Byrne, Princess Alexandra Hospital and Queensland University of Technology, Australia

P3.02b-045: Patritumab plus Erlotinib in EGFR Wild-Type Advanced Non-Small Cell Lung Cancer (NSCLC): Part a Results of HER3-Lung Study
Luis Paz-Ares, Hospital Universitario 12 de Octubre, Spain

P3.02b-046: Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial)
Sanjay Popat, Royal Marsden Hospital, UK

P3.02b-047: Co-Activation of STAT3 and YAP1 Signaling Pathways Limits EGFR Inhibitor Response in Lung Cancer
Niki Karachaliou, Instituto Oncológico Dr Rosell (IOR), Hospital Universitario Quirón-Dexeus, Spain

P3.02b-048: Oral Vinorelbine Monotherapy in Patients with EGFR+ NSCLC after Failure of EGFR-TKI in First Line: A Prospective Study
Dariusz Kowalski, The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology, Poland

P3.02b-049: EGFR-Mutated NSCLC: Clinical Practice Assessment and Gap Analysis
Elaine Hamarstrom, Medscape Education, USA

P3.02b-050: A Phase I/II Study of Erlotinib, Carboplatin, Pemetrexed and Bevacizumab for Advanced Non-Squamous NSCLC Harboring EGFR Mutation
Takashi Yokoi, Kansai Medical University, Japan

P3.02b-051: Outcome of Advanced EGFR-Mutated NSCLC Patients with MET-Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study
Simon Baldacci, CHU Lille, Univ. Lille, France
P3.02b-052: Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403
Sarah Goldberg, Yale School of Medicine, USA

P3.02b-053: A Randomized, Open Label, Phase II Study Comparing Pemetrexed plus Cisplatin versus Pemetrexed Alone in EGFR Mutant NSCLC after EGFR-TKI: QOL Data
Kwai Han Yoo, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

P3.02b-054: EGFR Mutation Profile in Newly Diagnosed Lung Adenocarcinoma in Persahabatan Hospital, Jakarta-Indonesia
Sita Laksmi Andarini, Faculty Of Medicine Universitas Indonesia, Indonesia

P3.02b-055: Impact of Pemetrexed Chemotherapy in Exon 19 or Exon 21 Mutated NSCLC
Vikas Talreja, Tata Memorial Hospital, India

P3.02b-056: Survival in EGFR Mutated Advanced Lung Cancer Adenocarcinoma Patients - A National Study
Erik Jakobsen, Odense University Hospital, Denmark

P3.02b-057: Network Meta-Analysis of First-Line and Maintenance Regimens in EGFR Mutated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Gilberto De Lima Lopes, Grupo Oncoclinicas, Brazil

P3.02b-058: Second-Line Therapy in EGFR Activating Mutation Positive Advanced NSCLC: Analysis from a Randomized Phase III First-Line Trial
Arun Chandrasekharan, Tata Memorial Hospital, India

P3.02b-059: The Role of Epidermal Growth Factor Receptor in the Onset of Skeletal Related Events in Non-Small Cell Lung Cancer
Shu-Mei Huang, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P3.02b-060: Comparative Analysis of the Efficacy of Three 1st/2nd Generation EGFR-TKIs for EGFR Mutated NSCLC in Clinical Practice
Kentaro Ito, Matsusaka Municipal Hospital, Japan

P3.02b-061: A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations
Christina Baik, University of Washington, Seattle Cancer Care Alliance, USA

P3.02b-062: Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Benjamin Besse, Gustave Roussy, France

P3.02b-063: Analysis of Survival in EGFR-Mutation-Positive Advanced Non-Small-Cell Lung Cancer Patients with Miliary Pulmonary Metastasis
Kageaki Watanabe, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

P3.02b-064: Time to EGFR-TKI Treatment for Patients with Advanced NSCLC and EGFR Activating Mutation in a Tertiary Cancer Center
Pascal Dô, Baclesse, France
P3.02b-065: Third Line Therapy in EGFR Positive Advanced Non-Small Cell Lung Cancer
Nikhil Pande, Tata Memorial Hospital, India

P3.02b-066: Phase II Trial of the C-Met Inhibitor Tepotinib in Advanced Lung Adenocarcinoma with MET Exon 14 Skipping Mutations after Failure of Prior Therapy
Paul Paik, Memorial Sloan Kettering Cancer Center, USA

P3.02b-067: A Single-Institution Experience of Afatinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Hiroyuki Minemura, Fukushima Medical University, Japan

P3.02b-068: Outcomes of Patients with Advanced EGFR Mutation Positive Adenocarcinoma of Lung Treated with Gefitinib in Northern Ireland 2010-2016
Michael-John Devlin, Northern Ireland Cancer Centre, UK

P3.02b-069: To Assess Efficacy of First Line TKIs in EGFR Mutant Advanced NSCLC Patients from North India
Ullas Batra, Rajiv Gandhi Cancer Institute and Research Centre, India

P3.02b-070: NSCLC with Detectable EGFR Mutation: Institutional Experience
Jose Minatta, Hospital Italiano, Argentina

P3.02b-071: First-Line Gefitinib for EGFR-Mutated Lung Adenocarcinoma Patients with Bone Metastases - A Single Institution Experience
Davorin Radosavljevic, Institute for Oncology and Radiology of Serbia, Serbia

P3.02b-072: A Multicenter Phase II Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Tae Kyu Lim, Veterans Health Service Medical Center, South Korea

P3.02b-073: A Phase II, Liquid Biopsy Study Using Digital PCR in EGFR Mutated, Lung Cancer Patients Treated with Afatinib (WJOG 8114LTR)
Hiroaki Akamatsu, Wakayama Medical University, Japan

P3.02b-074: Brain Radiotherapy with EGFR-TKI Plays an Important Role in 181 EGFR Mutant Non-Small Cell Lung Cancer Patients with Brain Metastasis
Wenxian Wang, Zhejiang Cancer Hospital, China

P3.02b-075: Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients
Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P3.02b-076: Bisphosphonates Enhance Effect of EGFR-TKIs in NSCLC Patients with EGFR Mutation and Bone Metastases
Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P3.02b-077: Osimertinib Expanded Access Program for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC
Edgardo Santos, Lynn Cancer Institute, USA

P3.02b-078: Non-Small Cell Lung Cancer with De Novo EGFR T790M Mutation: Clinical Features of 22 Cases
Myung-Ju Ahn, Samsung Medical Center, South Korea
P3.02b-079: Effects of Icotinib with and without Radiation Therapy on Patients with EGFR Mutant Non-Small Cell Lung Cancer and Brain Metastases
Yun Fan, Zhejiang Cancer Hospital, China

P3.02b-080: Analysis of Patient-Reported Symptom Response with Osimertinib (AZD9291) Treatment for Advanced Non-Small-Cell Lung Cancer
Silvia Novello, University of Turin, Italy

P3.02b-081: Comparative Outcome Assessment of EGFR TKIs for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis
Ramon Andrade De Mello, University of Algarve, Portugal

P3.02b-082: Gefitinib in First-Line Treatment of Caucasian Patients with NSCLC and EGFR Mutations in Exons 19 or 21
Jana Skrickova, University Hospital and Medical Faculty Brno, Czech Republic

P3.02b-083: Potential Usage of Afanitib in the Treatment of Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations
Taishi Harada, Fukuchiyama City Hospital, Japan

P3.02b-084: Rational Combinations to Improve Outcome for EGFR-TKIs in NSCLCs with EGFR Mutations
Barbara Helfrich, University of Colorado Anschutz Medical Center, USA

P3.02b-085: The Combination Therapy of S-1 and the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors beyond Progressive Disease
Lu Yang, Peking Union Medical College, China

P3.02b-086: ASP8273 Tolerability and Antitumor Activity in TKI-Naïve Japanese Subjects with EGFRmut+ NSCLC: Preliminary Results
Makoto Nishio, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan

P3.02b-087: Dose Escalation Study of CDDP plus PEM with Erlotinib and Bev Followed by PEM with Erlotinib and Bev for Non-SQ NSCLC Harboring EGFR Mutations
Akihiro Tamiya, National Hospital Organization Kinki-chuo Chest Medical Center, Japan

P3.02b-088: TKI as First Line Treatment in Advanced Non-Small-Cell Lung Cancer with EGFR Mutations
Inês Guerreiro, Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), Portugal

P3.02b-089: Treatment of NSCLC Patients with Malignant Pleural Effusion Harboring Exon 19 and 21 EGFR Mutations after First-Line and Second-Line TKIs
Xiance Jin, The 1st Affiliated Hospital of Wenzhou Medical University, China

P3.02b-090: Pemetrexed versus Gefitinib in EGFR Mutation Positive Lung Cancer: Results of a Phase 3 Study from India
Kumar Prabhash, Tata Memorial Centre, India

P3.02b-091: Liver Metastases Is the Negative Predictive Factor for First-Line EGFR TKIs Therapy in NSCLC Patients with EGFR Mutation
Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China
P3.02b-092: Central Nervous System (CNS) Responses to Osimertinib in Brain Metastases from Lung Cancer (NSCLC) with T790M: Effectiveness of the 80 Mg Dose
Raja Mudad, University of Miami, USA

P3.02b-093: Zoledronic Acid Enhances the Effects of Icotinib on Non-Small Cell Lung Cancer Patients with Bone Metastases
Wenxian Wang, Zhejiang Cancer Hospital, China

P3.02b ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - EGFR RES

P3.02b-094: Rebiopsy Post Progression in EGFR Mutated Lung Cancer
Arun Chandrasekharan, Tata Memorial Hospital, India

P3.02b-095: Tracing Spatiotemporal T790M Heterogeneity in Patients with EGFR-Mutant Advanced NSCLC after Acquired Resistance to EGFR TKIs
Yi-Chen Zhang, Guangdong Lung Cancer Institute; Guangdong General Hospital(GGH) & Guangdong Academy of Medical Sciences, China

P3.02b-096: Osimertinib (AZD9291) in Asia-Pacific Patients with T790M Mutation-Positive Advanced NSCLC: Open-Label Phase II Study Results
Caicun Zhou, Shanghai Pulmonary Hospital, Tongji University, China

P3.02b-097: Experience of Re-Biopsy (Biopsy at Progression) of EGFR Mutant Non-Small Cell Lung Cancer Patients in Japan: A Retrospective Study
Kaname Nosaki, Department of Thoracic Oncology, National Kyushu Cancer Center, Japan

P3.02b-098: Plasma T790M Mutation Associates with Extensive Progression in Non-small Cell Lung Cancer with Acquired Resistance to EGFR Inhibitors
Shirong Zhang, Hangzhou First People's Hospital, Nanjing Medical University, China

P3.02b-099: Pharmacokinetics of Osimertinib (AZD9291) in Chinese Patients with Advanced NSCLC: A Phase I Study
Junning Cao, Fudan University Shanghai Cancer Center, China

P3.02b-100: Comparison of Three T790M Testing Methods for the Detection of Non-Small Cell Lung Cancer after Tyrosine Kinase Inhibitor Failure
Shirong Zhang, Hangzhou First People's Hospital, Nanjing Medical University, China

P3.02b-101: EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib
Maximilian Hochmair, Otto Wagner Hospital, Austria

P3.02b-102: Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
Jordi Remon, Gustave Roussy, France

P3.02b-103: Identification of On-Target Mechanisms of Resistance to EGFR Inhibitors Using ctDNA Next-Generation Sequencing
Jessica Lin, Massachusetts General Hospital, USA

P3.02b-104: Rebiopsy for Patients with Non-Small-Cell Lung Cancer after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Failure
Xuefei Li, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China
P3.02b-105: Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing
Ying Jin, Zhejiang Cancer Hospital, China

P3.02b-106: Local Experience of Osimertinib Use; Retrospective Review Based on Plasma EGFR Using ddPCR Technique
Jacky Li, Queen Elizabeth Hospital, Hong Kong

P3.02b-107: Efficacy of Afatinib and Gefitinib in Lung Adenocarcinoma with EGFR Gene Mutation as 2nd or 3rd Line Treatment
Marisol Arroyo Hernandez, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico

P3.02b-108: Assessment of Clinical Usability of a cfDNA-Based Assay Detecting EGFR T790M Mutation in EGFR-TKI Refractory NSCLC Patients
Masaki Hanibuchi, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan

P3.02b-109: Molecular Profiling of EGFR-Positive NSCLC with Secondary T790M Resistance Mutation and Tertiary Transformation into Small-Cell Lung Cancer
Martin Faehling, Klinikum Esslingen, Germany

P3.02b-110: ROS1 Translocation as a Bystander Mutation in T790M EGFR Mutated NSCLC
Jan Stratmann, Universitätssklinik Frankfurt am Main, Germany

P3.02b-111: Can We Avoid Using Chemotherapy in Managing Acquired Resistance of EGFR-Mutated NSCLC?
Thongbliew Prempree, Chularat 3 Hospital, Thailand

P3.02b-112: Feasibility of Re-Biopsy in Patients with Non-Small Cell Lung Cancer after Failure of Epidermal Growth Factor Receptor Targeted Therapy
Yoo-Duk Choi, Chonnam National University Hwasun Hospital, South Korea

P3.02b-113: Clinical Course of NSCLC Patients with EGFR Mutation Undergoing Rebiopsy and Osimertinib Therapy
Kenichiro Hirai, Fukushima Medical University, Japan

P3.02b-114: Second Line Treatment of EGFR Positive Lung Adenocarcinoma - Our Experience
Marko Jakopovic, University Hospital Centre Zagreb, Croatia

P3.02b-115: Clinical Activity of Osimertinib in EGFR Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib
Shirish Gadgeel, Karmanos Cancer Institute/Wayne State University, USA

P3.02b-116: Molecular Mechanism of Transformation from Adenocarcinoma to Small-Cell Lung Cancer after EGFR-TKI
Zhong-Yi Dong, Guangdong Lung Cancer Institute, Guangdong General Hospital, China

P3.02b-117: Phase Ib Results from a Study of Capmatinib (INC280) + EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Daniel Shao-Weng Tan, National Cancer Centre Singapore, Singapore
P3.02b-118: Potential Mechanism Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to EGFR-TKIs
Jie Wang, Cancer Hospital Chinese Academy of Medical Sciences, China

P3.02b-119: YH25448, a Highly Selective 3rd Generation EGFR TKI, Exhibits Superior Survival over Osimertinib in Animal Model with Brain Metastases from NSCLC
Min Hee Hong, Division of Medical Oncology, Younsei Cancer Center, Yonsei University College of Medicine, South Korea

P3.02b-120: EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib
Yoshihisa Kobayashi, Kindai University Faculty of Medicine, Japan

P3.02b-121: Targeting miR-200c/LIN28B Axis in Acquired EGFR-TKI Resistance Non-Small Cell Lung Cancer Cells Harboring EMT Features
Kazuhiko Shien, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

P3.02b-122: Characterization of Afatinib Resistant Lung Cancer Cells (PC9/Afa) and Reversal of Resistance by T790M Specific Tyrosine Kinase Inhibitors
Anya Maan-Yuh Lin, Institute of Pharmacology, National Yang-Ming University, Taiwan

P3.02b-123: Lysimachia Capillipes Capilliposide Inhibits AKT Activation and Restores Sensitivity to Gefitinib in NSCLC with Acquired Gefitinib Resistance
Shirong Zhang, Hangzhou First People’s Hospital, Nanjing Medical University, China

P3.02b-124: Efficacy of Osimertinib in Patients with Non-Small-Cell Lung Cancer (NSCLC) and Pleural Effusion
Saki Manabe, Kanagawa Cancer Center, Japan

P3.02b-125: Failure to Tyrosine Kinase Inhibitors and Patterns of Progression in Patients with Advanced Non-Small Cell Lung Cancer
Oscar Arrieta, National Cancer Institute, Mexico

P3.02b-126: Clinical Activity of Olmutinib (HM61713) Used on a Compassionate IND Basis for Patients with Lung Adenocarcinoma (LADC) in Korea
Jin Soo Lee, National Cancer Center, South Korea

P3.02b-127: NSCLC Patients Harboring HER2 Mutation: Clinical Characteristics and Management in Real World Setting. EXPLORE GFPC 02-14
Jean Bernard Auliac, Hopital Quesnay, France

P3.02c: ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY

P3.02c-001: Phase I Study of Salazosulfapyridine Targeting Cancer Stem Cells in Combination with CDDP and Pemetrexed for Chemo-Naïve Advanced Non-Sq NSCLC
Kohei Otsubo, Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Japan
P3.02c-002: Mannosylated Poly (Propylene Imine) Dendrimer Mediated Lung Delivery of Anticancer Bioactive
Mani Bhargava, ICFAI University, India

P3.02c-003: TAX-TORC: The Novel Combination of Weekly Paclitaxel and the Dual mTORC1/2 Inhibitor AZD2014 for the Treatment of Squamous NSCLC
Matthew Krebs, The University of Manchester and The Christie NHS Foundation Trust, UK

P3.02c-004: SBI0206965, a Novel Inhibitor of Ulk1, Suppresses Non-Small Cell Lung Cancer Cell Growth via Modulating Both Autophagy and Apoptosis Pathways
Conghua Xie, Zhongnan Hospital of Wuhan University, China

P3.02c-005: MET Exon 14 Skipping in Quintuple-Negative (EGFR-/KRAS-/ALK-/ROS1-/RET-) Lung Adenocarcinoma
Geun Dong Lee, Gangnam Severance Hospital, Yonsei University College of Medicine, South Korea

P3.02c-006: EGFR and HER3 Inhibition - A Novel Therapy for Invasive Mucinous Non-Small Cell Lung Cancer Harboring an NRG1 Fusion Gene
Wolfgang Jacob, Roche Diagnostics GmbH, Germany

P3.02c-007: Assessment of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer
Anne Steino, DelMar Pharmaceuticals, Inc, Canada

P3.02c-008: A MET Inhibitor in the Treatment of Metastatic Non Small Cell Lung Cancer with MET Amplification
Junling Li, Cancer Institute & Hospital, Peking Union Medical College/Chinese Academy of Medical Science, China

P3.02c-009: Anti-VEGF and Anti-EGFR Reduce Malignant Pleural Effusion and Morbidity in an Experimental Adenocarcinoma Model
Vera Capelozzi, Faculdade de Medicina da USP, Brazil

P3.02c-010: Resistance Mechanisms to PI3K-mTOR Inhibition in NSCLC
Gillian Moore, Trinity College Dublin/St. James's Hospital, Ireland

P3.02c-011: A Phase 1b Open-Label Study of PEGPH20 Combined with Pembrolizumab in Patients with Selected Hyaluronan-High Solid Tumors
Alexander Spira, Virginia Cancer Specialists, USA

P3.02c-012: Apatinib, a New Small Molecular VEGFR2 Inhibitor, Suppresses the Activity of Lung Cancer Stem Cells
Caiyun Zhong, Nanjing Medical University, China

P3.02c-013: Combination Therapy of Oncolytic Herpes Simplex Virus Type 1 with Erlotinib in a Human Lung Cancer Xenograft Model
Yoshinori Sakata, Tokyo Medical University, Japan

P3.02c-014: Patients with Recurrence after Resection of Lung Cancer Are Good Candidates for the beyond over Progressive Disease Application of Bevacizumab
Tatsuya Yoshimasu, Wakayama Medical University, Japan
P3.02c-015: Phase II Trial of S-1/Cisplatin Combined with Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer: TCOG LC-1202
Yusuke Okuma, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Japan

P3.02c-016: Efficacy of Bevacizumab Combined with Chemotherapy in Lung Adenocarcinoma-Induced Malignant Pleural Effusion
Zhe Liu, Beijing Chest Hospital, Capital Medical University, China

P3.02c-017: '2nd Line' RET-Inhibition in a Female Patient with Non-KIF5B RET-Translocation
Tobias Overbeck, Goettingen University, Germany

P3.02c-018: Could COX-2 Inhibitors Enhance the Outcomes of Chemotherapeutic Agents in Lung Cancer?
Konstantinos Zarogoulidis, Aristotle University of Thessaloniki, Greece

P3.02c-019: The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes
Gordana Drpa, Clinic for Respiratory Diseases "Jordanovac", University Hospital Centre Zagreb, Croatia

P3.02c-020: More Than 3 Years Long-Term Maintenance Treatment of Bevacizumab for Advanced-Stage NSCLC: A Report of Three Cases
Hongxia Li, Beijing Chest Hospital, Capital Medical University, China

P3.02c-021: PD 0332991, a Selective Cyclin D Kinase 4/6 Inhibitor, Sensitizes Lung Cancer Cells to Killing by EGFR TKIs
Jun Chen, Tianjin Medical University General Hospital, China

P3.02c-022: Anticancer Activity of Sorafenib in Combined Treatment with Betulin in Human Non-Small Cell Lung Cancer Cell Lines
Justyna Kutkowska, Ludwik Hirsfeld Institute of Immunology and Experimental Therapy Polish Academy of Science, Poland

P3.02c-023: Mutation and Prognostic Analyses of PIK3CA in Patients with Completely Resected Lung Adenocarcinoma
Zhengbo Song, Zhejiang Cancer Hospital, China

P3.02c-024: Detection of Novel Activating FGFR Rearrangements, Truncations, and Splice Site Alterations in NSCLC by Comprehensive Genomic Profiling
Shirish Gadgeel, Karmanos Cancer Institute/Wayne State University, USA

P3.02c-025: Safety and Efficacy of Apatinib in Patients with Previously Heavily Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer
Feng Ying Wu, Shanghai Pulmonary Hospital, Tongji University, China

P3.02c-026: Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153
David Spigel, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, USA
P3.02c-027: Phase I and PK Study of the Folate Receptor-Targeted Small Molecule Drug Conjugate (SMDC) EC1456 in Advanced Cancer: Lung Cancer Subset
Martin Edelman, University of Maryland, USA

P3.02c-028: Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC)
Stephen Bagley, University of Pennsylvania, USA

P3.02c-029: Immune-Related Adverse Events and Their Effect on Outcomes in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab
Stephen Bagley, University of Pennsylvania, USA

P3.02c-030: Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Edward Garon, David Geffen School of Medicine at UCLA/Translational Research in Oncology- US Network, USA

P3.02c-031: Immune Checkpoint Inhibitors (IC) and Paradoxical Progressive Disease (PPD) in a Subset of Non-Small Cell Lung Cancer (NSCLC) Patients
Jihene Lahmar, Gustave Roussy, France

P3.02c-032: Interstitial Pneumonitis Associated with Immune Checkpoint Inhibitors Treatment in Cancer Patients
Myriam Delaunay, CHU Larrey, France

P3.02c-033: Patterns of Progression and Management of Acquired Resistance to Anti-PD-1 Antibodies in Advanced Non-Small Cell Lung Cancer
Antony Mersiades, Crown Princess Mary Cancer Care Centre, Westmead Hospital, Australia

P3.02c-034: A Single Institution Experience with Immunotherapy as an Effective Therapy Approach of Advance Non-Small Cell Lung Cancer (NSCLC)
Jesus Corral, Virgen del Rocio Hospital, Spain

P3.02c-035: Comparison of RECIST to Immune-Related Response Criteria (irRC) in Patients with NSCLC Treated with Immune-Check Point Inhibitor
Myung-Ju Ahn, Samsung Medical Center, South Korea

P3.02c-036: Management of Early Disease Progression during Treatment of Advanced Non-Small Cell Lung Cancer with Nivolumab
Carlo Genova, San Martino Hospital - National Institute for Cancer Research, Italy

P3.02c-037: Clinical Safety of Combinational Therapy of Immune Checkpoint Inhibitors and Viscum Album L. in Patients with Advanced or Metastasized Cancer
Anja Thronicke, Forschungsinstitut Havelhöhe gGmbH am Krankenhaus Havelhöhe, Germany

P3.02c-038: First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program
Frederico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Italy

P3.02c-039: Endocrinological Side-Effects of Nivolumab in Advanced Non-Small Cell Lung Cancer
Giovanni Rossi, San Martino Hospital - National Institute for Cancer Research, Italy
P3.02c-040: Checkmate 384: A Phase 3B/4 Dose-Frequency Optimization Trial of Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)  
Ronald Harris, Broome Oncology and US Oncology Research, USA

P3.02c-041: IMpower133: A Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC  
Stephen Liu, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, USA

P3.02c-042: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1-Selected Chemotherapy-Naive NSCLC Patients  
Filippo De Marinis, European Institute of Oncology, Italy

P3.02c-043: Immunotherapy in Non-Small Cell Lung Cancer: A New Approach and a New Challenge  
Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

P3.02c-044: Nivolumab-Response in a Patient with Advanced Squamous NSCLC Occurring Simultaneously with SIAD  
Parvis Sadjadian, Johannes Wesling Medical Center Minden. UKRUB, University of Bochum, Germany

P3.02c-045: Experience with Nivolumab in Compassionate Use in Non-Small Lung Carcinoma Patients Who Have Progressed to One or More Prior Lines of Chemotherapy  
Maria Marin Alcala, Corporació Sanitaria Parc Taulí, Spain

P3.02c-046: Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC  
Charles Rudin, Memorial Sloan Kettering Cancer Center, USA

P3.02c-047: Local Experience in an Expanded Access Program of Nivolumab in Advanced Non-Small Cell Lung Cancer in Brazil  
Luiz H. Araujo, Instituto COI de Educação e Pesquisa (ICOI) and Núcleo de Oncologia Torácica (NOT), Brazil

P3.02c-048: A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC  
Roy Decker, Yale School of Medicine, USA

P3.02c-049: Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrate Enhanced Antitumor Effect against Lung Cancer  
Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P3.02c-050: IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC  
Heather Wakelee, Stanford University School of Medicine, USA

P3.02c-051: A Pre-Treatment Serum Test Based on Complement and IL-10 Pathways Identifies Patients Benefiting from the Addition of Bavituximab to Docetaxel  
Rachel Sanborn, Providence Portland Medical Center, USA

P3.02c-052: Electronic Nose: An Early Response Biomarker for Anti-PD1 Therapy in Patients with NSCLC  
Mirte Muller, The Netherlands Cancer Institute, Netherlands
P3.02c-053: Clinical and Plasma Biomarkers for Disease Control with Nivolumab Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC)
Sameh Daher, Chaim Sheba Medical Center, Israel

P3.02c-054: Prognostic Role of cfDNA in Patients with NSCLC under Treatment with Nivolumab
Federica Biello, San Martino Hospital - National Institute for Cancer Research, Italy

P3.02c-055: Incidence and Grade of Pneumonitis in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Anti-PD-1 Antibodies
Andrew Yam, Crown Princess Mary Cancer Care Centre, Westmead Hospital, Australia

P3.02c-056: Interim Results From the Phase I Study of Nivolumab + nab-Paclitaxel + Carboplatin in Non-Small Cell Lung Cancer (NSCLC)
Jonathan W. Goldman, David Geffen School of Medicine at the University of California, USA

P3.02c-057: Viroimmunotherapy with Vesicular Stomatitis Virus Expressing Interferon-β (Vsv-IFNβ) in a Murine Model of NSCLC
Manish Patel, University of Minnesota, USA

P3.02c ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - IT BIOMARKERS

P3.02c-058: In-Depth Molecular Characterization of T Cell Clonal Expansion Induced by Anti-PD1 Therapy in NSCLC
Jyoti Patel, University of Chicago, USA

P3.02c-059: CD70 Immune Checkpoint Ligand is Associated with Epithelial-To-Mesenchymal Transition in Non-Small Cell Lung Cancer
Sandra Ortiz-Cuaran, INSERM U1052, CNRS UMR 5286. Cancer Research Center of Lyon, France

P3.02c-060: Dual Positive PD-L1 and CD8+ TIL Represents a Predominant Subtype in NSCLC and Correlates with Augmented Immunogenicity
Si-Yang Liu, Guangdong Lung Cancer Institute; Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P3.02c-061: Neutrophil/Lymphocyte Ratio Predicts the Efficacy of Anti-PD-1 Antibody in Patients with Advanced Lung Cancer
Koung Jin Suh, Seoul National University Bundang Hospital, South Korea

P3.02c-062: Anti-Lung Cancer Effect of CD8+ T Cells Transduced Retroviral Vector Encoding WT1-Specific TCRs and siRNAs Targeting Endogenous TCRs
Jun An, The Third Affiliated Hospital, Sun Yat-Sen University, China

P3.02c-063: Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint-Inhibitors for Patient with Advanced Non-Small-Cell Lung Cancer (NSCLC)
AM Martinez De Castro, Vall d’Hebron Institute of Oncology/Vall d’Hebron University Hospital, Spain

P3.02c-064: Higher PD-L1 Expression Correlates with Solid and High Grade Lung Adenocarcinomas: Implications for Immunotherapy Selection
Ross Miller, Houston Methodist Hospital, USA
P3.02c-065: Neutrophil-To-Lymphocyte and Other Ratios as Prognostic and Predictive Markers of Immune Checkpoint Inhibitors in Advanced NSCLC Patients
Laura Mezquita, Gustave Roussy, France

P3.02c-066: HLA-A2 Status and Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Laura Mezquita, Gustave Roussy, France

P3.02c-067: Validation of PD-L1 Expression on Circulating Tumor Cells in Lung Cancer
Veena Singh, Biocept, USA

P3.02c-068: Immunotherapy against Non Small Cell Lung Cancer (NSCLC): Looking for Predictive Factors to Avoid an Untargeted Shooting
Chiara Bennati, Medical Oncology, Santa Maria della Misericordia Hospital, Italy

P3.02c-069: Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) Predicts Outcomes with Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
Stephen Bagley, University of Pennsylvania, USA

P3.02c-070: Combination Immunotherapy with MEK Inhibitor for Treatment of Kras-Mutant Lung Cancer in Animal Model
J. Peter Koo, Yale Cancer Center, Yale School of Medicine, USA

P3.02c-071: Spatially Selective Depletion of Regulatory T Cells with near Infrared Photoinmunotherapy for Syngeneic Lewis Lung Carcinoma
Kazuhide Sato, Nagoya University, Japan

P3.02c-072: Predictive Immunologic Markers of Response to Nivolumab in Non-Small Cell Lung Cancer
Carlo Genova, San Martino Hospital - National Institute for Cancer Research, Italy

P3.02c-073: Evidence Suggesting a Dichotomous "Present vs absent" Determinant of PDL1 Inhibitor Efficacy in Non-Small Cell Lung Cancer (NSCLC)
David Stewart, University of Ottawa, Canada

P3.02c-074: Evaluation of a Pretreatment Serum Tests for Nivolumab Benefit in Patients with Non-Small Cell Lung Cancer
Francesco Grossi, IRCCS San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Italy

P3.02c-075: Could Blood Levels of Lymphocytes and Eosinophils Help Us to Identify the Efficacy or Toxicity of Immunotherapy?
Pilar Garrido, University Hospital Ramon y Cajal, Spain

P3.02c-076: Correlation of Neutrophil to Lymphocyte Ratio (NLR) with Clinical Benefit from Checkpoint Inhibitors in Advanced Lung Cancer
Alona Zer, Princess Margaret Cancer Centre, Canada

P3.02c-077: Cardiac Troponin-I Elevation in Patients with Non-Small Cell Lung Cancer during PD1/PDL1 Inhibition with Nivolumab
Erika Rijavec, San Martino Hospital - National Institute for Cancer Research, Italy
P3.02c-078: The Utilization of Pre-Treatment Neutrophil to Lymphocyte Ratio as a Predictive Marker for Efficacy of Immunotherapy in Non Small Cell Lung Cancer
Isabel Preeshagul, North Shore Long Island Jewish/ Northwell Health, USA

P3.02c-079: Immunotherapy in Non Small Cell Lung Cancer (NSCLC): Biomarkers Associated with Early Death
Ana Gomez, University Hospital Ramon y Cajal, Spain

P3.02c-080: The Beneficial Effect of Platelet Binding to Monocytes on the Clinical Response to Checkpoint Inhibitors
Margarita Majem, Hospital de la Santa Creu i Sant Pau, Spain

P3.02c-081: Complete Blood Count Parameters as Predictive Factors in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab
Diana Saravia, University of Miami Miller School of Medicine, USA

P3.02c-082: Altered Expression of Programmed Death-Ligand 1 after Neo-Adjuvant Chemotherapy in Patients with Lung Squamous Cell Carcinoma
Zhengbo Song, Zhejiang Cancer Hospital, China

P3.02c-083: Treatment Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center
Aaron Lisberg, UCLA Medical Center, USA

P3.02c-084: Predictive and Prognostic Clinical and Pathological Factors of Nivolumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Patients
Javier Garde-Noguera, Hospital Arnau de Vilanova, Spain

P3.02c-085: Neutrophil/Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer: Correlation with Prognosis and Response to Anti-PD1 Therapy
Domenico Galetta, Medical Oncology Unit, Clinical Cancer Centre “Giovanni Paolo II”, Italy

P3.02c-086: Genomic Heterogeneity in Tumors Demonstrating a Mixed Response to Nivolumab for Stage IV Squamous Cell Carcinoma of the Lung
Michael Menefee, Mayo Clinic, USA

P3.02c-087: The Relationship of TILs and PD-L1 Expression in NSCLC Adenocarcinoma in Little to Non-Smokers with Driver Mutations and Outcome Parameters
Sacha Mignon, Vrije Universiteit Brussel, Belgium

P3.02c-088: Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
Scott Gettinger, Yale School of Medicine, USA

P3.02c-089: ImmunoCHIC: A Prospective Nivolumab Monotherapy Cohort in Advanced Non-Small Cell Lung Cancer Patients in Routine Clinical Practice
Christos Chouaid, GRC OncoEst Creteil, France

P3.02c-090: The Role of ERCC-1 Polymorphisms as Predictive Biomarker of Response to Nivolumab in Advanced NSCLC
Marco Aiello, A.O.U. Policlinico Vittorio Emanuele, Italy
P3.02c-091: Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC
Alexandros Papachristofilou, Universitätsspital Basel, Switzerland

P3.02c-092: Nivolumab in Multi-Treated Patients with Advanced Sq-NSCLC: Data from the Italian Cohort of Expanded Access Programme (EAP)
Marcello Tiseo, University Hospital of Parma, Italy

P3.02c-093: A Prospective, Randomized, Multicenter, Phase III Study, Comparing rhTPO with rhIL-11 Treating CIT (NCT02344979)
Shun Lu, Shanghai Chest Hospital, Shanghai Jiaotong University, China

P3.02c-094: Italian Nivolumab Advanced Squamous NSCLC Expanded Access Program: Efficacy and Safety in Patients with Brain Metastases
Annamaria Catino, National Cancer Research Centre, Istituto Tumori “Giovanni Paolo II” Bari, Italy, Italy

P3.02c-095: Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non Small Cell Lung Cancer Patients
Lucio Crinò, Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Italy

P3.02c-096: Use of Nivolumab in Elderly Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP)
Francesco Grossi, National Institute for Cancer Research, Italy

P3.02c-097: Nivolumab in Elderly or Poor Performance Status Patients with Advanced Non-Small Cell Lung Cancer
Sho Watanabe, National Cancer Center Hospital, Japan

P3.02c-098: An Observational Study of the Efficacy and Safety of Nivolumab in Patients with Advanced NSCLC. A Galician Lung Cancer Group
Rosario García Campelo, Complejo Universitario de a Coruna, Spain

P3.02c-099: A Retrospective Study of the Efficacy and Safety of Nivolumab in Our Clinical Practice: A Single Institutional Experience
Tadashi Sakaguchi, Matsusaka Municipal Hospital, Japan

P3.02c-100: Nivolumab beyond First-Line (1L) Treatment in Metastatic Non-Small Cell Lung Cancer (NSCLC)
Miguel Sotelo, Hospital Universitario Infanta Cristina, Spain

P3.02c-101: Immunotherapy with Nivolumab in NSCLC Patients: One Centre Preliminary Results
Konstantinos Zarogoulidis, Aristotle University of Thessaloniki, Greece

P3.02c-102: Safety and Tolerability of Abemaciclib Combined with LY3023414 or with Pembrolizumab in Patients with Stage IV NSCLC
Jonathan W. Goldman, UCLA Medical Center, USA
P3.01 MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES - MESOTHELIOMA TRANSLATIONAL

P3.03-001: Targeting Cullin Ubiquitin Ligase Leads to Growths Arrest in Malignant Pleural Mesothelioma Cells
Mayura Meerang, University Hospital Zürich, Switzerland

P3.03-002: Inducible Changes in Cell Morphology and Gene Expression Reflecting the Histological Subtypes of Mesothelioma
Karin Schelch, Medical University of Vienna, Austria

P3.03-003: Mesothelium Covering Pleural Plaque Is Not Primarily Involved in Asbestos-Induced Mesothelial Carcinogenesis in Human
Yuichi Koda, Respiratory, Japan

P3.03-004: Genome-Wide Copy Number Aberrations in Mesothelioma and Its Correlation with Tumour Microenvironment including PD-L1 Expression
Bibhusal Thapa, Olivia Newton John Cancer Research Institute, Australia

P3.03-005: Inhibition of PRMT5 is Synthetic Lethal in Mesotheliomas Harboring MTAP Loss
Annabel Sharkey, University of Leicester, UK

P3.03-006: Optical Control of Growth Factor Receptors to Advance Signal Transduction Research and Drug Screening
Michael Grusch, Medical University of Vienna, Austria

P3.03-007: miR-137 Acts as a Tumour Suppressor via the Down-Regulation of YB-1 in Malignant Pleural Mesothelioma
Thomas Johnson, Asbestos Diseases Research Institute, Australia

P3.03-008: Hypoxia-Induced Changes in microRNA Levels Contribute to Drug Resistance in a 3D Model of Malignant Pleural Mesothelioma
Yuen Yee Cheng, Asbestos Diseases Research Institute, Australia

P3.03-009: Role of microRNAs as Biomarkers of Malignant Mesothelioma in Patients with Pleural Effusion
Alessandro Palleschi, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Italy

P3.03-010: Activation of p53 in Malignant Mesothelioma
Chuong Hoang, National Cancer Institute, USA

P3.03-011: Downregulated Expression of miR-30d Contributes to Pleural Malignant Mesothelioma Progression
Lijin Zhu, Zhejiang Academy of Medical Sciences, China

P3.03-012: Tumor-Infiltrating Lymphocytes, PDL-1, BAP-1, VEGFR-2 and IGF-1R Expression in Malignant Pleural Mesothelioma
Luca Ampollini, Thoracic Surgery, University Hospital of Parma, Italy

P3.03-013: BAP1 Immunostaining and FISH Analysis of p16 Help Making Distinction among Subtypes of Mesothelioma
Kenzo Hiroshima, Tokyo Women's Medical University, Japan
P3.03-014: Tumor Subtype-Specific Cells-Of-Origin of Malignant Pleural Mesothelioma
Hilda De Vries, Netherlands Cancer Institute, Netherlands

P3.03-015: BAP1 is Inactivated by Copy Number Loss, Mutation, and/or Loss of Expression in More Than 70% Malignant Peritoneal Mesotheliomas
Noémie Leblay, International Agency for Research on Cancer, France

P3.03-016: Association between the Stainability of the Neurofibromatosis Type 2 Gene-Related Protein Merlin and the Tumor Properties of Mesotheliomas
Kozo Kuribayashi, Hyogo College of Medicine, Japan

P3.03-017: Fluorescent in situ Hybridization Analysis of MET Gene Status in Malignant Mesothelioma
Antonella Vigani, ASL5 Spezzino, Italy

P3.03-018: Suppression of Tumor Growth by Pegylated Arginase in Malignant Pleural Mesothelioma
James Chung-Man Ho, The University of Hong Kong, Hong Kong

P3.03-019: Molecular Characterization of Malignant Pleural Mesothelioma (MPM) by next Generation Sequencing
Alejandro Navarro, Vall d´Hebron Institute of Oncology/Vall d´Hebron University Hospital, Spain

P3.03-020: Cytotoxicology Assessment of MWCNT on MeT-5A Cells
Li Ju, Zhejiang Academy Of Medical Sciences, China

P3.03-021: When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?
Steven Gray, LabMed Directorate, Ireland

P3.03-022: Serum CEA, VEGF and MMP-7 in Patients with Malignant Pleural Effusion. A Prospective Study with Logistic Regression Analysis of Accuracy
Franco Lumachi, University of Padua, School of Medicine, Italy

P3.03-023: High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma from Turkey
Salih Emri, Hacettepe University, School of Medicine, Turkey

P3.03-024: Malignant Pleural Mesothelioma: Gene Expression Profiling of the Main Histological Subtypes
Greta Ali, University Hospital of Pisa, Italy

P3.03-025: Investigating Phenotypic and Genomic Heterogeneity in Malignant Pleural Mesothelioma
Muhammad Alamgeer, Monash Cancer Centre, Australia

P3.03-026: Orotate Phosphoribosyltransferase is Overexpressed in Malignant Pleural Mesothelioma: Dramatically Responds One Case in High OPRT Expression
Yoichiro Hamamoto, National Hospital Organization Disaster Medical Center, Japan

P3.03-027: Growth Factor and Inflammatory Signaling Pathway Interactions Influence Outcomes Following Multimodality Therapy for Mesothelioma
Keith Cengel, University of Pennsylvania, USA
P3.03-028: Nivolumab for Advanced Malignant Pleural Mesothelioma outside of Clinical Trials: A Single Institution Experience
Jun Zhang, Baylor College of Medicine, USA

P3.03-029: EPP Followed by Hemithoracic IMRT - A Multicenter Study on Behalf of the Italian Association for Radiation Oncology Lung Cancer Study Group
Marco Trovo, CRO - Aviano, Italy

P3.03-030: Cisplatin with Pemetrexed or Gemcitabine in Prolonged Infusion for Inoperable Mesothelioma: A Phase II Randomized Trial
Danijela Strbac, Institute of Oncology, Slovenia

P3.03-031: Definitive Radiation Therapy is Associated with Improved Survival in Non-Metastatic Malignant Pleural Mesothelioma
Kenneth Rosenzweig, Mount Sinai, USA

P3.03-032: PET/CT for Patients with Very Early Clinical Stage of Malignant Pleural Mesothelioma: When Can PET/CT Detect Tumor Growth of T0/T1a Mesothelioma?
Yoshiki Negi, Hyogo College of Medicine, Japan

P3.03-033: The Influence of Geographic and Socioeconomic Factors on Prognosis and Treatment Provision in Malignant Pleural Mesothelioma
Anthony Linton, Asbestos Diseases Research Institute, Australia

P3.03-034: Comprehensive Immunophenotyping of the Blood and Pleural Fluid from Patients with Malignant Pleural Mesothelioma by Flow Cytometry
Tobias Peikert, Mayo Clinic, USA

P3.03-035: Prognostic Role of hENT1 and RRM1 in Patients with Advanced Pleural Mesothelioma Treated with Second Line Gemcitabine Based Regimens
Andrés Cardona, Clinical and Translational Oncology Group, Institute of Oncology, Clinica del Country, Colombia

P3.03-036: Prognostic Model for Mesothelioma Based on Cancer and Leukemia Group B (CALGB) Trials (Alliance)
Herbert Pang, The University of Hong Kong, China

P3.03-037: Impact of Sarcomatoid Component in Patients with Biphasic Mesothelioma: Review of 118 Patients
Andrea Bille, Guy’s and St Thomas’ NHS Foundation Trust, UK

P3.03-038: Improving Quality of Care and Outcomes for Patients Diagnosed with Pleural Mesothelioma in England
Susan Harden, Royal College of Physicians of London, UK

P3.03-039: Prognostic Biomarkers for Malignant Pleural Mesothelioma Treated with Chemotherapy
Hakan Akgun, Eskisehir Osmangazi University, Turkey

P3.03-040: Long Term Outcomes Following IMRT for Mesothelioma Post EPP and Unresectable
Aaron Allen, Davidoff Center, Israel
P3.03-041: FAS/FASL Genetic Polymorphisms Impact on Clinical Outcome of Malignant Pleural Mesothelioma
Ahmed Salem, Faculty of Pharmacy, Ain Shams University, Egypt

P3.03-042: Study Comparing Volume and TNM in Predicting Clinical Outcome in Malignant Pleural Mesothelioma
Marina Garassino, Fondazione IRCCS- Istituto Nazionale dei Tumori, Italy

P3.03-043: Trimodality Therapy with Extrapleural Pneumonectomy, Radiation Therapy, and Chemotherapy for Epithelioid Malignant Pleural Mesothelioma
Kazunori Okabe, Yamaguchi Ube Medical Center, Japan

P3.03-044: Is Toxicity Increased by Adding Intraoperative Chemotherapy to Preoperative Induction Chemotherapy for Mesothelioma Patients?
Isabelle Opitz, University Hospital Zürich, Switzerland

P3.03-045: Treatment of Malignant Pleural Mesothelioma beyond First-Line among Hispanics (MeSO-CLICaP)
Luís Corrales, Hospital San Juan de Dios (San José, Costa Rica), Costa Rica

P3.03-046: Prognostic Fibrinogen/Leucocyte Score at Diagnosis Predicts Survival and Benefit from Multimodality Treatment in MPM
Thomas Klikovits, Medical University Vienna, Austria

P3.03-047: Diagnostic Value of Secretary Leukocyte Peptide Inhibitor (SLPI) in Pleural Fluid in Malignant Pleural Mesothelioma
Nobukazu Fujimoto, Okayama Rosai Hospital, Japan

P3.03-048: Profiling Response to Chemotherapy in Malignant Pleural Mesothelioma among Hispanics (MeSO-CLICaP)
Andrés Cardona, Clinical and Traslational Oncology Group, Institute of Oncology, Clinica del Country, Colombia

P3.03-049: Optimisation of Malignant Mesothelioma Registration at the Belgian Cancer Registry
Jan Van Meerbeeck, University Hospital of Antwerp, Belgium

P3.03-050: Prognostic and Predictive Factors Affecting Course of Disease and Survival in Malignant Pleural Mesothelioma
Angela De Palma, University of Bari "Aldo Moro", Italy

P3.03-051: Establishment of Consultation System for Mesothelioma Diagnosis Using Remote Medicine by Internet
Kouki Inai, Pathological Diagnostic Center, Inc., Japan

P3.03-052: Diagnostic Utility of Mesothelin, Osteopontin and Megakaryocyte Potentiation Factor in Turkish Patients with Malignant Mesothelioma
Salih Emri, Hacettepe University, School of Medicine, Turkey

P3.03-053: Malignant Mesothelioma in Iranian Patients: A Study from National Institute of Tuberculosis and Lung Disease
Sharareh Seifi, National Institute of Tuberculosis and Lung Disease (NRTILD), Iran
P3.03-054: Review and Descriptive Analysis of 140 Patients Diagnosed with Malignant Mesothelioma at Consorci Sanitari Parc Tauli
Juan Carlos Pardo Ruiz, Corporacio Sanitaria Parc Tauli, Spain

P3.03-055: Results of Second-Line Chemotherapy in Pleural Mesothelioma: A Single-Centre, Retrospective Study
Juan Carlos Pardo Ruiz, Corporacio Sanitaria Parc Tauli, Spain

P3.03-056: Retrospective Study Comparing Two Frontline Chemotherapy Schemes in Unresectable Malignant Mesothelioma
Juan Carlos Pardo Ruiz, Corporacio Sanitaria Parc Tauli, Spain

P3.03-057: Granulocyte Colony-Stimulating Factor-Producing Malignant Pleural Mesothelioma: Report of Two Cases
Eisuke Matsuda, Saiseikai Imabari Hospital, Japan

P3.03-058: A Retrospective Evaluation of 64 Hospitalised Malignant Pleural Mesothelioma (MPM) Patients
Aida Ustamujić, Clinic for Lung Disease and TB Podhrastovi, Clinical Center University of Sarajevo, Bosnia and Herzegovina

P3.03-059: Diaphragmatic and Pericardial Reconstruction by Heterologous Pericardial Patch after Extrapleural Pneumonectomy for Mesothelioma
Domenico Galetta, European Institute of Oncology, Italy

P3.03-060: Characteristics and Long Term Outcomes of Advanced Pleural Mesothelioma in Latin America (MeSO-CLICaP)
Oscar Arrieta, Instituto Nacional de Cancerologia, Mexico

P3.03-061: Burden of Disease and Management of Mesothelioma in France: A National Cohort Analysis
Christos Chouaid, GRC OncoEst Creteil, France

P3.03-062: Response to Pembrolizumab in a Malignant Pleural Mesothelioma with Sarcomatoid Histology: A Case Report
Vera Wienhausen-Wilke, Klinikum Esslingen, Germany

P3.03-063: Phase 1/2 Trial of WT1 TCR-Transduced Central Memory and Naïve CD8+T Cells for Patients with Mesothelioma and Non-Small Cell Lung Cancer
Sylvia Lee, University of Washington, Seattle Cancer Care Alliance, USA

P3.04  SURGERY

P3.04  SURGERY - MISCELLANEOUS I

P3.04-001: Near-Infrared Fluorescent Identification of Lymphatic Flow in Non-Small Cell Lung Cancer
Andrey Akopov, Pavlov First State Medical University, Russia

P3.04-002: Reducing the Amount of Resection after Induction Photodynamic and Chemotherapy in Inoperable Non-Small Cell Lung Cancer
Andrey Akopov, Pavlov First State Medical University, Russia
P3.04-003: Incidence and Outcome of Female Patients with Previous Breast Cancer Undergoing Curative Resection for Lung Cancer
Sabrina Tahon, Medical University Vienna, Austria

P3.04-004: The Risk Factor of the Thrombus Formation in Pulmonary Vein Stump after Left Upper Lobectomy for Lung Cancer
Reiko Shimizu, Shizuoka Cancer Center, Japan

P3.04-005: Evaluation of Noninvasive Lung Adenocarcinoma Using 3D-CT Imaging
Katsuyuki Suzuki, Yamagata Prefectural Central Hospital, Japan

P3.04-006: The Effect of Preoperative Multi-Disciplinary Support Commenced at Outpatient Clinic on Lung Cancer Patients
Masafumi Kataoka, Okayama Saiseikai General Hospital, Japan

P3.04-007: Detection of Brain Metastasis in Resected Lung Cancer with the New Postoperative Follow-Up Program
Rie Nakahara, Tochigi Cancer Center, Japan

P3.04-008: CATS: Computed Tomography-Assisted Thoracoscopic Surgery - A Novel Approach in Patients with Deep Intrapulmonary Lesions of Unknown Dignity
Peter Hohenberger, Mannheim University Medical Center, Germany

P3.04-009: Photodynamic Therapy (PDT) Turns 21: Indications, Applications and Outcomes for NSCLC
Patrick Ross, Main Line Health System, USA

P3.04-010: Changes of Right Lung Volume after Right Upper Lobectomy for Lung Cancer
Hyeong Ryul Kim, Asan Medical Center, University of Ulsan College of Medicine, South Korea

P3.04-011: Salvage Surgery for Isolated Local Recurrence after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small Cell Lung Cancer
Hiroshi Date, Kyoto University Graduate School of Medicine, Japan

P3.04-012: Bronchial Sutures in Anatomic Pulmonary Resections: The Clinical Experience of 865 Cases
Aleksei Aksarin, Surgut District Clinical Hospital, Russia

P3.04-013: The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma
Morgan Cox, Duke University, USA

P3.04-014: Surgical Outcome and Diagnosis of cN1 Lung Cancers after Introducing PET/CT
Satoshi Shiono, Yamagata Prefectural Central Hospital, Japan

P3.04-015: Usefulness of Carotid Ultrasonography for Postoperative Cerebrovascular Complication Prevention in Patients with Lung Cancer
Sadanori Takeo, National Kyusyu Medical Center, Japan

P3.04-016: Surgical Implications of the New Lung Adenocarcinoma Classification - Usefulness for Selecting Cases Undergoing Sublobar Resection
Akira Shimamoto, Mie University Graduate School of Medicine, Japan
P3.04-017: Wedge Resection for Clinical-n0 Non-Small Cell Lung Cancer
Hiroaki Tsunezuka, Kyoto Prefectural University of Medicine, Japan

P3.04-018: Recurrence Dynamic of Completely Resected Non-Small Cell Lung Cancer in Perspective of Follow-Up Surveillance
In Kyu Park, Seoul National University Hospital, South Korea

P3.04-019: Nodal Upstaging in cN0 Lung Cancer is More Influenced by Tumor Size Than The Surgical Approach
Florian Augustin, Medical University Innsbruck, Austria

P3.04-020: Segmentectomy in Patients with Pulmonary Malignancies Using 3D-CT Reconstruction and Bronchovascular Separation
Oleg Pikin, Hertzen Research Institute of Oncology, Russia

P3.04-021: Readmission Rate is Not Increased with Shortened Hospital Stay after Lung Cancer Surgery
Kei Yarimizu, Yamagata Prefectural Central Hospital, Japan

P3.04-022: Unexpected Residual Carcinoma in the Bronchial Stump after Surgery for Lung Cancer
Yohei Kameda, Kanagawa Cardiovascular and Respiratory Center, Japan

P3.04-023: Perioperative Management of Antiplatelet Therapy in Patients with Coronary Stent Who Need Thoracic Surgery
Shunki Hirayama, Juntendo University School of Medicine, Japan

P3.04-024: Long-Term Outcome of Sublobar Resection versus Lobectomy for Stage I and II Non-Small Cell Lung Cancer
Su Kyung Hwang, Asan Medical Center, University of Ulsan College of Medicine, South Korea

P3.04-025: Repeated Lung Resection of Ipsilateral Lung Cancer That is Detected after Segmentectomy for Primary Lung Cancer
Masanori Tsuchida, Niigata University Graduate School of Medical and Dental Sciences, Japan

P3.04-026: A Simultaneous Surgical Strategy for Patients with Lung Cancer and Severe Cardiac Diseases Requiring Surgical Treatment
Jae Jun Jung, Sungkyunkwan University School of Medicine, Samsung Medical Center, South Korea

P3.04-027: Feasibility of Lung Cancer Surgery for the Patient with Previous History of Coronary Artery Bypass Grafting
Yutaro Koike, Juntendo University Hospital, Japan

P3.04-028: The Left Upper Division Sacrifice for Bronchoplasty for an Adenoid Cystic Carcinoma of the Left Main Bronchus
Satoshi Yamamoto, Medical Kouhoukai Takagi Hospital, Japan

P3.04 - MISCELLANEOUS II

P3.04-029: A Prospective Randomized Trial of Perioperative Administration of Neutrophil Elastase Inhibitor in Patients with Interstitial Pneumonias
Mariko Fukui, Juntendo University School of Medicine, Japan
P3.04-030: Examination of the Relevance of Prolonged Air Leakage after Pulmonary Resection for Lung Cancer and Factors Affecting Delayed Wound Healing
Koshi Nagano, Bell-Land General Hospital, Japan

P3.04-031: Intermittent Chest Tube Clamping May Shorten Chest Tube Duration and Postoperative Hospital Stay of Lung Cancer Surgery
Shi Yan, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

P3.04-032: Sternal Reconstruction with a Custom-Made Titanium Neosternum after Resection of a Solitary Breast Cancer Metastasis
Ihsan Alloubi, CHU Oujda, Morocco

P3.04-033: Digital Drainage System Reduces Chest Tube Duration and Hospitalization after Anatomic Pulmonary Resections for Malignancies
Ricardo Terra, Instituto do Câncer do Estado de São Paulo - ICESP, Brazil

P3.04-034: Differences between Pleurodesis Using Talc and Silver Nitrate at Different Times of Pleural Disease in Mice
Ricardo Terra, University of Sao Paulo Medical School, Brazil

P3.04-035: Pleurodesis with a 50% Glucose Solution for Post-Operative Pneumothorax, after Curative Lung Cancer Resection
Hiroyuki Sumitomo, Tokushima Municipal Hospital, Japan

P3.04-036: Clinical Analysis of the Association between Lung Cancer and Connective Tissue Disease
Kazuhito Nii, Kagawa University, Japan

P3.04-037: Rare Giant Malignant Tumors of the Chest: Reconstructive Challenge
Krzysztof Kurowski, Hospital Universitario del Vinalopo, Spain

P3.04-038: Pulmonary Resection for Metastatic Pancreaticobiliary Cancer: Can It Be Justified as a Treatment of Choice?
Toshiki Okasaka, Nagoya University Graduate School of Medicine, Japan

P3.04-039: Solitary Fibrous Tumor of the Pleura Associated with Gynecomastia: A Case Report
Omer Giray Intepe, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Turkey

P3.04-040: A Rare Case of Intrathoracic Mass: Intrathoracic Desmoid Tumor
Omer Giray Intepe, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Turkey

P3.04-041: Giant Solitary Fibrous Tumor of the Pleura Saved by Biopsy and Following Extended Resection: A Long Term Surviving Case
Jun Zhang, China Medical University Lung Cancer Center, The First Hospital of China Medical University, China

P3.04-042: 2 Cases of Fast-Growing Emphysematous Bullae Following Lobectomy for Lung Cancer
Hirofumi Suzuki, Saiseikai Suita Hospital, Japan

P3.04-043: Minimally Invasive Small Incision, Muscle- and Rib-Sparing Thoracotomy (miMRST) for Multiple Sclerosing Pneumocytomas
Jun Zhang, The First Hospital Of China Medical University, China
P3.04-044: Surgical Management of Arteriovenous Malformations: Our Experience
Fadil Gradica, University Hospital Shefqet Ndroqi, Albania

P3.04-045: Primary Lung Cancer Presenting as Pneumothorax
Fadil Gradica, University Hospital Shefqet Ndroqi, Albania

P3.04-046: Cases of Surgical Resection of Post-Operative Lymph Node Recurrences from Primary Lung Cancer
Ema Mitsui, Okayama Saiseikai General Hospital, Japan

P3.04-047: The Incidence and Outcome of Hoarseness after Systematic Upper Mediastinal Nodal Dissection by Radical Surgery for Primary Lung Cancer
Yoshifumi Sano, Ehime University Medical School, Japan

P3.05 PALLIATIVE CARE/ETHICS

P3.05 PALLIATIVE CARE/ETHICS - SYMPTOMS, THERAPEUTIC INTERVENTIONS

P3.05-001: Psychological Intervention to Treat Distress and Suffering Experienced by People with Lung Cancer Nearing the End-Of-Life
Mary Duffy, Peter MacCallum Cancer Centre, Australia

P3.05-002: Malnutrition is an Independent Risk Factor on Survival on EGFR Mutated Patients Diagnosed with Non-Small Cell Lung Cancer
Ana Gonzalez-Ling, Instituto Nacional de Cancerología, Mexico

P3.05-003: Anxiety and Depression in Patients with EGFR+ NSCLC Receiving Treatment with TKIs
Ana Gonzalez-Ling, Instituto Nacional de Cancerología, Mexico

P3.05-004: Psycho-Social Function and Caregiver’s Burden in Patients with Advanced Lung Cancer
Annamaria Catino, Clinical Cancer Center “Giovanni Paolo II”, Italy

P3.05-005: Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer
Lore Decoster, UZ Brussel, Belgium

P3.05-006: Anxiolytic Effect of Acupuncture in a Phase II Study of Acupuncture and Morphine for Dyspnoea in Lung Cancer and Mesothelioma
Anna Minchom, Royal Marsden Hospital NHS Foundation Trust, UK

P3.05-007: Prospective Evaluation for Combination Antiemetic Therapy on CINV in NSCLC Receiving Carboplatin-Based Chemotherapy of MEC
Mototsugu Shimokawa, National Kyushu Cancer Center, Japan

P3.05-008: Mindfulness-Based Stress Reduction Added to Care as Usual for Lung Cancer Patients and Their Partners: A Randomized Controlled Trial
Miep Van Der Drift, Radboud University Medical Centre, Netherlands

P3.05-009: Medical Marijuana and Lung Cancer: Patients’ Knowledge and Attitude towards Its Use
Raja Mudad, University of Miami, USA

P3.05 PALLIATIVE CARE/ETHICS - QOL, OTHERS
P3.05-010: Developing Tools for a Successful Thoracic Rapid Tissue Donation Program
Andrea Shaffer, H Lee Moffitt Cancer Center and Research Institute, USA

P3.05-011: Importance of Assessment of Malnutrition Risk in Lung Cancer Patients
Tomi Kovacevic, Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia

P3.05-012: Assessment of the Impact of Palliative Care on the Quality of Life in Advanced Non-Small Cell Lung Cancer Patients - A Longitudinal Study
Fawaz Pullishery, Educare Institute of Dental Sciences, India

P3.05-013: Development of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program
Jamie Studts, University of Kentucky College of Medicine, USA

P3.05-014: Evaluation of Hyponatraemia in Lung Cancer Patients: A U.K. Teaching Hospital Experience
Joyce Thompson, Heart of England NHS Trust, UK

P3.05-015: Sleep Quality and Fatigue in Patients with Lung Cancer
Nudra Malik, Lahore college women university, Pakistan

P3.05-016: Mitochondrial Pathway Mediated Apoptosis is Involved in Erlotinib-Induced Cytoxicity in Hepatic Cells
Xueqin Chen, Hangzhou First People's Hospital, China

P3.05-017: Survivor Guilt: The Secret Burden of Lung Cancer Survivorship
Kay Bayne, Lung Cancer Alliance, USA

P3.05-018: Assessment of Skeletal Muscle Mass as a Predictive Factor for Chemotherapy Toxicity and TTP in Advanced NSCLC Patients with Cancer Cachexia
Drazena Srdic, University Hospital Centre Zagreb, Croatia

P3.05-019: Patients with Advanced Lung Cancer: What Do They Know, What Would They Like to Know, What Should They Know about Their Disease
Elke Vandenbroucke, AZ Monica, Belgium

P3.05-020: Patients’ Perception of Rapid Onset Opioids
Choonhee Son, Dong-A University Hospital, South Korea

P3.06 TRIAL DESIGN/STATISTICS

P3.06 TRIAL DESIGN/STATISTICS - CLINICAL STUDIES

P3.06-001: Phase I/II Study to Evaluate Safety and Efficacy DCVAC/LuCa with 1st Line Chemotherapy +/- Immune Enhancers vs Chemotherapy, Stage IV NSCLC
Libor Havel, Thomayer Hospital, Czech Republic

P3.06-002: ATLANTIS Trial: Phase III Study of PM01183/Doxorubicin vs. CAV or Topotecan in SCLC after One Platinum-Containing Line
Anna Farago, Massachusets General Hospital, USA
P3.06-003: SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomised Phase III Trial
David Landau, Guy's and St Thomas' NHS Foundation Trust, UK

P3.06-004: A Systematic Review of Outcome Reporting in Studies of Radical Radiotherapy and Chemoradiotherapy in Lung Cancer
Sarah Cruickshank, University of Aberdeen, UK

P3.06 TRIAL DESIGN/STATISTICS - OTHERS

P3.06-005: Blastomatoid Pulmonary Carcinosarcoma, Combined with Lepidic Adenocarcinoma
Yu-Deok Choi, Chonnam National University Medical School, South Korea

P3.06-006: Endpoints in Reports on Clinical Trials for Advanced Lung Cancer
Matjaz Zwitter, Institute of Oncology Ljubljana, Slovenia

P3.06-007: The Consequence of Incomplete Follow-up in Hospital-based Survival Study as Compared with National Vital Status-based Results
Jin Soo Lee, National Cancer Center, South Korea

P3.06-008: Employing Remote Web Consenting and Social Media to Facilitate Enrollment to an International Trial on Young Lung Cancer
Barbara Gitlitz, University of Southern California Keck School of Medicine, USA

P3.06-009: Multiple Oral Presentations at Major International Conferences from a Single Clinical Trial Are Common
Edward Garon, UCLA Medical Center, USA

P3.07 REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH

P3.07-001: Nivolumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis including PD-L1 Testing
Oliver Gautschi, Cantonal Hospital Luzern, Switzerland

P3.07-002: Complications and Costs of Diagnostic and Post-Progression Biopsies among Patients with Non-Small Cell Lung Cancer (NSCLC)
Ronan Kelly, Johns Hopkins University, USA

P3.07-003: Effectiveness of Pemetrexed in Advanced Non-Squamous NSCLC and Estimation of Its Impact on Public Health in France
Katherine Bellebaum Winfree, Eli Lilly and Company, USA

P3.07-004: Nivolumab for Non-Small Cell Lung Cancer (NSCLC): An Economic Model for Risk Sharing Based on Real-Life Data
Elizabeth Dudnik, Davidoff Cancer Center, Israel

P3.07-005: US Healthcare without Payer Restrictions or Out-Of-Pocket Costs: Treatment of Advanced NSCLC in the Military Health System
Matthew Peterson, San Antonio Military Medical Center, USA
Andrea Ferris, LUNGevity Foundation, USA

P3.07-007: Compassionate Use Program for New Cancer Drugs in Israel - Shortcut for Reimbursement Approval
Hiba Reches, Davidoff Cancer Center, Israel

P3.07-008: METASTATIC NSCLC: Treatment Reality from 182 Cases of Lung Adenocarcinoma in a Brazilian Public Cancer Health Service
Leonardo Lago, Hospital Sao Lucas da Pucrs, Brazil

P3.07-009: Use of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: The Real-World Clinical Practice in Taiwan
Bin-Chi Liao, National Taiwan University Hospital, Taiwan

P3.07-010: Economic Evaluation of Gefitinib vs. Erlotinib for First Line in NSCLC EGFRm under the Perspective of Brazilian Health System
Marcelo Custodio, AstraZeneca, Brazil

P3.07 REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH - OTHER- GEOGRAPHICAL DIFFERENCES

P3.07-011: Geographical Variation in the Use of Radiotherapy and Surgical Resection for Treatment of Non-Small Cell Lung Cancer in England
Daniela Tataru, Public Health England, UK

P3.07-012: Disparities in Guideline-Concordant Treatment for Node-positive Non-Small Cell Lung Cancer Following Surgery
David Harpole, Duke University, USA

P3.07-013: Determining EGFR and ALK Status in a Population-Based Cancer Registry: A Natural Language Processing Validation Study
Bernardo Goulart, Fred Hutchinson Cancer Research Center, USA

P3.07-014: Patient and Caregiver Experiences: Identifying Gaps in Access to High Quality Care for Lung Cancer Patients
Jennifer King, Lung Cancer Alliance, USA

P3.07-015: Patterns and Risk Factors of Patient Flows across Different Geographic Health Service Units for Lung Cancer Surgery
Emanuela Taioli, Icahn School of Medicine at Mount Sinai, USA

P3.07-016: Ontario's Episode-Based Funding Model Reveals Practice Variation in Adjuvant NSCLC Chemotherapy
William Evans, Cancer Care Ontario, Canada

P3.07-017: Joinpoint Regression Analysis of Lung Cancer Mortality, Turkey
Sedat Altin, Erzincan University Faculty of Medicine, Turkey

P3.07-018: New European Clinical Trial Regulation: What's Going On?
Francesca Arizio, AOU San Luigi Gonzaga, Italy
P3.07-019: AMDAT Lung, An Ideal Lung Cancer MDT Dataset
Emily Stone, St Vincent's Hospital, Australia

P3.07-020: Implementation of an International Value-Based Standard Set of Outcomes for Lung Cancer Patients in a Brazilian Center
Clarissa Baldotto, Instituto COI de Educação e Pesquisa (ICOI) and Núcleo de Oncologia Torácica (NOT), Brazil

P3.07-021: Prevalence of EGFR Mutations in Brazilian Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
Ellias Abreu Lima, Instituto Mário Penna, Brazil

P3.07-022: Progress against Non-Small-Cell Lung Cancer (NSCLC) Compared to Other Solid Tumors
Silvia Paddock, Rose Li and Associates, Inc., USA